[
  {
    "objectID": "index.html",
    "href": "index.html",
    "title": "BS4018: Biology of Aging and Neurodegeneration",
    "section": "",
    "text": "This is a Quarto book.\nTo learn more about Quarto books visit https://quarto.org/docs/books.\n\n1 + 1\n\n[1] 2"
  },
  {
    "objectID": "chapters/week1.html",
    "href": "chapters/week1.html",
    "title": "1  Aging and Neurodegeneration",
    "section": "",
    "text": "Trends in Prolonging Human Life\nThe average human life expectancy has dramatically risen since the 1940s. The above figure suggests that there has been a three-month increase in the life expectancy for women per year for the past 160 years of history. A similar argument could also be said for men given the high \\(R^2\\) values (which describes how well a trend is being explained).\nNevertheless, the above trends have also altered the way that the world’s population pyramid is being shaped. Whereas the said curve looked more like a pyramid in the past, it is now starting to look more uniform (i.e., like a bottle).\nIn Singapore at least, at least 14.4% of Singaporeans are above 65 years old. This figure is expected to grow to about 28% by 2030 and to about 47% in 2050. With so many aging Singaporeans in the future, it’s not unrealistic to think that the government will soon start spending big bucks on healthcare-related expenses.\nThis course is relevant as aging is the biggest risk factor of multiple (chronic) diseases - including neurodegenerative ones like Alzheimer’s, cancer, diabetes, cardiovascular diseases, and much more.\nA healthspan is the number of years that a person in good health lives for. This metric is used to measure somebody’s quality of life as they age. A lifespan - on the contrary - refers to the number of years that a person lives from the time that they are born to the time that they die. In other terms, a lifespan is just how long somebody lives for - this metric is often used in demographic studies and life expectancy tables.\nRejuvenation is the idea that neurons and neural circuits (i.e., a bunch of neurons that are connected via synapses or gaps) can be restored via intervening, if not slowing down age-related degeneration processes and promoting neural cell regeneration.\nThe above graphic also depicts parabiosis: this is a surgical technique whereby the circulatory systems of two living animals are joined in such a way that they can exchange blood along with other proteins. In this example, parabiosis between a young and an old mouse is suggested to improve neural tissue regeneration, muscle function, cardiac function, and other bodily regulations in the old mouse, but have the reverse effect in the young mouse."
  },
  {
    "objectID": "chapters/week1.html#hallmarks-of-aging",
    "href": "chapters/week1.html#hallmarks-of-aging",
    "title": "1  Aging and Neurodegeneration",
    "section": "1.1 Hallmarks of Aging",
    "text": "1.1 Hallmarks of Aging\n\n\n\n\n\nSeveral Hallmarks of Aging\n\n\n\n\nThe above nine hallmarks or causes of aging will be explained upon in a future lesson. This week’s lecture only aims to provide a brief overview.\n\n1.1.1 Loss of Proteostasis\n\n\n\n\n\nLoss of Regulation of Proteostasis\n\n\n\n\nIn any living organism, outside or inside stressors such as heat, free radicals, something from the mitochondria may cause a normally-folded protein to unfold. The body typically has one of many ways to deal with the unfolded protein:\n\nAutophagy: the unfolded protein is uptaken by the lysosomes via an endosome (i.e., a container) or via means of a protein called Hsc70: a chaperone.\nDegradation: the unfolded protein could be ubiquinated and subsequently targeted for degradation by the ubiquitin-proteasome system.\nRefolding: the protein could just get refolded with the help of chaperone proteins.\n\nHowever, in the event that the cell is unable to perform any one of the above three functions, these unfolded proteins could aggregate and form plaques or tangles, hence leading to aging-related illnesses.\n\n\n1.1.2 Free Radical Theory of Aging\n\n\n\n\n\nOxidation Reactions on the Miotchondria\n\n\n\n\n\n\n\nOxidation Reactions on the Miotchondria\n\n\n\n\nThe free radical theory of aging suggests that the process of aging is partly caused by the damage that free radicals can inflict on our cells over time. Free radicals are unstable molecules that can harm our cells by causing oxidative stress, which can lead to various age-related diseases and the overall decline of our bodies as we get older.\nIn the late 1960s, scientists discovered an enzyme called superoxide dismutase (SOD). This enzyme plays a crucial role in our bodies by helping to neutralize free radicals and reduce the damage they can cause to our cells.\n\n\n\n\n\nMitochondria Degeneration Leading to Aging Effects\n\n\n\n\nNonetheless, when mitochondria age, a process called mitophagy occurs that engulfs damage mitochondria and remove them by degrading them. However, when an organism ages, mitophagy isn’t able to occur as readily and so, the damaged mitochondria accumulate and lead to the creation of reactive oxygen species (i.e., ROS) and age-related issues.\n\n\n1.1.3 Cell Senesence\n\n\n\n\n\nIllustration of Cell Senesence\n\n\n\n\nWhenever a cell divides, the ends of its chromosomes (i.e., its telomeres) shorten a little. These chromosomes are unable to be shortened past a certain point - because of this, cells can only divide so many times (which is shown by that graph on the left).\n\n\n1.1.4 Epigenetics\n\n\n\n\n\nHow Epigenetics Can Influence Aging\n\n\n\n\nThe above figure shows some processes that occur on the epigenetic-level that may contribute to aging-related health issues."
  },
  {
    "objectID": "chapters/week1.html#possible-interventions-to-expand-healthcare",
    "href": "chapters/week1.html#possible-interventions-to-expand-healthcare",
    "title": "1  Aging and Neurodegeneration",
    "section": "1.2 Possible Interventions to Expand Healthcare",
    "text": "1.2 Possible Interventions to Expand Healthcare\n\n\n\n\n\nPossible Ways to Prolong One’s Lifespan\n\n\n\n\nAll of the above will be explained in subsequent lectures."
  },
  {
    "objectID": "chapters/week2.html",
    "href": "chapters/week2.html",
    "title": "2  Ubiquitin Proteasome System",
    "section": "",
    "text": "Roles of the Ubiquitin Protein in the Cell\nAlthough ubiquitin is generally used to target proteins for degradation via the E3 ubiquitin ligase system, it also has roles in other cellular processes - for instance, the cell cycle, quality control, and metabolism."
  },
  {
    "objectID": "chapters/week2.html#e3-ligase-and-ubiquitylation",
    "href": "chapters/week2.html#e3-ligase-and-ubiquitylation",
    "title": "2  Ubiquitin Proteasome System",
    "section": "2.1 E3 Ligase and Ubiquitylation",
    "text": "2.1 E3 Ligase and Ubiquitylation\n\n\n\n\n\nE1, E2, and E3 Ubiquitination Cascade\n\n\n\n\nThis process is threefold and has the following steps - it is usually used to tag proteins for degradation within the cell and is important for maintaining homeostasis, cellular processes, and also protein levels:\n\nE1 Activation: The process begins with an enzyme called E1 (ubiquitin-activating enzyme). E1 activates ubiquitin, a small protein found in cells that serves as a tag for proteins destined for degradation. Activation involves the binding of ubiquitin to E1 in an ATP-dependent manner, forming a thioester bond between the ubiquitin molecule and E1.\nE2 Conjugation: Once activated, the ubiquitin molecule is transferred to a second enzyme called E2 (ubiquitin-conjugating enzyme). E2 works as a carrier for the ubiquitin molecule, shuttling it to the target protein.\nE3 Ligase: The E2 enzyme, now loaded with ubiquitin, interacts with a third enzyme called E3 ligase (ubiquitin-protein ligase). E3 ligase plays a crucial role in recognizing specific target proteins and facilitating the transfer of ubiquitin from E2 to the target protein.\nUbiquitination: The E3 ligase, along with the assistance of E2, transfers the ubiquitin molecule from the E2 enzyme to a lysine residue on the target protein, forming an isopeptide bond. This process can be repeated multiple times, resulting in the addition of multiple ubiquitin molecules to the target protein, forming a polyubiquitin chain.\nProteasomal Degradation: Once the target protein is tagged with ubiquitin chains, it is recognized and degraded by a large multi-subunit complex called the proteasome. The proteasome acts as the cell’s “garbage disposal,” breaking down tagged proteins into smaller peptides that can be recycled by the cell.\n\n\n2.1.1 Terminal Regions of Ubiquitin\n\n\n\n\n\nCys, Lys, and C-Termini of Ubiquitin\n\n\n\n\nUbiquitin is a small protein found in cells that plays a crucial role in tagging other proteins for degradation through the ubiquitin-proteasome system. Its structure consists of 76 amino acid residues and includes several key functional elements:\n\nCysteine (Cys): Ubiquitin contains a reactive thiol group (-SH) on its C-terminal glycine residue. This cysteine residue is where ubiquitin forms a thioester bond with the active site of the E1 ubiquitin-activating enzyme during the first step of the ubiquitination cascade. This thioester bond formation activates ubiquitin for conjugation to target proteins.\nLysine (Lys): Ubiquitin contains seven lysine residues (K6, K11, K27, K29, K33, K48, and K63), any of which can serve as attachment sites for additional ubiquitin molecules during the process of polyubiquitination. The type of polyubiquitin chain formed (e.g., K48-linked, K63-linked) determines the fate of the tagged protein, such as degradation by the proteasome or involvement in other cellular processes.\nC-Terminus: The C-terminus of ubiquitin is where its Gly76 residue is located. This glycine residue is crucial for the formation of the isopeptide bond between ubiquitin and the lysine residue of the target protein during ubiquitination. The C-terminus is also where the ubiquitin molecule is initially activated by the E1 enzyme, forming a thioester bond with the cysteine residue of E1.\n\n\n\n2.1.2 RING and HECT E3 Ligases\n\n\n\n\n\nIllustration of RING and HECT Ligases\n\n\n\n\nTwo primary classes of E3 ligases, known as RING (Really Interesting New Gene) ligases and HECT (Homologous to the E6-AP Carboxyl Terminus) ligases, operate distinctly within this ubiquitination process.\nFirstly, RING ligases function by directly mediating the transfer of ubiquitin from the E2 enzyme to the target protein without forming a covalent intermediate with ubiquitin. Although RING ligases lack intrinsic catalytic activity for ubiquitin transfer, they serve as scaffolds, bringing the E2 enzyme and the target protein into close proximity to facilitate efficient ubiquitin transfer. The RING domain, a characteristic feature of RING ligases, orchestrates the interaction between the E2 enzyme and the target protein, thereby enabling the ubiquitination process. Examples of RING ligases include Cullin-RING ligases (CRLs), which participate in the ubiquitination of diverse cellular proteins involved in crucial processes like cell cycle regulation and signal transduction.\nOn the other hand, HECT ligases operate differently by forming a thioester intermediate with ubiquitin prior to transferring it to the target protein. The HECT domain, distinctive to HECT ligases, contains a catalytic cysteine residue that forms a thioester bond with ubiquitin, facilitating its transfer to the target protein. Typically, HECT ligases exhibit a specific domain architecture, featuring an N-terminal domain responsible for substrate recognition and a C-terminal HECT domain accountable for ubiquitin transfer. Notable examples of HECT ligases include E6-AP (E6-associated protein) and NEDD4 (Neural Precursor Cell Expressed, Developmentally Down-Regulated 4), which respectively target specific proteins for ubiquitination and regulate the ubiquitination of membrane proteins and signaling molecules.\n\n2.1.2.1 Cullin-RING Ligases\n\n\n\n\n\nCullin-Ring Ligase Mechanisms\n\n\n\n\nThe Cullin-RING ubiquitin ligase (CRL) is a type of RING E3 ubiquitin ligase that plays a crucial role in the ubiquitination and subsequent degradation of specific target proteins within the cell. CRLs are part of a large family of multisubunit E3 ligases, and they are involved in the regulation of various cellular processes, including cell cycle progression, signal transduction, and response to environmental stimuli. Some key features of CRLs include:\n\nComposition: CRLs are modular complexes composed of multiple subunits. The core components include a cullin protein, a RING finger protein, an adaptor protein, and a substrate recognition module. The cullin protein acts as a scaffold, providing a platform for the assembly of the other components.\nCullin Family Members: Cullin proteins are a family of scaffold proteins, with Cul1, Cul2, Cul3, Cul4, Cul5, and Cul7 being the most well-known members. Each cullin family member associates with specific adaptor proteins and substrate recognition modules, conferring specificity to the CRL complex.\nRING Finger Protein: The RING finger protein, often referred to as Rbx1 or Rbx2, is responsible for binding to the E2 ubiquitin-conjugating enzyme and facilitating the transfer of ubiquitin from the E2 enzyme to the target protein.\nAdaptor Protein: The adaptor protein (e.g., Skp1, Elongin C) connects the cullin scaffold to the substrate recognition module, ensuring proper substrate recruitment.\nSubstrate Recognition Module: This module is responsible for recognizing and binding to specific target proteins marked for ubiquitination. Different CRLs have distinct substrate recognition modules, contributing to the specificity of ubiquitination events.\nUbiquitin Transfer: Once assembled, the CRL complex catalyzes the transfer of ubiquitin molecules from the E2 enzyme to the lysine residues on the target protein, leading to the formation of a polyubiquitin chain. This ubiquitin chain serves as a signal for the targeted protein to be recognized and degraded by the proteasome.\nRegulation of CRL Activity: The activity of CRLs is tightly regulated. Post-translational modifications, such as neddylation (attachment of the small ubiquitin-like modifier NEDD8 to cullin), are essential for CRL activation. Additionally, CRLs can be regulated by specific inhibitors and adaptors.\nCellular Functions: Due to their involvement in the ubiquitin-proteasome system, CRLs play critical roles in maintaining cellular homeostasis by controlling the levels of key regulatory proteins. Dysregulation of CRLs has been implicated in various diseases, including cancer.\n\n\n\n\n2.1.3 Marking Proteins by Ubiquitin\n\n\n\n\n\nProtein Marking by Ubiquitin\n\n\n\n\nThe marking of proteins by ubiquitin is a crucial process in cells, ensuring proper protein turnover and regulation. Ubiquitin is a small protein consisting of 76 amino acids. Its structure contains seven lysine residues (K6, K11, K27, K29, K33, K48, and K63) and an N-terminal methionine residue; each possible linkage leads to different cellular reactions.\n\n\n\n\n\nDifferent Linkage Types and Functions of Ubiquitin\n\n\n\n\n\n\n\nDifferent Linkage Types and Functions of Ubiquitin\n\n\n\n\nUbiquitin can attach to target proteins through its lysine residues or its N-terminal methionine residue, forming different types of ubiquitin chains. The most well-characterized ubiquitin chain types are formed through the linkage of ubiquitin molecules via one of its seven lysine residues or through the N-terminal methionine residue. These different linkages lead to diverse cellular outcomes:\n\nLinear Chains: Ubiquitin can also form linear chains where the C-terminal glycine of one ubiquitin molecule is linked to the N-terminal methionine of the next ubiquitin molecule. Linear chains are involved in various signaling pathways, including NF-κB activation and apoptosis."
  },
  {
    "objectID": "chapters/week2.html#n-end-rule-pathway",
    "href": "chapters/week2.html#n-end-rule-pathway",
    "title": "2  Ubiquitin Proteasome System",
    "section": "2.2 N-End Rule Pathway",
    "text": "2.2 N-End Rule Pathway\n\n\n\n\n\nVarious Roles of Deubiquitinase\n\n\n\n\nDeubiquitinases (DUBs) are enzymes that play a crucial role in the regulation of ubiquitin-mediated signaling pathways by removing ubiquitin molecules from proteins. While ubiquitination marks proteins for degradation or alters their function, deubiquitination mediated by DUBs reverses these modifications, allowing for precise control over protein stability, localization, and activity within the cell. They play some of the following roles in cells:\n\nRegulation of Protein Stability: DUBs counteract the activity of ubiquitin ligases by removing ubiquitin chains from proteins targeted for degradation. By deubiquitinating these proteins, DUBs can stabilize them and prevent their degradation by the proteasome. This process is crucial for maintaining the appropriate levels of key regulatory proteins involved in various cellular processes.\nControl of Signaling Pathways: Ubiquitination plays a central role in the regulation of signaling pathways involved in cell growth, differentiation, apoptosis, and immune responses. DUBs modulate these signaling pathways by removing ubiquitin chains from signaling molecules, thereby regulating their activity and localization. For example, DUBs can terminate signaling cascades by deubiquitinating and inactivating key signaling molecules.\nDNA Repair: DUBs are involved in the regulation of DNA repair pathways by controlling the ubiquitination status of proteins involved in DNA damage response and repair. By removing ubiquitin chains from DNA repair proteins, DUBs help maintain genomic integrity and prevent the accumulation of DNA damage.\nEndocytosis and Vesicular Trafficking: DUBs regulate the ubiquitination status of proteins involved in endocytosis, vesicular trafficking, and membrane protein turnover. By deubiquitinating membrane proteins, DUBs can control their internalization, recycling, and degradation, thereby regulating cellular processes such as receptor signaling and membrane protein turnover.\nMitochondrial Dynamics: DUBs play a role in regulating mitochondrial dynamics and function by modulating the ubiquitination status of proteins involved in mitochondrial quality control, fusion, fission, and mitophagy (selective autophagy of damaged mitochondria).\n\n\n2.2.1 What is the Rule?\n\n\n\n\n\nDepiction of the N-End Rule Pathway\n\n\n\n\nThe N-end rule pathway is a proteolytic system found in cells that targets proteins for degradation based on the identity of their N-terminal amino acid residue. This pathway was first proposed by Alexander Varshavsky in the late 1980s and has since been extensively studied in various organisms, including yeast, plants, and mammals. Key features of the N-end rule pathway include:\n\nRecognition of N-terminal Residues: The N-end rule pathway recognizes specific amino acids at the N-terminus of proteins. The identity of the N-terminal residue determines the fate of the protein. Certain amino acids, known as destabilizing residues, target proteins for degradation, while others are considered stabilizing residues.\nDegradation Signal: Proteins with destabilizing N-terminal residues are marked for degradation by the covalent attachment of ubiquitin molecules. This process involves the sequential action of enzymes known as N-terminal amino peptidases and E3 ubiquitin ligases, which recognize and ubiquitinate the target proteins, respectively.\nRecognition by the Proteasome: Ubiquitinated proteins are recognized and degraded by the proteasome, a large multi-subunit protease complex found in the cytoplasm and nucleus of eukaryotic cells. The proteasome cleaves ubiquitinated proteins into short peptides, which can then be further degraded into amino acids by cellular peptidases.\nFunction in Protein Quality Control: The N-end rule pathway serves as an important mechanism for maintaining protein quality control in cells. It targets misfolded or damaged proteins for degradation, thereby preventing the accumulation of potentially harmful protein aggregates and promoting cellular homeostasis.\nRegulation of Cellular Processes: The N-end rule pathway regulates various cellular processes, including cell cycle progression, DNA repair, apoptosis, and response to environmental stresses. By controlling the stability of key regulatory proteins, the N-end rule pathway helps orchestrate cellular responses to internal and external cues.\n\nExamples of destabilizing N-terminal residues include methionine (Met) followed by certain amino acids such as arginine (Arg), lysine (Lys), phenylalanine (Phe), and tryptophan (Trp). These residues are recognized by specific components of the N-end rule pathway and targeted for degradation.\n\n\n2.2.2 Substrates Produced\n\n\n\n\n\nPhysiological Substrates of the N-End Rule Pathway\n\n\n\n\nHere are some examples of physiological substrates of the N-end rule pathway:\n\nTranscription Factors: Certain transcription factors are targeted by the N-end rule pathway for degradation, regulating gene expression and cellular responses to environmental cues. For example, the transcription factor MATα2 in yeast and the transcription factor Pd in mammals are degraded by the N-end rule pathway.\nCell Cycle Regulators: Proteins involved in cell cycle regulation, such as cyclins and cyclin-dependent kinase inhibitors (CDKIs), are substrates of the N-end rule pathway. Degradation of these proteins by the N-end rule pathway helps control cell cycle progression and ensures proper cell division.\nDNA Repair Proteins: Components of DNA repair pathways, including proteins involved in base excision repair, nucleotide excision repair, and homologous recombination, can be targeted by the N-end rule pathway. Degradation of damaged or misfolded DNA repair proteins helps maintain genomic integrity and prevents the accumulation of DNA lesions.\nApoptotic Regulators: Proteins involved in apoptosis, or programmed cell death, are regulated by the N-end rule pathway. For example, certain pro-apoptotic proteins, such as Bid in mammals, are degraded by the N-end rule pathway, contributing to the control of apoptosis.\nCell Signaling Proteins: Components of cell signaling pathways, including kinases, phosphatases, and signaling adapters, can be targeted by the N-end rule pathway. Degradation of signaling proteins by the N-end rule pathway helps regulate cellular responses to extracellular signals and maintain signaling homeostasis.\nProteins with Misfolded or Damaged Domains: Proteins that become misfolded or damaged due to cellular stresses or mutations can be recognized and degraded by the N-end rule pathway. Degradation of misfolded or damaged proteins prevents the accumulation of toxic protein aggregates and promotes cellular health."
  },
  {
    "objectID": "chapters/week2.html#protein-quality-control-by-ups",
    "href": "chapters/week2.html#protein-quality-control-by-ups",
    "title": "2  Ubiquitin Proteasome System",
    "section": "2.3 Protein Quality Control by UPS",
    "text": "2.3 Protein Quality Control by UPS\n\n\n\n\n\nProtein Quality Control by the UPS\n\n\n\n\nThe above figure shows how denatured or misfolded proteins are targeted for destruction by the 26s proteasome. Ubiquitin conjugation marks structures for degradation as previously mentioned.\n\n2.3.1 Protein Secretory Pathway\n\n\n\n\n\nProtein Secretory Pathway\n\n\n\n\nThe protein secretory pathway is a fundamental cellular process responsible for the synthesis, modification, and transport of proteins destined for secretion or localization to various cellular compartments. It involves a series of highly coordinated steps that occur within different organelles and membrane-bound compartments of the cell. Here’s an overview of the protein secretory pathway:\n\nProtein Synthesis in the Cytoplasm: Protein synthesis begins on ribosomes in the cytoplasm, where messenger RNA (mRNA) molecules are translated into polypeptide chains. These polypeptide chains contain signal sequences, often located at the N-terminus, which direct them to the endoplasmic reticulum (ER) for further processing and secretion.\nTranslocation into the Endoplasmic Reticulum (ER): Proteins targeted for secretion or membrane insertion are co-translationally translocated into the lumen of the ER. This process involves the recognition of signal sequences by the signal recognition particle (SRP) and its receptor, which direct the ribosome-nascent chain complex to the ER membrane. Translocation occurs through proteinaceous channels called translocons.\nProtein Folding and Modification in the Endoplasmic Reticulum (ER): Once inside the ER lumen, newly synthesized proteins undergo folding, assembly, and post-translational modifications such as glycosylation, disulfide bond formation, and proteolytic cleavage. These processes ensure proper protein conformation and functionality.\nQuality Control in the Endoplasmic Reticulum (ER): The ER contains mechanisms for quality control to ensure that only properly folded and assembled proteins are transported further along the secretory pathway. Misfolded or unassembled proteins are recognized and targeted for degradation by the ER-associated degradation (ERAD) pathway.\nExport from the Endoplasmic Reticulum (ER): Proteins that pass quality control in the ER are packaged into transport vesicles derived from the ER membrane. These vesicles bud off and fuse with the Golgi apparatus, a central organelle in the secretory pathway.\nProcessing and Sorting in the Golgi Apparatus: Within the Golgi apparatus, proteins undergo further post-translational modifications, including glycosylation, sulfation, phosphorylation, and proteolytic cleavage. The Golgi also acts as a sorting station, directing proteins to their final destinations, such as the plasma membrane, lysosomes, or secretion outside the cell.\nSecretion and Exocytosis: Proteins destined for secretion are transported in vesicles from the trans-Golgi network to the cell surface. Upon reaching the plasma membrane, these vesicles fuse with the membrane through a process called exocytosis, releasing their contents into the extracellular space.\n\n\n\n2.3.2 ER-Associated Degradation\n\n\n\n\n\nDepiction of ERAD\n\n\n\n\n\n\n\n\n\nATPase in Protein Degradation\n\n\n\n\nERAD, or ER-associated degradation, is a quality control mechanism in eukaryotic cells responsible for identifying and targeting misfolded or unassembled proteins in the endoplasmic reticulum (ER) for degradation. The ERAD pathway ensures that only properly folded and functional proteins are allowed to proceed through the secretory pathway and reach their intended destinations within the cell. Here’s how ERAD works:\n\nRecognition of Misfolded Proteins: During protein synthesis, the ER serves as the primary site for the folding and maturation of secretory and membrane proteins. However, not all proteins fold correctly, and misfolded or improperly assembled proteins may accumulate in the ER lumen or membrane. These misfolded proteins are recognized by ER quality control systems, which include chaperone proteins and lectins that monitor protein folding status.\nUbiquitination: Upon recognition of misfolded proteins, they are targeted for degradation through the covalent attachment of ubiquitin molecules. Ubiquitination is mediated by a series of enzymes, including ubiquitin-activating enzymes (E1s), ubiquitin-conjugating enzymes (E2s), and ubiquitin ligases (E3s). In the case of ERAD, specific E3 ubiquitin ligases recognize misfolded proteins and facilitate their ubiquitination.\nExtraction from the ER Membrane: Misfolded membrane proteins must be extracted from the ER membrane before they can be degraded by the proteasome, a large proteolytic complex found in the cytoplasm. This extraction process involves the action of protein complexes such as the ATPase-containing Cdc48/p97 complex (also known as valosin-containing protein, VCP, in mammals), which extracts the misfolded proteins from the ER membrane into the cytoplasm.\nDegradation by the Proteasome: Once extracted from the ER membrane, ubiquitinated misfolded proteins are targeted to the proteasome for degradation. The proteasome recognizes polyubiquitinated proteins and proteolytically cleaves them into short peptides. These peptides can then be further degraded into amino acids by cytoplasmic peptidases.\nRegulation and Coordination: The ERAD pathway is tightly regulated to ensure efficient removal of misfolded proteins while minimizing the degradation of properly folded proteins. It involves coordination between various components, including chaperones, ubiquitin ligases, and the proteasome, as well as post-translational modifications and signaling pathways.\n\n\n2.3.2.1 Cdc48 / p97: AAA+ ATPase in Protein Degradation\n\n\n\n\n\nATPase Types in Organisms and Activities\n\n\n\n\n\n\n\nATPase Types in Organisms and Activities\n\n\n\n\n\n\n\n\n\nATPase Activities in ERAD\n\n\n\n\nThe AAA+ (ATPases Associated with diverse cellular Activities) family of proteins is a large and diverse group of ATPases found in all domains of life. These proteins share a common structural feature known as the AAA+ domain, which is characterized by conserved sequence motifs and is responsible for ATP binding and hydrolysis. AAA+ proteins participate in a wide range of cellular processes, including protein degradation, DNA replication, DNA repair, membrane fusion, and vesicle trafficking. Here’s an overview of the general mechanism of AAA+ family proteins:\n\nOligomerization: AAA+ proteins typically function as oligomers, forming complex structures composed of multiple subunits. These subunits may assemble into hexameric rings, double rings, or other higher-order oligomeric structures depending on the specific protein and its function.\nATP Binding and Hydrolysis: The AAA+ domain contains conserved Walker A and Walker B motifs, which are responsible for ATP binding and hydrolysis, respectively. Upon ATP binding, conformational changes occur within the AAA+ domain, resulting in the formation of a catalytically active ATPase site. ATP hydrolysis fuels the mechanical work performed by AAA+ proteins, driving conformational changes that are often essential for their biological functions.\nSubstrate Recognition and Binding: AAA+ proteins interact with specific substrate molecules through specialized substrate-binding domains or motifs located adjacent to the AAA+ domain. These substrate-binding domains recognize and bind to target proteins, nucleic acids, or other substrates, facilitating their processing, modification, or degradation.\nMechanical Work and Substrate Remodeling: ATP hydrolysis by AAA+ proteins generates mechanical force that drives conformational changes in the protein complex. These conformational changes can result in the remodeling, unfolding, or translocation of substrates, depending on the specific function of the AAA+ protein. For example, AAA+ proteins involved in protein degradation may unfold and translocate substrate proteins through a central pore formed by the AAA+ oligomer.\nRegulation and Coordination: The activity of AAA+ proteins is tightly regulated to ensure proper timing and coordination of cellular processes. Regulation may involve factors such as post-translational modifications, cofactors, allosteric regulators, and interactions with other proteins or cellular components. For example, ATP binding and hydrolysis kinetics, as well as interactions with regulatory proteins, can modulate the activity of AAA+ proteins involved in DNA replication or protein degradation.\n\n\n\n\n2.3.3 Cdc48 / p97 Function in UBS\n\n\n\n\n\nRole of Cdc48 / p97 in the UBS\n\n\n\n\nCdc48, also known as p97 in mammals, is a highly conserved AAA+ (ATPases Associated with diverse cellular Activities) ATPase protein that plays a crucial role in various cellular processes, including the ubiquitin-proteasome system (UPS). Its function in the UPS is diverse and multifaceted, contributing to protein quality control, protein degradation, and various cellular pathways. Here’s an overview of the functions of Cdc48/p97 in the ubiquitin-proteasome system:\n\nProtein Degradation and ERAD (ER-Associated Degradation): Cdc48/p97 is a central player in ERAD, a quality control mechanism responsible for identifying and targeting misfolded or unassembled proteins in the endoplasmic reticulum (ER) for degradation by the proteasome. Cdc48/p97 extracts ubiquitinated substrates from the ER membrane and facilitates their delivery to the proteasome for degradation. It collaborates with other ERAD components, including E3 ubiquitin ligases and ubiquitin-conjugating enzymes, to ensure efficient protein degradation and maintain ER homeostasis.\nUbiquitin-Dependent Protein Degradation: Cdc48/p97 participates in the degradation of ubiquitinated proteins in the cytoplasm and nucleus. It collaborates with specific ubiquitin ligases to extract ubiquitinated proteins from cellular structures, protein complexes, or membranes, facilitating their degradation by the proteasome. Cdc48/p97 also plays a role in disassembling protein complexes or aggregates targeted for degradation, promoting the recycling of ubiquitin and preventing the accumulation of toxic protein aggregates.\nCell Cycle Regulation: Cdc48/p97 is involved in various aspects of cell cycle regulation, including mitotic progression, DNA replication, and DNA repair. It participates in the turnover of cell cycle regulators, DNA replication factors, and checkpoint proteins by facilitating their ubiquitin-dependent degradation. Cdc48/p97-mediated protein degradation ensures proper cell cycle progression and maintenance of genomic integrity.\nProtein Quality Control and Stress Response: Cdc48/p97 contributes to protein quality control and stress response pathways by eliminating misfolded, damaged, or aggregated proteins. It collaborates with molecular chaperones, proteases, and other protein quality control factors to recognize, extract, and degrade aberrant proteins, thereby maintaining cellular homeostasis and viability under stress conditions.\nMembrane Dynamics and Vesicle Trafficking: Cdc48/p97 participates in membrane dynamics, vesicle trafficking, and organelle biogenesis by regulating the turnover of membrane-associated proteins and lipid-modifying enzymes. It mediates the extraction and degradation of membrane proteins involved in membrane fusion, vesicle formation, and organelle assembly, contributing to the maintenance of cellular membrane integrity and function."
  },
  {
    "objectID": "chapters/week2.html#degradation-by-the-proteasome",
    "href": "chapters/week2.html#degradation-by-the-proteasome",
    "title": "2  Ubiquitin Proteasome System",
    "section": "2.4 Degradation by the Proteasome",
    "text": "2.4 Degradation by the Proteasome\n\n\n\n\n\nStructure of the Proteasome\n\n\n\n\nThe proteasome, a critical component of cellular protein degradation machinery, is a large, multi-subunit protease complex found within eukaryotic cells. It plays a fundamental role in maintaining cellular homeostasis by selectively degrading proteins marked for destruction by ubiquitin. Structurally, the proteasome consists of a core particle, known as the 20S proteasome, which serves as the central catalytic unit responsible for protein degradation. This cylindrical core particle comprises four stacked rings, with two outer rings composed of seven α subunits each and two inner rings made up of seven β subunits each.\nEach β subunit within the 20S proteasome possesses catalytic activity, allowing the proteasome to cleave peptide bonds within target proteins. The β subunits are categorized into three distinct types: β1, β2, and β5, each exhibiting specific peptidase activities. The β1 subunits display caspase-like activity, cleaving after acidic residues; the β2 subunits exhibit trypsin-like activity, cleaving after basic residues; and the β5 subunits demonstrate chymotrypsin-like activity, cleaving after hydrophobic residues.\nProteins targeted for degradation are tagged with a small protein called ubiquitin, marking them for recognition and processing by the proteasome. The recognition and degradation of ubiquitinated proteins involve a complex series of events coordinated by various cellular components, including E1 ubiquitin-activating enzymes, E2 ubiquitin-conjugating enzymes, and E3 ubiquitin ligases. Once recognized, ubiquitinated proteins are unfolded and translocated into the central chamber of the 20S proteasome, where they undergo proteolytic degradation into short peptide fragments.\n\n2.4.1 Multiple Myeloma and Proteasome Inhibitor\n\n\n\n\n\nInhibitors of the Proteasome and Multiple Myeloma\n\n\n\n\nMultiple myeloma is a kind of cancer of the plasma cells. One’s risk of developing multiple myeloma increases as they become older - most people who have this kind of cancer get diagnosed in their mid-60s.\n\n\n\n\n\nComparison Between a B Cell and a Plasma Cell\n\n\n\n\nSome symptoms of this cancer include:\n\nAnemia (i.e., a shortage of red blood cells) resulting in fatigue\nThrombocytopenia (i.e., a lack of platelets) resulting in easy bleeding and bruising\nLeukopenia (i.e., a lack of white blood cells) resulting in frequent infections\n\n\n\n2.4.2 Aneuploidy and Toxic Stress\n\n\n\n\n\nAneuploidy and Toxic Stress\n\n\n\n\nAneuploidy refers to an abnormal number of chromosomes in a cell, typically resulting from errors in cell division processes such as mitosis or meiosis. This condition leads to cells having either fewer or more chromosomes than the normal diploid number characteristic of the species. Aneuploidy can occur in various organisms, including humans, and it is associated with several health conditions, including developmental disorders and cancer.\nProteotoxic stress, on the other hand, refers to the cellular stress caused by an imbalance in protein homeostasis, leading to the accumulation of misfolded or aggregated proteins. Proteotoxic stress can result from various factors such as environmental stressors, genetic mutations, or disruptions in protein quality control mechanisms. The accumulation of misfolded proteins can overwhelm the cellular protein degradation systems, including the ubiquitin-proteasome system and autophagy pathways, leading to cellular dysfunction and disease.\nAneuploid cells often experience proteotoxic stress due to alterations in gene dosage and expression resulting from chromosome imbalances. The abnormal expression levels of genes encoding chaperones, proteases, and components of the protein degradation machinery can disrupt protein folding, assembly, and turnover processes, contributing to proteotoxic stress in aneuploid cells.\nConversely, proteotoxic stress can also promote aneuploidy by inducing genomic instability and impairing cell division processes. Misfolded or aggregated proteins can interfere with the function of key cellular pathways involved in DNA replication, repair, and chromosome segregation, leading to the accumulation of genetic abnormalities and aneuploidy over time.\n\n\n2.4.3 Problems with Proteasomal Degradation\n\n\n\n\n\nProblems Associated with Proteasomal Degradation\n\n\n\n\n\n\n\nProblems Associated with Proteasomal Degradation\n\n\n\n\nSeveral problems can arise when proteasomal degradation is impaired or dysregulated:\n\nAccumulation of Misfolded or Damaged Proteins: Impaired proteasomal degradation can lead to the accumulation of misfolded or damaged proteins within cells. These proteins may form aggregates or toxic oligomers, disrupting cellular function and contributing to the pathogenesis of neurodegenerative diseases such as Alzheimer’s, Parkinson’s, and Huntington’s disease.\nDysregulation of Protein Turnover: Proper protein turnover is essential for maintaining cellular function and responding to dynamic changes in cellular environments. Dysregulation of proteasomal degradation can disrupt protein turnover rates, leading to the accumulation of specific proteins that are not degraded when they should be, or the premature degradation of proteins essential for cellular processes.\nProtein Aggregation and Neurodegeneration: Impaired proteasomal degradation is implicated in the pathogenesis of neurodegenerative diseases characterized by the accumulation of protein aggregates, such as tau tangles in Alzheimer’s disease and α-synuclein aggregates in Parkinson’s disease. The failure to clear these aggregates can lead to neuronal dysfunction and cell death.\nCell Cycle Dysregulation: The proteasome plays a crucial role in regulating cell cycle progression by degrading key cell cycle regulators, such as cyclins and cyclin-dependent kinase inhibitors. Dysregulation of proteasomal degradation can lead to aberrant cell cycle progression, uncontrolled cell proliferation, and genomic instability, contributing to cancer development and progression.\nImmune System Dysfunction: The proteasome is involved in the processing of antigens for presentation on major histocompatibility complex (MHC) molecules, a critical step in the activation of the immune response. Impaired proteasomal degradation can lead to defects in antigen presentation, compromising immune surveillance and response to pathogens.\nDrug Resistance in Cancer: Cancer cells often develop resistance to chemotherapy drugs by upregulating proteasomal activity, leading to increased degradation of anti-cancer proteins. Targeting the proteasome with proteasome inhibitors can overcome drug resistance in some cases by inducing apoptosis in cancer cells.\nAging and Age-Related Diseases: Dysregulation of proteasomal degradation is associated with aging and age-related diseases. As cells age, the efficiency of proteasomal degradation declines, leading to the accumulation of damaged proteins and contributing to the aging process and age-related diseases."
  },
  {
    "objectID": "chapters/week2.html#ups-and-neurodegeneration",
    "href": "chapters/week2.html#ups-and-neurodegeneration",
    "title": "2  Ubiquitin Proteasome System",
    "section": "2.5 UPS and Neurodegeneration",
    "text": "2.5 UPS and Neurodegeneration\n\n\n\n\n\nImpact of Protein Aggregates on the UPS\n\n\n\n\nProtein aggregates, which result from the misfolding and aggregation of proteins, can have significant impacts on the Ubiquitin-Proteasome System (UPS), the primary mechanism responsible for protein degradation in eukaryotic cells. Here are some key impacts of protein aggregates on the UPS:\n\nOverload of the UPS: Protein aggregates can overwhelm the capacity of the UPS, leading to a backlog of ubiquitinated proteins awaiting degradation. The UPS relies on the coordinated action of E1 ubiquitin-activating enzymes, E2 ubiquitin-conjugating enzymes, and E3 ubiquitin ligases to tag proteins with ubiquitin for degradation by the proteasome. However, the excessive accumulation of misfolded or aggregated proteins can saturate the UPS, impairing its ability to degrade other cellular proteins.\nInhibition of Proteasomal Activity: Protein aggregates can directly inhibit proteasomal activity by physically obstructing the proteasome’s access to substrate proteins or by interfering with the unfolding and translocation of substrates into the proteasomal core particle. Additionally, certain types of protein aggregates, such as amyloid fibrils, can bind to and sequester proteasomal subunits, further impairing proteasome function.\nInduction of Proteasome Stress: The presence of protein aggregates within cells can induce a cellular stress response known as proteasome stress. Proteasome stress is characterized by the upregulation of genes encoding proteasome subunits, as well as components of the UPS and protein quality control machinery. While proteasome stress initially serves to enhance the cell’s capacity to degrade misfolded proteins, chronic or severe proteasome stress can lead to cellular dysfunction and apoptosis.\nFormation of Resistant Aggregates: Some protein aggregates, particularly those associated with neurodegenerative diseases such as Alzheimer’s and Parkinson’s disease, are highly stable and resistant to degradation by the UPS. These aggregates may contain cross-linked or ubiquitinated proteins that are difficult for the proteasome to recognize and process. As a result, the accumulation of resistant protein aggregates can exacerbate proteotoxicity and contribute to disease progression.\nImpairment of Protein Quality Control Pathways: The presence of protein aggregates can impair other protein quality control pathways, such as chaperone-mediated autophagy (CMA) and macroautophagy. While the UPS primarily degrades short-lived and soluble proteins, autophagy pathways are responsible for the degradation of larger protein aggregates and damaged organelles. However, the chronic accumulation of protein aggregates can overwhelm autophagy pathways, further exacerbating proteotoxicity and cellular dysfunction."
  },
  {
    "objectID": "chapters/week3.html",
    "href": "chapters/week3.html",
    "title": "3  Regulating Protein Synthesis",
    "section": "",
    "text": "Outline of the Central Dogma\nThe central dogma of molecular biology is a fundamental principle that describes the flow of genetic information within a biological system, particularly in cells. Proposed by Francis Crick in 1958, the central dogma outlines the sequential processes by which genetic information encoded in DNA is transferred to RNA and eventually translated into proteins. The central dogma can be summarized in three main steps:"
  },
  {
    "objectID": "chapters/week3.html#structure-and-synthesis-of-the-ribosome",
    "href": "chapters/week3.html#structure-and-synthesis-of-the-ribosome",
    "title": "3  Regulating Protein Synthesis",
    "section": "3.1 Structure and Synthesis of the Ribosome",
    "text": "3.1 Structure and Synthesis of the Ribosome\n\n\n\n\n\nDifferences Between Eukaryotic and Prokaryotic Ribosomes\n\n\n\n\nProkaryotic ribosomes are composed of two subunits: a large 50S subunit and a small 30S subunit, which together form the 70S ribosome. The 70S ribosome is the site of protein synthesis in prokaryotic cells. Prokaryotic ribosomes are smaller than eukaryotic ribosomes, with the 50S subunit having a sedimentation coefficient of 50S and the 30S subunit having a sedimentation coefficient of 30S. They contain ribosomal RNA (rRNA) and protein components, with the 50S subunit containing 23S and 5S rRNA molecules, and the 30S subunit containing 16S rRNA.\nEukaryotic ribosomes are larger and more complex than prokaryotic ribosomes, consisting of a large 60S subunit and a small 40S subunit, which together form the 80S ribosome. The 80S ribosome is the site of protein synthesis in eukaryotic cells. Eukaryotic ribosomes are larger than prokaryotic ribosomes, with the 60S subunit having a sedimentation coefficient of 60S and the 40S subunit having a sedimentation coefficient of 40S. They also contain rRNA and protein components, with the 60S subunit containing 28S, 5.8S, and 5S rRNA molecules, and the 40S subunit containing 18S rRNA.\n\n3.1.1 Ribosome Synthesis\n\n\n\n\n\nRibosome Synthesis Outline\n\n\n\n\nRibosome synthesis primarily occurs within the nucleolus, a distinct subcompartment of the cell nucleus responsible for ribosome biogenesis. The nucleolus is the site where ribosomal RNA (rRNA) transcription, processing, and assembly with ribosomal proteins take place, leading to the formation of functional ribosomes. Here’s an overview of ribosome synthesis in the nucleolus:\n\nrRNA Transcription: The process of ribosome synthesis begins with the transcription of rRNA genes by RNA polymerase I (Pol I) within the nucleolus. These rRNA genes are organized into tandem repeats known as nucleolar organizer regions (NORs) located on specific chromosomes. The transcription of rRNA genes generates a large precursor molecule called pre-rRNA.\nPre-rRNA Processing: The pre-rRNA transcript undergoes extensive processing to generate mature rRNAs, including the 18S, 5.8S, and 28S rRNAs found in eukaryotic ribosomes. Processing involves the removal of spacer sequences and the cleavage of pre-rRNA intermediates by a complex machinery of small nucleolar ribonucleoproteins (snoRNPs) and endonucleases. This processing occurs in distinct subcompartments of the nucleolus, known as the fibrillar center and the dense fibrillar component.\nAssembly of Ribosomal Subunits: Once processed, the mature rRNAs associate with ribosomal proteins to form the small (40S) and large (60S) ribosomal subunits. The assembly of ribosomal subunits occurs in a stepwise manner, involving the coordinated binding of ribosomal proteins to specific regions of the rRNA molecules. The nucleolus provides the necessary environment and factors for efficient assembly, ensuring the proper folding and stability of the ribosomal subunits.\nExport of Ribosomal Subunits: After assembly, the mature ribosomal subunits are exported from the nucleolus to the cytoplasm, where they participate in protein synthesis. This export process involves the recognition of specific export signals within the ribosomal subunits by nuclear export receptors and the translocation of ribosomal subunits through nuclear pores. Once in the cytoplasm, the small and large ribosomal subunits associate with messenger RNA (mRNA) and transfer RNA (tRNA) molecules to form functional ribosomes capable of protein synthesis.\n\n\n\n3.1.2 RNA Binding Sites\n\n\n\n\n\nThe Four RNA Binding Sites\n\n\n\n\nRibosomes possess three primary binding sites crucial for the translation process: the A (Aminoacyl) site, the P (Peptidyl) site, and the E (Exit) site. These sites facilitate the interaction between mRNA, tRNA, and ribosomal subunits during protein synthesis. In the A site, incoming aminoacyl-tRNA molecules bearing amino acids align with the mRNA codon, ensuring the correct addition of amino acids to the growing polypeptide chain. The P site harbors the peptidyl-tRNA, where the nascent polypeptide chain is elongated by the addition of amino acids. Finally, the E site accommodates the exit of deacylated tRNA molecules following peptide bond formation, enabling the recycling of tRNA for subsequent rounds of translation.\nTranslation proceeds through four main steps: initiation, elongation, termination, and ribosome recycling. During initiation, the small ribosomal subunit binds to the mRNA molecule at the start codon, guided by initiation factors and the initiator tRNA. Following initiation, the large ribosomal subunit joins the complex, forming the functional ribosome ready for protein synthesis. In the elongation phase, aminoacyl-tRNA molecules enter the A site, and peptide bond formation occurs between the amino acids carried by the tRNAs in the A and P sites. The ribosome moves along the mRNA in a 5’ to 3’ direction, synthesizing the polypeptide chain one amino acid at a time.\nTermination occurs when the ribosome encounters a stop codon (UAA, UAG, or UGA) on the mRNA. Release factors bind to the A site, promoting the hydrolysis of the bond between the completed polypeptide chain and the tRNA in the P site. This leads to the release of the polypeptide chain from the ribosome and the dissociation of the ribosomal subunits from the mRNA. Finally, in the ribosome recycling phase, ribosome recycling factors facilitate the disassembly of the ribosome complex, allowing the small and large subunits to be reused for subsequent rounds of translation. This cycle ensures the continuous synthesis of proteins in the cell, crucial for various cellular functions and processes."
  },
  {
    "objectID": "chapters/week3.html#initiating-translation",
    "href": "chapters/week3.html#initiating-translation",
    "title": "3  Regulating Protein Synthesis",
    "section": "3.2 Initiating Translation",
    "text": "3.2 Initiating Translation\n\n\n\n\n\nDepiction of the Shine-Dalgarno Sequence\n\n\n\n\nIn prokaryotes, the Shine-Dalgarno sequence is a conserved nucleotide sequence found in the mRNA, typically positioned upstream of the start codon (AUG) within the ribosome binding site (RBS). The Shine-Dalgarno sequence facilitates the recognition and binding of the mRNA by the small ribosomal subunit during the initiation of translation.\nThe Shine-Dalgarno sequence is characterized by the presence of a purine-rich region, often containing the consensus sequence AGGAGG. This sequence is complementary to a region of the 16S ribosomal RNA (rRNA) found in the small ribosomal subunit. The interaction between the Shine-Dalgarno sequence in the mRNA and the complementary sequence in the 16S rRNA helps position the ribosome correctly on the mRNA, ensuring accurate initiation of protein synthesis.\nDuring translation initiation in prokaryotes, the small ribosomal subunit, along with initiation factors, recognizes and binds to the Shine-Dalgarno sequence on the mRNA. This binding facilitates the scanning of the mRNA by the ribosome until it reaches the start codon (usually AUG). Once the start codon is encountered, the large ribosomal subunit joins the complex, and protein synthesis proceeds along the mRNA.\n\n3.2.1 Initiation Factors in Bacteria\n\n\n\n\n\nSome Bacterial Initiation Factors\n\n\n\n\nIn bacterial translation initiation, several initiation factors play critical roles in orchestrating the assembly of the translation initiation complex and ensuring accurate start codon recognition. Two key initiation factors in bacteria are IF1 and IF3, which prevent premature association of the large 50S ribosomal subunit with the small 30S subunit, thereby promoting the formation of the initiation complex on the mRNA.\n\nIF1: IF1 is an initiation factor that helps prevent the premature binding of the 50S ribosomal subunit to the 30S subunit, ensuring that translation initiation occurs accurately at the start codon. IF1 also stabilizes the 30S subunit and helps maintain its integrity during the initiation process.\nIF3: IF3 is another initiation factor that contributes to the fidelity of translation initiation by preventing the association of the 50S subunit with the 30S subunit until the initiation complex is properly assembled on the mRNA. IF3 also helps dissociate ribosomes at the termination of translation.\n\nIn addition to IF1 and IF3, IF2 is a critical initiation factor responsible for delivering the initiator tRNA (fMet-tRNAfMet) to the ribosomal complex during translation initiation. IF2 is a GTPase, meaning it hydrolyzes GTP to GDP during its function in the initiation process. The binding of IF2-GTP to the initiator tRNA stabilizes its interaction with the 30S ribosomal subunit and helps position it correctly within the ribosomal P site, ensuring accurate start codon recognition and initiation of protein synthesis.\n\n\n3.2.2 In Eukaryotes\n\n\n\n\n\nInitiating Translation in Eukaryotes\n\n\n\n\nHere’s an overview of the key steps involved in translation initiation in eukaryotic cells:\n\nRecognition of the 5’ Cap Structure: Translation initiation in eukaryotes begins with the recognition of the 5’ cap structure present at the 5’ end of the mRNA molecule. The 5’ cap is recognized by the eukaryotic initiation factor 4E (eIF4E), which forms part of the eIF4F complex along with eIF4A (helicase) and eIF4G (scaffolding protein).\nRecruitment of the 40S Ribosomal Subunit: The eIF4F complex, bound to the 5’ cap structure, recruits the 40S small ribosomal subunit. This recruitment is facilitated by the interaction between eIF4G and the poly(A)-binding protein (PABP) bound to the poly(A) tail of the mRNA, forming a closed-loop structure that enhances translation efficiency.\nScanning for the Start Codon: The 40S subunit, together with initiation factors (eIF1, eIF1A, and eIF3), scans along the mRNA in a 5’ to 3’ direction until it encounters the start codon (AUG) within a favorable Kozak sequence context. The Kozak sequence (consensus sequence: GCCRCCAUGG) surrounding the start codon helps ensure accurate start codon recognition.\nInitiator tRNA Binding: Upon recognition of the start codon, the initiator tRNA (Met-tRNAiMet) bound to eukaryotic initiation factor 2 (eIF2) and GTP forms a ternary complex. This ternary complex is then recruited to the ribosome, where it base pairs with the start codon in the mRNA.\nAssembly of the 80S Initiation Complex: Once the initiator tRNA is properly positioned at the start codon, GTP bound to eIF2 is hydrolyzed to GDP and Pi, resulting in the release of eIF2-GDP from the ribosome. The 60S large ribosomal subunit then joins the 40S subunit to form the 80S initiation complex, with the initiator tRNA occupying the P site of the ribosome.\nInitiation Factor Dissociation and Start of Elongation: Following the assembly of the 80S initiation complex, initiation factors eIF1, eIF1A, and eIF3 are released from the ribosome, allowing for the start of elongation. Elongation factors, along with charged tRNAs and GTP, facilitate the stepwise addition of amino acids to the growing polypeptide chain.\n\n\n\n3.2.3 5’ UTR in Eukaryotes\n\n\n\n\n\nIllustration of the 5’ UTR in Eukaryotes\n\n\n\n\nIn eukaryotic translation initiation, the 5’ untranslated region (5’ UTR) of mRNA plays a crucial role in directing ribosomes to the correct start codon for protein synthesis. The process of 5’ UTR scanning involves the stepwise movement of ribosomes along the 5’ UTR until they identify and initiate translation at the appropriate start codon. Here’s how 5’ UTR scanning occurs in eukaryotes:\n\nRecognition of the 5’ Cap Structure: Translation initiation begins with the recognition of the 5’ cap structure present at the 5’ end of the mRNA molecule. The 5’ cap consists of a modified guanosine nucleotide (7-methylguanosine) added during mRNA transcription. The cap structure is recognized by eukaryotic initiation factors (eIFs), particularly eIF4E, which is a component of the eIF4F complex.\nRecruitment of the 43S Pre-initiation Complex: The eIF4F complex, bound to the 5’ cap structure, recruits the 43S pre-initiation complex, which comprises the 40S small ribosomal subunit, eIF3, eIF1, eIF1A, and the ternary complex consisting of initiator tRNA (Met-tRNAiMet) and eIF2-GTP (eukaryotic initiation factor 2 bound to guanosine triphosphate).\nScanning of the 5’ UTR: The 43S pre-initiation complex, guided by eIF4F, scans along the 5’ UTR of the mRNA in a 5’ to 3’ direction. The scanning process is facilitated by the interaction between eIF4G, a component of the eIF4F complex, and the poly(A)-binding protein (PABP) bound to the poly(A) tail of the mRNA. This interaction helps maintain the circular structure of the mRNA, allowing the ribosome to scan efficiently.\nRecognition of the Start Codon: As the 43S pre-initiation complex scans along the 5’ UTR, it encounters the start codon (AUG) embedded within the Kozak consensus sequence. The Kozak sequence (GCC(A/G)CCAUGG) surrounding the start codon helps facilitate accurate start codon recognition by the ribosome.\nFormation of the 48S Initiation Complex: Upon recognition of the start codon, base pairing occurs between the initiator tRNA (Met-tRNAiMet) and the start codon. GTP bound to eIF2 is hydrolyzed to GDP and Pi, leading to the release of eIF2-GDP and other initiation factors. The 60S large ribosomal subunit then joins the 40S subunit to form the 80S initiation complex, ready for translation elongation.\n\n\n\n3.2.4 Prokaryotic and Eukaryotic mRNA\n\n\n\n\n\nDifferent Kinds of mRNA\n\n\n\n\nProkaryotic and eukaryotic mRNA serve as intermediaries between DNA and protein synthesis, yet they exhibit notable differences in structure, processing, and regulation. Prokaryotic mRNA tends to have a simpler structure, lacking extensive post-transcriptional modifications commonly found in eukaryotic mRNA. In prokaryotes, mRNA molecules are often polycistronic, capable of encoding multiple proteins within a single transcript. Conversely, eukaryotic mRNA is typically monocistronic, encoding only one protein per transcript, adding to the complexity of gene expression regulation.\nEukaryotic mRNA undergoes comprehensive post-transcriptional processing, including 5’ capping, splicing, and polyadenylation, which stabilize the molecule and optimize translation initiation. This processing ensures the production of mature mRNA molecules ready for efficient translation. In contrast, prokaryotic mRNA generally lacks such extensive post-transcriptional modifications, being synthesized as mature transcripts directly by RNA polymerase.\nRegulatory mechanisms governing mRNA expression differ significantly between prokaryotes and eukaryotes. In eukaryotic cells, gene expression is tightly regulated at various levels, including chromatin remodeling, transcription initiation, mRNA processing, nuclear export, and mRNA stability. Prokaryotic gene expression, on the other hand, primarily occurs at the transcriptional level, although regulatory RNA elements and proteins can also modulate mRNA stability and translation efficiency.\nProkaryotic mRNA features a Shine-Dalgarno sequence upstream of the start codon, facilitating ribosome binding and translation initiation. In contrast, eukaryotic mRNA lacks a Shine-Dalgarno sequence and relies on the recognition of the 5’ cap structure by initiation factors to initiate translation. The ribosome then scans along the 5’ untranslated region until it encounters the start codon."
  },
  {
    "objectID": "chapters/week3.html#regulating-translation-initiation",
    "href": "chapters/week3.html#regulating-translation-initiation",
    "title": "3  Regulating Protein Synthesis",
    "section": "3.3 Regulating Translation Initiation",
    "text": "3.3 Regulating Translation Initiation\n\n\n\n\n\nmTORC1 Phosphorylating eIF4E-Binding Protein\n\n\n\n\nThe phosphorylation of eIF4E-binding proteins (4E-BPs) by the mechanistic target of rapamycin complex 1 (mTORC1) is a critical regulatory event in the control of protein synthesis in eukaryotic cells. 4E-BPs are a family of proteins that bind to eIF4E, preventing its interaction with the mRNA 5’ cap structure and thereby inhibiting translation initiation. Here’s an overview of how mTORC1 regulates protein synthesis through the phosphorylation of 4E-BPs:\n\nmTORC1 Activation: The mechanistic target of rapamycin complex 1 (mTORC1) is a key regulator of cell growth and metabolism that integrates various signals, including growth factors, nutrients, energy status, and stress, to control protein synthesis and cell proliferation. When activated, mTORC1 phosphorylates downstream targets involved in protein synthesis, including 4E-BPs.\nPhosphorylation of 4E-BPs: In response to favorable growth conditions and signaling cues, mTORC1 phosphorylates 4E-BPs at multiple serine and threonine residues. Phosphorylation of 4E-BPs induces a conformational change that reduces their affinity for eIF4E, allowing eIF4E to interact with eIF4G and other initiation factors to form the eIF4F complex. The eIF4F complex then associates with the mRNA 5’ cap structure, promoting translation initiation.\nRelease of eIF4E: Upon phosphorylation by mTORC1, 4E-BPs dissociate from eIF4E, freeing eIF4E to participate in the assembly of the translation initiation complex. By releasing eIF4E from its inhibitory interaction with 4E-BPs, mTORC1 activation promotes the recruitment of ribosomes to mRNA transcripts and enhances protein synthesis rates.\nRegulation of Gene Expression: The phosphorylation of 4E-BPs by mTORC1 represents a key regulatory mechanism that controls the translation of specific mRNAs involved in cell growth, proliferation, and metabolism. By modulating the activity of 4E-BPs, mTORC1 fine-tunes the translational output of cells in response to extracellular signals and nutrient availability, ensuring efficient protein synthesis under conditions favorable for cell growth and survival.\n\n\n3.3.1 eIF2 Cycle\n\n\n\n\n\nCycle of eIF2\n\n\n\n\nThe eukaryotic translation initiation factor 2 (eIF2) cycle is a fundamental process in protein synthesis regulation, controlling the initiation of translation in response to various cellular stresses and environmental cues. Here’s an overview of the eIF2 cycle:\n\nGTP-bound eIF2 Complex Formation: In its inactive state, eIF2 is bound to guanosine triphosphate (GTP) and forms a complex with initiator tRNA (Met-tRNAiMet), termed the ternary complex (eIF2-GTP-Met-tRNAiMet). This ternary complex plays a crucial role in delivering the initiator tRNA to the ribosome during translation initiation.\nRecognition of Start Codon: The eIF2-GTP-Met-tRNAiMet complex associates with the small ribosomal subunit (40S) and scans the mRNA transcript for the start codon (AUG). Once the start codon is recognized, the ternary complex positions the initiator tRNA at the ribosomal P site, ready to initiate translation.\nGTP Hydrolysis: Upon accurate recognition of the start codon, GTP bound to eIF2 is hydrolyzed to guanosine diphosphate (GDP) and inorganic phosphate (Pi) by the GTPase activity of eIF2. This hydrolysis reaction is facilitated by eIF5, a GTPase-activating protein (GAP) that stimulates the intrinsic GTPase activity of eIF2.\nRelease of eIF2-GDP: Following GTP hydrolysis, eIF2-GDP is released from the ribosome and recycled back to its active form through the exchange of GDP for GTP. This exchange is catalyzed by eIF2B, a guanine nucleotide exchange factor (GEF) that promotes the reactivation of eIF2 by loading GTP onto eIF2, allowing it to participate in subsequent rounds of translation initiation.\nRegulation by Phosphorylation: The activity of eIF2 is tightly regulated by phosphorylation of its α-subunit at a conserved serine residue (Ser51) by specific kinases in response to various stress signals. Phosphorylation of eIF2α inhibits the guanine nucleotide exchange activity of eIF2B, leading to a decrease in the formation of active eIF2-GTP complexes and a consequent reduction in global protein synthesis rates. This integrated stress response (ISR) helps cells adapt to adverse conditions by conserving energy and resources.\n\n\n3.3.1.1 Inactivating eIF2\n\n\n\n\n\nHow eIF2 Can be Inactivated\n\n\n\n\nThe inactivation of eukaryotic translation initiation factor 2B (eIF2B) by phosphorylated eIF2 is a key regulatory mechanism in the integrated stress response (ISR) pathway. eIF2B is a guanine nucleotide exchange factor (GEF) responsible for catalyzing the exchange of guanosine diphosphate (GDP) for guanosine triphosphate (GTP) on eukaryotic translation initiation factor 2 (eIF2), thereby promoting the formation of the active eIF2-GTP ternary complex essential for translation initiation. Here’s how the inactivation process occurs:\n\nPhosphorylation of eIF2: In response to various stress stimuli such as amino acid deprivation, viral infection, endoplasmic reticulum (ER) stress, or oxidative stress, specific kinases phosphorylate the alpha subunit of eIF2 (eIF2α) at a conserved serine residue (Ser51). These kinases include protein kinase R (PKR), heme-regulated inhibitor kinase (HRI), PKR-like endoplasmic reticulum kinase (PERK), and general control non-derepressible 2 (GCN2). Phosphorylation of eIF2α at Ser51 inhibits the GDP-GTP exchange activity of eIF2B, leading to the sequestration of eIF2 in its inactive GDP-bound form.\nAttenuation of Guanine Nucleotide Exchange Activity: Phosphorylated eIF2 (eIF2α-P) binds tightly to eIF2B, resulting in the sequestration and inhibition of eIF2B’s guanine nucleotide exchange activity. As a consequence, the recycling of eIF2-GDP to its active GTP-bound form is impaired, leading to a reduction in the levels of the active eIF2-GTP ternary complex available for translation initiation.\nGlobal Attenuation of Protein Synthesis: The inhibition of eIF2B by phosphorylated eIF2 results in a general attenuation of protein synthesis rates in the cell. Translation initiation is hindered due to the reduced availability of the active eIF2-GTP ternary complex, which is essential for the formation of the pre-initiation complex and the recruitment of ribosomes to mRNA transcripts.\nInduction of Stress-Responsive Gene Expression: The reduction in global protein synthesis rates during the ISR is coupled with the selective translation of specific stress-responsive mRNAs encoding proteins involved in adaptive cellular processes. This selective translational control allows cells to conserve energy and resources while prioritizing the synthesis of proteins required for stress adaptation and survival.\n\n\n\n\n3.3.2 Integrated Stress Response\n\n\n\n\n\nIntegrated Stress Response Depictions\n\n\n\n\nThe integrated stress response (ISR) is a conserved cellular signaling pathway that coordinates adaptive responses to various environmental stresses and perturbations. It serves as a crucial mechanism for maintaining cellular homeostasis and promoting cell survival under adverse conditions. Here’s an overview of the integrated stress response:\n\nInitiation of the Integrated Stress Response: The ISR is initiated by the phosphorylation of the alpha subunit of eukaryotic translation initiation factor 2 (eIF2α) at a conserved serine residue (Ser51) in response to diverse stress stimuli. Several stress-responsive protein kinases, including protein kinase R (PKR), heme-regulated inhibitor kinase (HRI), PKR-like endoplasmic reticulum kinase (PERK), and general control non-derepressible 2 (GCN2), phosphorylate eIF2α in a context-specific manner.\nGlobal Attenuation of Protein Synthesis: Phosphorylation of eIF2α inhibits the guanine nucleotide exchange activity of eIF2B, leading to a reduction in the formation of the active eIF2-GTP ternary complex required for translation initiation. As a result, global protein synthesis rates are attenuated, conserving cellular resources and energy during stress conditions.\nSelective Translation of Stress-Responsive mRNAs: Despite the general inhibition of protein synthesis, the ISR promotes the selective translation of a subset of mRNAs encoding stress-responsive proteins involved in adaptive cellular processes. These mRNAs often contain upstream open reading frames (uORFs) or specific regulatory elements in their untranslated regions (UTRs) that confer sensitivity to eIF2α phosphorylation and enable preferential translation under stress conditions.\nInduction of Stress-Responsive Genes: Activation of the ISR leads to the transcriptional upregulation of stress-responsive genes through the activation of transcription factors such as ATF4 (activating transcription factor 4). ATF4 induces the expression of genes involved in amino acid metabolism, redox regulation, autophagy, and apoptosis, facilitating cellular adaptation and survival in response to stress.\nIntegration with Other Signaling Pathways: The ISR is integrated with other stress signaling pathways, including the unfolded protein response (UPR), oxidative stress response, and DNA damage response, to coordinate cellular stress responses and maintain homeostasis. Crosstalk between these pathways allows cells to mount appropriate adaptive responses tailored to specific stressors and environmental cues."
  },
  {
    "objectID": "chapters/week3.html#elongating-translation",
    "href": "chapters/week3.html#elongating-translation",
    "title": "3  Regulating Protein Synthesis",
    "section": "3.4 Elongating Translation",
    "text": "3.4 Elongating Translation\n\n\n\n\n\nElongating Translation via Eukaryotes\n\n\n\n\nEukaryotic translation elongation is the stage of protein synthesis where amino acids are added to the growing polypeptide chain according to the sequence encoded by the mRNA. It involves the movement of ribosomes along the mRNA template, decoding successive codons, and facilitating the transfer of amino acids from charged tRNAs to the growing peptide chain. Here’s an overview of eukaryotic translation elongation:\n\nRibosome Movement: Once the ribosome is assembled on the mRNA and the initiator tRNA is positioned at the start codon (AUG), elongation begins with the binding of the second aminoacyl-tRNA to the A site of the ribosome. The ribosome then translocates along the mRNA in a 5’ to 3’ direction, shifting the peptidyl-tRNA from the A site to the P site and making space for the next incoming aminoacyl-tRNA.\nCodon Recognition and Peptide Bond Formation: During each cycle of elongation, the ribosome decodes the mRNA by recognizing the next codon in the A site. Aminoacyl-tRNAs carrying the corresponding amino acids bind to the A site through complementary base pairing between the anticodon of the tRNA and the mRNA codon. Peptide bond formation then occurs between the amino acid carried by the peptidyl-tRNA in the P site and the amino acid carried by the aminoacyl-tRNA in the A site, catalyzed by peptidyl transferase activity in the ribosome.\nTranslocation: After peptide bond formation (which is formed via a nucleophilic attack by the N-terminus of an amino acid to the center carbon), the ribosome undergoes a translocation step, facilitated by elongation factor EF-G (eEF2 in eukaryotes) and GTP hydrolysis. This translocation process moves the ribosome along the mRNA by one codon, shifting the peptidyl-tRNA from the A site to the P site and the deacylated tRNA from the P site to the E (exit) site. The mRNA and the newly formed peptidyl-tRNA now occupy the A site, ready for the next cycle of elongation.\nElongation Factors: Elongation factors play critical roles in facilitating the elongation process. In addition to EF-G, eukaryotic elongation factors include eEF1A, which delivers aminoacyl-tRNAs to the ribosome, and eEF1B, which promotes the binding of aminoacyl-tRNAs to eEF1A. These factors help ensure the accurate and efficient addition of amino acids to the growing polypeptide chain.\nTermination: Elongation continues until a stop codon (UAA, UAG, or UGA) is encountered in the A site of the ribosome. Termination factors, such as eRF1 and eRF3 in eukaryotes, recognize the stop codon and promote the release of the completed polypeptide chain from the ribosome. The ribosome dissociates into its subunits, and the newly synthesized protein is released into the cytoplasm for further processing or folding.\n\n\n3.4.1 tRNA Charging\n\n\n\n\n\ntRNA Charging\n\n\n\n\ntRNA charging, also known as tRNA aminoacylation, is a crucial step in protein synthesis where specific amino acids are covalently attached to their corresponding transfer RNA (tRNA) molecules by aminoacyl-tRNA synthetases (aaRSs). This process ensures that the correct amino acid is delivered to the ribosome during translation. Here’s an overview of tRNA charging by aminoacyl-tRNA synthetases:\n\nRecognition of Amino Acids: Each aminoacyl-tRNA synthetase is specific to a particular amino acid. Before aminoacylation, the amino acid to be attached to the tRNA is first recognized and selected by the corresponding aminoacyl-tRNA synthetase. This recognition process involves the binding of the amino acid to a specific binding pocket within the active site of the synthetase enzyme.\nAminoacylation Reaction: Once the correct amino acid is bound to the synthetase enzyme, the aminoacylation reaction occurs. The enzyme catalyzes the transfer of the amino acid to the 3’ end of the appropriate tRNA molecule, forming an aminoacyl-tRNA complex. This reaction is driven by the hydrolysis of ATP, which provides the energy required for the formation of the high-energy aminoacyl-AMP intermediate.\nSpecificity Determinants: Aminoacyl-tRNA synthetases possess mechanisms to ensure the fidelity and accuracy of tRNA charging. These enzymes contain specific recognition sites that interact with both the amino acid and the tRNA molecule, allowing them to distinguish between correct and incorrect substrates. The accuracy of tRNA charging is critical for maintaining the fidelity of protein synthesis and preventing errors in translation.\nProofreading and Editing: Despite the high specificity of aminoacyl-tRNA synthetases, errors in tRNA charging can still occur. To minimize errors, some synthetases have proofreading or editing mechanisms that hydrolyze incorrectly charged aminoacyl-tRNA complexes. These editing activities help to correct mischarged tRNAs and maintain the integrity of the translation process.\nRole in Protein Synthesis: Once aminoacylated, the charged tRNA molecules serve as adapters between the mRNA codons and the corresponding amino acids during translation elongation. Each tRNA molecule carries a specific amino acid attached to its 3’ end and contains an anticodon sequence that base-pairs with the complementary mRNA codon. This ensures that the correct amino acid is incorporated into the growing polypeptide chain according to the genetic code.\n\n\n3.4.1.1 eEF1A\n\n\n\n\n\neEF1A Delivering Aminoacyl-tRNAs\n\n\n\n\nEukaryotic elongation factor 1A (eEF1A) plays a crucial role in protein synthesis by delivering aminoacyl-tRNA (aa-tRNA) molecules to the ribosome during the elongation phase of translation. Here’s how eEF1A facilitates the delivery of aminoacyl-tRNAs:\n\nBinding to Aminoacyl-tRNA (aa-tRNA): eEF1A binds to aminoacyl-tRNA molecules in a GTP-dependent manner. Each eEF1A molecule forms a complex with a single aa-tRNA, where the amino acid is attached to the 3’ end of the tRNA molecule. This binding occurs at the ribosomal A (aminoacyl) site during the elongation phase of translation.\nGTP Hydrolysis: The binding of eEF1A to aa-tRNA is accompanied by the hydrolysis of GTP bound to eEF1A. GTP hydrolysis triggers a conformational change in eEF1A, promoting the release of GDP and inorganic phosphate (Pi) from the protein. This conformational change is essential for the efficient delivery of aa-tRNA to the ribosome.\nDelivery to the Ribosome: Once eEF1A is bound to aa-tRNA and GTP is hydrolyzed, the eEF1A-aa-tRNA complex undergoes a structural rearrangement that allows it to interact with the ribosome. eEF1A delivers the aa-tRNA to the ribosomal A site, where the anticodon of the tRNA base-pairs with the complementary mRNA codon.\nTranslocation and Peptide Bond Formation: After the aa-tRNA is delivered to the ribosome, the ribosome catalyzes the formation of a peptide bond between the amino acid carried by the aa-tRNA in the A site and the growing polypeptide chain attached to the peptidyl-tRNA in the P (peptidyl) site. This process is facilitated by elongation factors and ribosomal RNA (rRNA) within the ribosomal complex.\nGDP Dissociation and Recycling: Following peptide bond formation, eEF1A dissociates from the ribosome, releasing GDP from its active site. The released GDP is then exchanged for GTP by guanine nucleotide exchange factors (GEFs), such as eEF1B, regenerating the active form of eEF1A and allowing it to participate in subsequent rounds of aa-tRNA delivery.\n\n\n\n\n3.4.2 Elongation by eEF2\n\n\n\n\n\neEF2 Promoting Translation Elongation\n\n\n\n\nEukaryotic elongation factor 2 (eEF2) is a GTPase protein that facilitates translocation by promoting the movement of the ribosome along the mRNA template. Here’s how eEF2 mediates translocation:\n\nRibosome Movement: After the formation of the peptide bond between the amino acid attached to the tRNA in the A site and the growing polypeptide chain on the tRNA in the P site, the ribosome needs to shift to the next codon on the mRNA template to continue elongation.\nGTP Binding and Hydrolysis: eEF2 binds to the ribosome in a GTP-bound form. GTP hydrolysis by eEF2 is coupled with the translocation process. The hydrolysis of GTP into GDP and inorganic phosphate (Pi) provides the energy necessary for ribosome movement along the mRNA.\nRibosome Translocation: Upon GTP hydrolysis, eEF2 undergoes a conformational change, which results in the movement of the ribosome along the mRNA in a 5’ to 3’ direction. This translocation step shifts the peptidyl-tRNA from the A site to the P site, and the deacylated tRNA from the P site to the E (exit) site of the ribosome.\nGDP Release and Recycling: After translocation, eEF2-GDP is released from the ribosome, and GDP is exchanged for GTP by guanine nucleotide exchange factors (GEFs), such as eEF2B. The recycling of eEF2 to its active GTP-bound form allows it to participate in subsequent rounds of translocation during translation elongation.\nAccuracy and Efficiency: The translocation process facilitated by eEF2 is essential for the accurate and efficient synthesis of proteins. It ensures that the ribosome moves along the mRNA in a stepwise manner, decoding each codon and adding the corresponding amino acid to the growing polypeptide chain.\n\n\n\n3.4.3 Profiling\n\n3.4.3.1 Polysomes\n\n\n\n\n\nSteps Involved in Polysome Profiling\n\n\n\n\nPolysome profiling is a technique used to analyze the translational activity of mRNA molecules within cells. It involves subjecting cell lysates to centrifugation in a sucrose density gradient, which separates ribosomes and associated mRNA molecules based on their sedimentation rates. Polysomes, which consist of multiple ribosomes translating a single mRNA molecule, sediment at higher sucrose densities, while free ribosomes and untranslated mRNA sediment at lower densities.\nBy analyzing the distribution of ribosomes and mRNA along the gradient, polysome profiling provides valuable information about the efficiency of translation and the regulation of gene expression at the level of mRNA translation. This technique is widely used in molecular biology and cell biology research to study translational control mechanisms, cellular responses to stress, and changes in gene expression under different physiological conditions.\n\n\n3.4.3.2 Ribosome Profiling\n\n\n\n\n\nSteps Involved in Ribosome Profiling\n\n\n\n\nRibosome profiling, also known as ribosome footprinting or ribo-seq, is a powerful technique used to study the global landscape of translation at a genome-wide level. It involves the deep sequencing of ribosome-protected mRNA fragments (ribosome footprints) to identify the positions of ribosomes along mRNA molecules. The technique begins by treating cells with a translation inhibitor to arrest ribosomes at specific positions on mRNA transcripts. Subsequently, ribosomes are digested away, leaving behind ribosome-protected mRNA fragments. These fragments are then isolated, converted into cDNA libraries, and sequenced using high-throughput sequencing technologies.\nRibosome profiling provides detailed information about the density and position of ribosomes on mRNAs, allowing researchers to determine which mRNAs are actively translated, the efficiency of translation, and the locations of translation initiation and termination."
  },
  {
    "objectID": "chapters/week3.html#terminating-translation",
    "href": "chapters/week3.html#terminating-translation",
    "title": "3  Regulating Protein Synthesis",
    "section": "3.5 Terminating Translation",
    "text": "3.5 Terminating Translation\n\n\n\n\n\neRF1 and eRF3 Terminating Translation\n\n\n\n\nAt the termination stage of translation, eukaryotic release factor 1 (eRF1) and eukaryotic release factor 3 (eRF3) play crucial roles in recognizing and facilitating the termination of protein synthesis at stop codons. Here’s how they function at the stop codon:\n\nRecognition of Stop Codon: As the ribosome moves along the mRNA during translation elongation, it encounters stop codons (UAA, UAG, or UGA) that signal the end of protein synthesis. When a stop codon enters the ribosomal A (aminoacyl) site, it does not code for an amino acid but instead signals the termination of translation.\nRole of eRF1: eRF1 is responsible for recognizing stop codons and promoting the release of the nascent polypeptide chain from the ribosome. It binds to the stop codon in the A site of the ribosome, mimicking the structure of a tRNA molecule. However, instead of carrying an amino acid, eRF1 triggers the hydrolysis of the ester bond between the nascent polypeptide chain and the tRNA molecule in the P (peptidyl) site, resulting in the release of the polypeptide from the ribosome.\nInteraction with eRF3: eRF3 is a GTPase protein that interacts with eRF1 during translation termination. It enhances the efficiency of termination by stimulating the activity of eRF1 and promoting its release of the polypeptide chain. eRF3 also helps to recycle eRF1 by facilitating the dissociation of eRF1 from the ribosome after termination.\nGTP Hydrolysis: The interaction between eRF1 and eRF3 is GTP-dependent. eRF3 binds to GTP, and upon interaction with eRF1 at the ribosome, GTP hydrolysis occurs. This hydrolysis event is coupled with the termination process and facilitates the dissociation of eRF1 and eRF3 from the ribosome, allowing the ribosome to be recycled for another round of translation.\n\n\n3.5.1 Recycling Ribosomes\n\n\n\n\n\nRibosomes are Recycled After Translation\n\n\n\n\nRibosome recycling is a critical process in protein synthesis that ensures the efficient reuse of ribosomes after the termination of translation. It involves the dissociation of ribosomes from mRNA and the recycling of ribosomal subunits for subsequent rounds of translation. Here’s how ribosome recycling occurs:\n\nTermination of Translation: Ribosome recycling begins after the termination of translation, when a stop codon is encountered on the mRNA template. Release factors, such as eukaryotic release factor 1 (eRF1) and eukaryotic release factor 3 (eRF3), facilitate the release of the synthesized polypeptide chain from the ribosome.\nDissociation of Ribosomes: Once translation is terminated, the ribosome complex consisting of the large and small subunits needs to be disassembled from the mRNA molecule. This dissociation is facilitated by ribosome recycling factors, such as ribosome recycling factor (RRF) and elongation factor G (EF-G) in bacteria, and Rli1/ABCE1 in eukaryotes. These factors promote the separation of the ribosomal subunits and disengage the ribosome from mRNA.\nRibosome Splitting: In bacteria, RRF and EF-G work together to split the ribosome into its large and small subunits. RRF binds to the ribosomal A site, while EF-G hydrolyzes GTP and promotes the splitting of the ribosome complex. In eukaryotes, Rli1/ABCE1 acts as a ribosome-splitting factor by hydrolyzing ATP and disrupting the intersubunit bridges between the large and small ribosomal subunits.\nRecycling of Ribosomal Subunits: After the ribosome is split into its subunits, both bacterial and eukaryotic ribosomal subunits are recycled for further rounds of translation. The small ribosomal subunit is particularly important, as it recognizes the mRNA start codon and initiates translation. The recycling process ensures the efficient utilization of ribosomal components and enables the cell to maintain high rates of protein synthesis."
  },
  {
    "objectID": "chapters/week4.html",
    "href": "chapters/week4.html",
    "title": "4  Chaperones and Protein Homeostasis",
    "section": "",
    "text": "Christian Anfinsen, winner of the 1972 Nobel Prize in Chemistry, once pondered the questions of who is right and what is true. These questions are fundamental to understanding the world around us. In his research, Anfinsen explored how proteins fold, a process essential for their function. His work shed light on the complex mechanisms governing life at a molecular level.\nSimilarly, scientists F. Ulrich Hartl and Arthur Horwich have made significant contributions to our understanding of biology. Their research delves into the intricate world of protein folding, unraveling the mysteries of how cells function and how diseases like Alzheimer’s and Parkinson’s develop.\nProtein folding, the process by which proteins assume their functional three-dimensional shapes, is crucial for their proper functioning within living organisms. Imagine a bustling city with crowded streets; similarly, within our cells, proteins fold in a crowded environment filled with other molecules.\nThis crowded environment presents challenges for proteins as they fold. They must navigate through a sea of other molecules, jostling and interacting with them along the way. Sometimes, this crowded space can hinder the folding process, leading to misfolded proteins that may not function correctly.\nScientists like F. Ulrich Hartl and Arthur Horwich have dedicated their research to understanding how proteins fold in such crowded conditions. By studying the intricate dance of molecules within cells, they have uncovered mechanisms that assist proteins in folding properly despite the crowded environment.\nChaperones play vital roles in the proteostasis network, which is the cellular system responsible for maintaining the proper balance of proteins. Think of chaperones as the guardians of protein health within our cells.\nOne of the primary functions of chaperones is to assist proteins in folding correctly. Proteins start as long chains of amino acids and need to fold into specific shapes to perform their functions effectively. Chaperones help guide this folding process, ensuring that proteins adopt their proper three-dimensional structures.\nAdditionally, chaperones prevent protein misfolding and aggregation. Sometimes, proteins can misfold or clump together, which can be harmful to the cell. Chaperones act as quality control agents, identifying misfolded or aggregated proteins and either refolding them into their correct shapes or targeting them for degradation.\nChaperones also play a role in protein transport within the cell. They help ferry proteins to their designated locations, ensuring they reach the right organelles or compartments where they are needed.\nFurthermore, chaperones assist in protein degradation. When proteins are damaged or no longer needed, they must be broken down and recycled. Chaperones help facilitate this process by guiding proteins to degradation machinery where they can be dismantled into their component parts for reuse."
  },
  {
    "objectID": "chapters/week4.html#protein-folding-pathways-in-bacteria",
    "href": "chapters/week4.html#protein-folding-pathways-in-bacteria",
    "title": "4  Chaperones and Protein Homeostasis",
    "section": "4.1 Protein Folding Pathways in Bacteria",
    "text": "4.1 Protein Folding Pathways in Bacteria\n\n\n\n\n\nProtein Folding Pathway in Bacteria\n\n\n\n\nOne of the primary pathways involved in protein folding in bacteria is the chaperone-mediated folding pathway. Chaperones are specialized proteins that assist other proteins in folding correctly. Within this pathway, chaperones interact with newly synthesized proteins as they emerge from ribosomes, guiding them through the folding process to ensure they attain their functional shapes.\nAnother important pathway in bacterial protein folding is the co-translational folding pathway. In this pathway, proteins begin to fold even as they are being synthesized by ribosomes. As the protein chain emerges from the ribosome, it starts to fold into its native structure with the help of chaperones and other folding factors. This simultaneous folding and synthesis process ensure that the protein is properly folded as soon as it is synthesized.\nFurthermore, bacteria utilize protein degradation pathways to maintain protein homeostasis. If a protein fails to fold correctly despite chaperone assistance or becomes damaged or obsolete, it may be targeted for degradation. Bacterial cells have proteases, enzymes specialized in breaking down proteins, which dismantle misfolded or unwanted proteins into smaller peptides or amino acids for recycling.\n\n4.1.0.1 Hsp70-Hsp40 System\n\n\n\n\n\nIllustration of the Hsp70-Hsp40 System\n\n\n\n\nThe Hsp70-Hsp40 system is a critical molecular machinery found in cells, including bacteria, that helps in protein folding and quality control. These components are often referred to as chaperones because they assist other proteins in folding correctly and prevent misfolding.\nAt the heart of this system is the Hsp70 protein, which acts as a molecular chaperone. Hsp70 binds to exposed hydrophobic regions on proteins, which are common during the folding process. By doing so, Hsp70 prevents these regions from sticking together inappropriately, thus helping the protein fold properly into its functional shape. However, Hsp70 alone can be slow in its action.\nThis is where the Hsp40 co-chaperone comes into play. Hsp40 interacts with Hsp70 and helps accelerate its activity. It does this by stimulating the ATPase activity of Hsp70, which is crucial for its chaperone function. By enhancing the ATPase activity, Hsp40 increases the efficiency of Hsp70 in binding to and releasing its client proteins, thereby facilitating the protein folding process.\nTogether, the Hsp70-Hsp40 system forms a dynamic duo in the cell, working hand in hand to ensure that proteins fold correctly and maintain their proper structures. This system is essential for cellular health and is involved in various cellular processes, including protein synthesis, protein trafficking, and response to stress.\n\n\n4.1.1 Chaperonin\n\n\n\n\n\nIllustration of Chaperonin\n\n\n\n\nChaperonins are like tiny cages within the cell that provide a protected environment for protein folding. These remarkable structures play a crucial role in ensuring that proteins fold correctly, without interference from other molecules in the crowded cellular environment.\nThe key feature of chaperonins is their hollow, barrel-like structure, which forms a chamber where proteins can fold undisturbed. One of the most well-known types of chaperonins is called GroEL-GroES, found in bacteria.\nWhen a protein needs to fold, it enters the central cavity of the chaperonin. Once inside, the chaperonin closes like a lid, encapsulating the protein within its chamber. This isolation shields the folding protein from potential disruptions by other cellular components, allowing it to fold properly.\nInside the chaperonin chamber, the folding protein is provided with the ideal conditions for folding. The enclosed space allows the protein to explore different conformations without interference, helping it find its correct three-dimensional structure.\nTo further assist in the folding process, chaperonins often work in conjunction with co-chaperones, such as GroES in the case of GroEL. GroES acts as a lid, sealing the top of the chaperonin chamber and creating an even more secluded environment for protein folding.\nOnce the folding process is complete, the chaperonin releases the folded protein, which can then go on to perform its specific function within the cell."
  },
  {
    "objectID": "chapters/week4.html#chaperone-families-in-eukaryotes-and-their-functions",
    "href": "chapters/week4.html#chaperone-families-in-eukaryotes-and-their-functions",
    "title": "4  Chaperones and Protein Homeostasis",
    "section": "4.2 Chaperone Families in Eukaryotes and Their Functions",
    "text": "4.2 Chaperone Families in Eukaryotes and Their Functions\n\n\n\n\n\nNAC and RAC\n\n\n\n\nIn eukaryotic cells, there are specialized chaperones that assist in protein folding as soon as the proteins are synthesized by ribosomes. Two prominent examples of these ribosome-binding chaperones are RAC (Ribosome-associated complex) and NAC (Nascent polypeptide-associated complex).\n\n\n\n\n\nIllustration of NAC and RAC Mechanism\n\n\n\n\nRAC serves as a cofactor of Hsp70, another important chaperone protein, facilitating its activity in protein folding. As proteins are being synthesized by ribosomes, RAC interacts with the ribosome and recruits Hsp70 to the nascent polypeptide chain as it emerges from the ribosome. This interaction helps to prevent premature folding or aggregation of the nascent protein, ensuring that it attains its proper three-dimensional structure.\nNAC, on the other hand, directly binds to the nascent polypeptide chain as it emerges from the ribosome. This association helps to shield the newly synthesized protein from interactions with other cellular components and provides a conducive environment for proper folding. NAC also assists in targeting the nascent protein to its correct cellular location, ensuring that it reaches its designated organelle or compartment.\n\n4.2.1 Functions of Hsp70\n\n\n\n\n\nCellular Functions of Hsp70\n\n\n\n\nFirstly, Hsp70 assists in protein folding. It interacts with newly synthesized or misfolded proteins, preventing them from aggregating and guiding them along the correct folding pathways. By doing so, Hsp70 ensures that proteins adopt their proper three-dimensional structures, which is essential for their biological activity.\nSecondly, Hsp70 plays a role in protein transport within the cell. It helps to ferry proteins across membranes or guide them to specific cellular compartments where they are needed for various functions. This transport function ensures that proteins reach their correct destinations within the cell, allowing them to perform their designated roles.\nAdditionally, Hsp70 is involved in protein degradation. It interacts with misfolded or damaged proteins, targeting them for degradation by cellular machinery such as proteasomes. This process helps to remove aberrant proteins from the cell, preventing them from interfering with normal cellular processes and maintaining protein quality control.\nMoreover, Hsp70 plays a crucial role in cellular stress responses. When cells are exposed to stressful conditions such as heat, oxidative stress, or nutrient deprivation, the expression of Hsp70 is often upregulated. Hsp70 helps cells cope with these stresses by stabilizing proteins, preventing their denaturation, and promoting cell survival under adverse conditions.\n\n\n4.2.2 TRiC\n\n\n\n\n\nTRiC Illustration\n\n\n\n\nTRiC, also known as TCP-1 Ring Complex, is a type II chaperonin found in the cytosol of eukaryotic cells. It is composed of two stacked rings, each containing eight different subunits. TRiC plays a crucial role in facilitating the folding of diverse cytosolic proteins, ensuring their proper structure and function.\nOne of the key functions of TRiC is to assist in the folding of newly synthesized proteins as they emerge from ribosomes. As proteins are synthesized, they often require assistance to attain their correct three-dimensional shapes. TRiC provides a protected environment within its chamber-like structure, allowing proteins to fold properly without interference from other cellular components. This function is particularly important for proteins with complex folding patterns or those prone to misfolding.\nAdditionally, TRiC is involved in the folding of proteins that are crucial for cellular processes such as cell cycle regulation, cytoskeletal dynamics, and signal transduction. By facilitating the folding of these essential proteins, TRiC contributes to the proper functioning of the cell.\nMoreover, TRiC is implicated in the maintenance of protein homeostasis and cellular integrity under stress conditions. When cells are exposed to environmental stressors such as heat or toxins, TRiC helps to prevent protein misfolding and aggregation, thereby promoting cell survival.\n\n\n4.2.3 Protein Folding in Eukaryotes\n\n\n\n\n\nProtein Folding in Eukaryotes\n\n\n\n\nIn eukaryotic cells, cytosolic protein folding involves a series of coordinated pathways and molecular chaperones that ensure newly synthesized proteins attain their correct three-dimensional structures. Here’s an overview of the key players and steps involved in cytosolic protein folding:\n\nRAC (Ribosome-associated complex) and NAC (Nascent polypeptide-associated complex): These complexes interact with ribosomes and nascent polypeptide chains emerging from ribosomes, respectively. RAC recruits Hsp70 to the nascent chain, while NAC directly binds to the nascent polypeptide, protecting it and facilitating its proper folding.\nHsp70: Heat Shock Protein 70 is a major molecular chaperone involved in protein folding. It interacts with exposed hydrophobic regions on proteins, preventing misfolding and aggregation. Hsp70’s activity is regulated by ATP and co-chaperones such as Hsp40 (also known as DnaJ).\nHsp40 (DnaJ): Hsp40 acts as a co-chaperone to Hsp70, stimulating its ATPase activity and enhancing its chaperone function. It helps to deliver substrate proteins to Hsp70 and stabilize their binding.\nNEF (Nucleotide Exchange Factor): NEF assists in the dissociation of ADP from Hsp70, allowing for the binding of fresh ATP. This ATP hydrolysis and exchange cycle is essential for the chaperone activity of Hsp70.\nHOP (Hsp70-Hsp90 Organizing Protein): HOP acts as a co-chaperone that bridges the interaction between Hsp70 and Hsp90. This interaction is crucial for the transfer of client proteins from Hsp70 to Hsp90 during their folding process.\nHsp90: Heat Shock Protein 90 is another important molecular chaperone involved in protein folding. It acts downstream of Hsp70 and plays a role in the maturation and stabilization of client proteins. Hsp90’s activity is also ATP-dependent.\nTRiC (TCP-1 Ring Complex): TRiC is a large multi-subunit chaperonin complex that provides a protected environment for the folding of diverse cytosolic proteins. It assists in the folding of a wide range of substrates, particularly those with complex folding patterns.\n\n\n\n4.2.4 Polyribosomes\n\n\n\n\n\nIllustration of Polyribosomes\n\n\n\n\nPolyribosomes, also known as polysomes, are clusters of ribosomes found within eukaryotic cells that are actively translating mRNA molecules into proteins. These structures play a crucial role in protein synthesis, allowing multiple ribosomes to simultaneously translate a single mRNA strand. Within eukaryotic cells, polyribosomes can exist in two primary forms: free polyribosomes and membrane-bound polyribosomes.\nFree polyribosomes are dispersed throughout the cytoplasm, existing independently of any membrane-bound structures such as the endoplasmic reticulum (ER). They are responsible for synthesizing proteins that are intended to remain within the cytosol or to be transported to various organelles such as the nucleus or mitochondria. Proteins synthesized by free polyribosomes often fulfill essential cellular functions related to metabolism, cytoskeletal organization, and signaling pathways.\nOn the other hand, membrane-bound polyribosomes are attached to the endoplasmic reticulum (ER) membrane. These polyribosomes are typically found in close association with the rough ER, contributing to its characteristic rough appearance observed under electron microscopy. Proteins synthesized by membrane-bound polyribosomes are translocated into the lumen of the ER as they are being synthesized. These proteins undergo further processing, such as folding and glycosylation, within the ER before being transported to their final destinations. Membrane-bound polyribosomes primarily synthesize proteins that are destined for secretion, incorporation into the plasma membrane, or localization within the endomembrane system, including lysosomes and the Golgi apparatus.\n\n\n4.2.5 Secretory Protein Binding\n\n\n\n\n\nSecretory Protein Binding Illustration\n\n\n\n\nSecretory protein folding is a complex process that occurs within the endoplasmic reticulum (ER) of eukaryotic cells. As proteins destined for secretion are synthesized by ribosomes attached to the rough ER, they undergo a series of folding and modification steps to attain their native conformations. Several key molecular players are involved in this process, including BiP (binding protein), Hsp70 chaperone, and Protein disulfide isomerase (PDI).\nBiP, also known as GRP78, is an ER-resident chaperone protein that plays a central role in protein folding and quality control within the ER lumen. It interacts with newly synthesized polypeptide chains to prevent misfolding and aggregation, guiding them along the folding pathway. BiP also assists in the translocation of proteins across the ER membrane and facilitates the assembly of multiprotein complexes.\nHsp70 chaperone, similar to BiP, is involved in the folding of secretory proteins within the ER. It interacts with exposed hydrophobic regions on nascent polypeptide chains, preventing nonproductive interactions and promoting correct folding. Hsp70’s activity is regulated by ATP hydrolysis and is coordinated with other ER-resident chaperones to ensure efficient protein folding.\nProtein disulfide isomerase (PDI) is an enzyme that catalyzes the formation and breakage of disulfide (S-S) bonds within secretory proteins. Disulfide bonds play a crucial role in stabilizing protein structures, particularly in secretory and membrane proteins. PDI helps to ensure the proper formation of disulfide bonds, which are essential for protein stability and function. Additionally, PDI can catalyze the rearrangement of incorrect disulfide bonds, ensuring that secretory proteins attain their correct native conformations.\n\n\n4.2.6 Protein Glycosylation\n\n\n\n\n\nProtein Glycosylation\n\n\n\n\nProtein glycosylation is a common post-translational modification that occurs in the endoplasmic reticulum (ER) of eukaryotic cells. This process involves the addition of sugar molecules, such as glucose, mannose, and N-acetylglucosamine, to specific amino acid residues on nascent polypeptide chains as they are being synthesized by ribosomes attached to the ER membrane. The process of protein glycosylation in the ER involves several steps:\n\nEnzymatic addition of a pre-formed oligosaccharide: The initial step of protein glycosylation involves the transfer of a pre-formed oligosaccharide (a short sugar chain) from a lipid carrier molecule to specific asparagine residues on the nascent polypeptide chain. This process is catalyzed by an enzyme complex known as the oligosaccharyltransferase (OST) complex, which is embedded in the ER membrane.\nModification and processing of the glycan chain: After the oligosaccharide is transferred to the protein, it undergoes further modifications and processing steps within the ER lumen. These modifications include trimming of the sugar chain by specific enzymes and the addition of additional sugar residues to form complex glycan structures.\nQuality control and protein folding: During or after glycosylation, the newly synthesized protein undergoes quality control checks to ensure proper folding and assembly. Chaperone proteins such as BiP and lectin-like chaperones assist in protein folding and recognize misfolded or improperly glycosylated proteins, targeting them for degradation if necessary.\nGlycoprotein trafficking: Once properly folded and glycosylated, the glycoproteins are transported from the ER to the Golgi apparatus for further processing and sorting. In the Golgi, additional modifications may occur, and glycoproteins are sorted for secretion or delivery to specific cellular compartments.\n\n\n4.2.6.1 Role of Glycosylation During ER Protein Folding\n\n\n\n\n\nRole of Glycosylation in ER Protein Folding\n\n\n\n\nGlycosylation plays a crucial role in protein folding within the endoplasmic reticulum (ER), and calnexin is a key player in this process. Calnexin is a type I integral membrane protein located in the ER membrane and functions as a lectin, specifically a carbohydrate-binding protein.\nDuring protein synthesis, nascent polypeptide chains are co-translationally glycosylated by the addition of a pre-formed oligosaccharide chain. This glycosylation is essential for proper protein folding and quality control. Calnexin recognizes specific monosaccharides, such as glucose and mannose, present on the glycosylated proteins.\nCalnexin interacts with newly synthesized glycoproteins that have not yet folded correctly. By binding to the oligosaccharide chains on these proteins, calnexin helps to stabilize them and prevent premature degradation. This interaction provides a quality control mechanism, allowing the glycoproteins to undergo proper folding and assembly.\nFurthermore, calnexin collaborates with other chaperones and folding enzymes within the ER, such as BiP (binding immunoglobulin protein) and protein disulfide isomerase (PDI), to facilitate protein folding. Together, these ER-resident proteins ensure that glycosylated proteins attain their native conformations and are properly folded before being transported to their final destinations within the cell.\n\n\n\n4.2.7 ERAD Substrate Recognition\n\n\n\n\n\nERAD Pathway Mechanism\n\n\n\n\nERAD (Endoplasmic Reticulum-Associated Degradation) is a cellular quality control mechanism responsible for identifying and targeting misfolded or unassembled proteins in the endoplasmic reticulum (ER) for degradation. Substrate recognition is a crucial step in the ERAD process, ensuring that only aberrant proteins are targeted for degradation while properly folded proteins are spared.\nThe recognition of ERAD substrates involves multiple checkpoints and mechanisms:\n\nQuality control during protein folding: The ER contains a network of chaperones and folding enzymes that assist in the folding of nascent proteins. Properly folded proteins are able to escape recognition by ERAD machinery and proceed to their intended destinations. However, misfolded or unassembled proteins are retained in the ER and subjected to further scrutiny.\nGlycan-dependent recognition: Many ERAD substrates bear characteristic glycan modifications that serve as signals for recognition by ERAD machinery. Lectins, such as calnexin and calreticulin, recognize these glycan structures and facilitate the interaction between misfolded proteins and ERAD components.\nUbiquitin-dependent recognition: Misfolded or unassembled proteins are tagged with ubiquitin, a small protein that serves as a signal for degradation by the proteasome. This ubiquitination process is mediated by ER-resident E3 ubiquitin ligases, which specifically recognize and target ERAD substrates for ubiquitination.\nERAD receptors: ERAD substrates are recognized and bound by ER-resident receptors that bridge the interaction between the misfolded protein and the ERAD machinery. These receptors contain specific domains that recognize either the glycan modifications or the ubiquitin chains on ERAD substrates. Examples of ERAD receptors include Derlin proteins and Hrd1 complex components.\nER quality control checkpoints: The ER contains quality control checkpoints that monitor the folding status of proteins. If a protein fails to fold properly or assemble into its functional form, it is recognized by ER quality control sensors, leading to its retrotranslocation from the ER lumen to the cytosol for degradation via ERAD."
  },
  {
    "objectID": "chapters/week4.html#cellular-responses-to-proteotoxic-stresses",
    "href": "chapters/week4.html#cellular-responses-to-proteotoxic-stresses",
    "title": "4  Chaperones and Protein Homeostasis",
    "section": "4.3 Cellular Responses to Proteotoxic Stresses",
    "text": "4.3 Cellular Responses to Proteotoxic Stresses\n\n4.3.1 Proteostasis Network\n\n\n\n\n\nProteostasis Network\n\n\n\n\nThe Proteostasis Network refers to the intricate system within cells that regulates protein homeostasis, ensuring that proteins are properly folded, assembled, trafficked, and degraded. Maintaining proteostasis is essential for cellular health and function, as proteins are involved in virtually every aspect of cellular processes, from structural support to enzymatic reactions and signaling pathways.\nThe Proteostasis Network consists of various molecular components and pathways that work together to maintain protein quality control:\n\nChaperones and Folding Factors: Molecular chaperones, such as Hsp70 and Hsp90, assist in protein folding, preventing misfolding and aggregation. They guide nascent polypeptide chains to their proper three-dimensional structures and help proteins navigate through folding intermediates. Folding factors, such as protein disulfide isomerases (PDIs), aid in the formation of disulfide bonds, a crucial step in protein folding.\nProtein Degradation Pathways: Misfolded or damaged proteins are targeted for degradation by proteolytic systems such as the ubiquitin-proteasome system (UPS) and autophagy-lysosome pathway. The UPS involves the tagging of proteins with ubiquitin molecules, marking them for degradation by the proteasome. Autophagy sequesters cytoplasmic components, including protein aggregates, into autophagosomes for delivery to lysosomes, where they are degraded.\nQuality Control Mechanisms: Cells have quality control mechanisms that monitor protein folding and assembly. If a protein fails to fold properly or assemble correctly, it may be targeted for degradation or undergo retrotranslocation from the ER (endoplasmic reticulum) to the cytosol for ER-associated degradation (ERAD).\nRegulatory Pathways: Various signaling pathways and transcriptional regulators modulate the expression of chaperones, folding factors, and components of protein degradation pathways in response to cellular stress or changes in protein homeostasis. These regulatory mechanisms help cells adapt to changing conditions and maintain proteostasis under different physiological states.\nOrganelle-Specific Proteostasis: Different organelles within the cell, such as the ER, mitochondria, and nucleus, have specialized proteostasis networks tailored to their specific needs. For example, the ER is responsible for folding and processing secretory and membrane proteins, while the mitochondria have their own chaperones and quality control mechanisms to maintain mitochondrial protein homeostasis.\n\n\n\n4.3.2 Heat Shock Response\n\n\n\n\n\nHeat Shock Protein Illustration\n\n\n\n\nThe Heat Shock Response (HSR) is a cellular defense mechanism that is activated in response to elevated temperatures and other stressors, such as oxidative stress, heavy metals, and toxins. The primary function of the HSR is to protect cells from damage caused by these stressors and to restore cellular homeostasis.\nWhen cells are exposed to stress, heat shock transcription factors (HSFs), particularly HSF1, are activated. HSF1 undergoes a conformational change, leading to its trimerization and translocation to the nucleus. Once in the nucleus, HSF1 binds to specific DNA sequences known as heat shock elements (HSEs) located in the promoters of heat shock genes.\nActivation of HSF1 leads to the transcriptional upregulation of heat shock proteins (HSPs), a group of molecular chaperones that play essential roles in protein folding, stabilization, and degradation. HSPs help to protect cells from stress-induced damage by assisting in the refolding of denatured proteins, preventing protein aggregation, and facilitating the degradation of irreversibly damaged proteins.\nThe induction of HSP expression by the HSR is a highly conserved and tightly regulated process across species, from bacteria to humans. HSPs are classified into families based on their molecular weight, including HSP70, HSP90, HSP60, and small HSPs (sHSPs).\nIn addition to their roles in protein homeostasis, HSPs have been implicated in various cellular processes, including signal transduction, cell cycle regulation, and apoptosis. They also play important roles in development, immunity, and disease.\n\n4.3.2.1 HSF1 in Cancer and Neurodegenerative Diseases?\nTumorigenesis: HSF1 contributes to tumorigenesis by promoting cancer cell survival and proliferation through the regulation of heat shock proteins (HSPs). Elevated levels of HSPs induced by HSF1 activation confer a survival advantage to cancer cells by facilitating protein folding, inhibiting apoptosis, and enhancing cell migration and invasion.\nChemo- and Radiotherapy Resistance: HSF1 activation can lead to resistance to chemotherapy and radiation therapy in cancer cells. The upregulation of HSPs induced by HSF1 activation can protect cancer cells from the cytotoxic effects of these treatments, contributing to treatment failure and disease recurrence.\nMetastasis: HSF1 may also play a role in cancer metastasis by promoting epithelial-to-mesenchymal transition (EMT), a process that enhances cancer cell migration and invasion. HSF1-mediated upregulation of HSPs can facilitate EMT-associated changes in gene expression and cellular morphology, promoting metastatic spread.\nProtein Misfolding and Aggregation: HSF1 is activated in response to protein misfolding and aggregation, characteristic features of neurodegenerative diseases such as Alzheimer’s, Parkinson’s, and Huntington’s diseases. HSF1 activation leads to the upregulation of HSPs, which can help to refold or degrade misfolded proteins, thereby mitigating their toxic effects.\nNeuronal Protection: Activation of HSF1 and induction of HSP expression provide neuroprotection in experimental models of neurodegenerative diseases. By promoting protein homeostasis and reducing cellular stress, HSPs can help to preserve neuronal function and viability in the face of disease-related insults.\nPotential Therapeutic Target: Targeting HSF1 or its downstream effectors, such as HSPs, has emerged as a potential therapeutic strategy for neurodegenerative diseases. Modulation of HSF1 activity may help to enhance cellular proteostasis and alleviate disease-associated pathology.\n\n\n\n4.3.3 Unfolded Protein Response\n\n\n\n\n\nIllustration of the UPR\n\n\n\n\nThe Unfolded Protein Response (UPR) is a cellular stress response pathway activated in response to the accumulation of unfolded or misfolded proteins within the endoplasmic reticulum (ER), a cellular organelle involved in protein synthesis and folding. The UPR plays a critical role in maintaining protein homeostasis, or proteostasis, by alleviating ER stress and restoring normal cellular function.\nWhen unfolded or misfolded proteins accumulate in the ER, they trigger the activation of three main transmembrane proteins: inositol-requiring enzyme 1 (IRE1), protein kinase RNA-like ER kinase (PERK), and activating transcription factor 6 (ATF6). These sensors initiate signaling cascades that culminate in a coordinated cellular response aimed at reducing ER stress and promoting cell survival.\n\nIRE1 Pathway: Upon activation, IRE1 splices an mRNA encoding the transcription factor X-box binding protein 1 (XBP1), leading to the production of an active transcription factor called spliced XBP1 (XBP1s). XBP1s translocates to the nucleus and activates the transcription of genes involved in ER-associated degradation (ERAD), protein folding, and lipid biosynthesis, promoting ER function and protein folding capacity.\nPERK Pathway: PERK activation leads to the phosphorylation of eukaryotic translation initiation factor 2 alpha (eIF2α), resulting in global attenuation of protein synthesis. This temporary reduction in protein synthesis alleviates the burden on the ER, allowing cells to cope with ER stress. Additionally, PERK activation induces the expression of ATF4, a transcription factor that regulates the expression of genes involved in antioxidant defense, amino acid metabolism, and apoptosis.\nATF6 Pathway: ATF6 is transported to the Golgi apparatus upon ER stress, where it undergoes proteolytic cleavage to generate an active transcription factor fragment. This fragment translocates to the nucleus and activates the expression of genes encoding ER chaperones, such as BiP/GRP78, and other proteins involved in protein folding and ERAD.\n\nThe combined actions of these UPR pathways help to restore ER homeostasis by increasing the capacity of the ER to fold and degrade proteins, reducing the load of unfolded proteins, and promoting cell survival. However, if ER stress is severe or prolonged, the UPR can also induce apoptosis to eliminate irreversibly damaged cells and maintain overall tissue integrity.\n\n4.3.3.1 Splicing of XBP1 mRNA\n\n\n\n\n\nRegulating the Splicing of XBP1 mRNA\n\n\n\n\nThe splicing of X-box binding protein 1 (XBP1) mRNA is a critical step in the activation of the unfolded protein response (UPR), particularly the IRE1 pathway. This process, known as regulated splicing, is tightly regulated and plays a key role in the cellular response to endoplasmic reticulum (ER) stress.\nWhen unfolded or misfolded proteins accumulate in the ER, the ER stress sensor protein inositol-requiring enzyme 1 (IRE1) becomes activated. IRE1 is a transmembrane protein located in the ER membrane. Upon activation, IRE1 undergoes oligomerization and autophosphorylation, leading to its activation as an endoribonuclease.\nIRE1 then catalyzes the unconventional splicing of XBP1 mRNA, a process that removes a 26-nucleotide intron from the mRNA. This splicing event generates a shorter mRNA transcript, referred to as spliced XBP1 (XBP1s). XBP1s encodes a transcription factor that is a potent activator of genes involved in ER-associated degradation (ERAD), protein folding, and lipid biosynthesis.\nThe splicing of XBP1 mRNA is a highly regulated process that is specific to ER stress conditions. Under normal conditions, XBP1 mRNA remains unspliced, and the protein encoded by unspliced XBP1 (XBP1u) does not have transcriptional activity. However, upon ER stress, IRE1-mediated splicing of XBP1 mRNA is rapidly induced, leading to the production of XBP1s and subsequent activation of UPR target genes.\nThe activation of XBP1s and its downstream target genes is critical for restoring ER homeostasis and promoting cell survival during ER stress. XBP1s regulates the expression of genes involved in protein folding, ERAD, and lipid metabolism, thereby increasing the capacity of the ER to handle the influx of misfolded proteins and alleviate ER stress.\n\n\n4.3.3.2 PERK Activation\n\n\n\n\n\nActivation of PERK\n\n\n\n\nProtein kinase RNA-like ER kinase (PERK) is a key component of the unfolded protein response (UPR) pathway, activated in response to endoplasmic reticulum (ER) stress. One of the main functions of PERK activation is to suppress global translation initiation, a process essential for protein synthesis. This translational attenuation helps to alleviate the burden on the ER by reducing the influx of newly synthesized proteins into the ER lumen, where protein folding occurs.\nUpon activation, PERK phosphorylates the alpha subunit of eukaryotic translation initiation factor 2 (eIF2α), a critical component of the translation initiation complex. Phosphorylation of eIF2α inhibits its activity, preventing the formation of the ternary complex required for translation initiation. As a result, global protein synthesis is attenuated, reducing the overall protein load on the ER and allowing cells to cope with ER stress.\nWhile global translation is suppressed, the translation of specific mRNAs is selectively enhanced or maintained during PERK activation. For example, the mRNA encoding activating transcription factor 4 (ATF4) contains specific regulatory elements in its 5’ untranslated region (UTR), known as upstream open reading frames (uORFs), which allow for preferential translation even under conditions of eIF2α phosphorylation. ATF4 is a transcription factor that regulates the expression of genes involved in various cellular processes, including antioxidant defense, amino acid metabolism, and apoptosis."
  },
  {
    "objectID": "chapters/week5.html",
    "href": "chapters/week5.html",
    "title": "5  Mitochondria in Aging and Neurodegeneration",
    "section": "",
    "text": "Photo of a Mitochondrion\n\n\n\n\nThe mitochondrion, often referred to as the “powerhouse of the cell,” is a complex organelle with a distinct structure that allows it to carry out essential cellular functions, particularly energy production through oxidative phosphorylation. Here’s an overview of its structure:\n\nMatrix:\nThe matrix is the innermost compartment of the mitochondrion and contains a gel-like substance rich in enzymes, including those involved in the oxidation of pyruvate and fatty acids, as well as enzymes of the Krebs cycle (also known as the citric acid cycle or tricarboxylic acid cycle). Additionally, the matrix houses the mitochondrial DNA (mtDNA) and the machinery for gene expression, including RNA polymerase and ribosomes.\nInner Membrane:\nThe inner membrane surrounds the matrix and is highly folded into structures called cristae, which increase the surface area available for biochemical reactions. The inner membrane contains the electron transport chain (ETC), a series of protein complexes that transfer electrons derived from nutrients to generate ATP through oxidative phosphorylation. It also houses ATP synthase, an enzyme complex responsible for ATP production, as well as various transporters that regulate the passage of ions and metabolites across the membrane.\nOuter Membrane:\nThe outer membrane surrounds the inner membrane and separates the mitochondrial interior from the cytoplasm. It is relatively permeable to small molecules with a molecular weight of less than 5 kilodaltons (kDa), allowing for the passage of ions, metabolites, and other small molecules.\nIntermembrane Space:\nThe intermembrane space is the region between the inner and outer mitochondrial membranes. It contains a lower concentration of proteins compared to the matrix but may contain proteins involved in processes such as apoptosis regulation.\n\n\n\n\n\n\n\n\nEnergy Converting Metabolism Diagram\n\n\n\n\nEnergy-converting metabolism in mitochondria is a complex process that involves several interconnected pathways aimed at generating adenosine triphosphate (ATP), the cell’s primary energy currency. Mitochondria play a central role in cellular respiration, a process that involves the oxidation of nutrients to produce ATP through oxidative phosphorylation. Here’s an overview of the key metabolic pathways involved:\n\nGlycolysis: Glycolysis is the initial stage of glucose metabolism that occurs in the cytoplasm. Glucose is broken down into pyruvate, producing a small amount of ATP and reducing equivalents in the form of NADH. Pyruvate is then transported into the mitochondria for further metabolism.\nPyruvate Oxidation: Pyruvate produced from glycolysis enters the mitochondria, where it undergoes oxidation to produce acetyl-CoA. This process generates reducing equivalents in the form of NADH and releases carbon dioxide. Acetyl-CoA then enters the citric acid cycle (also known as the Krebs cycle) for further metabolism.\nCitric Acid Cycle (Krebs Cycle): The citric acid cycle takes place in the mitochondrial matrix. Acetyl-CoA combines with oxaloacetate to form citrate, which undergoes a series of enzymatic reactions, ultimately regenerating oxaloacetate and producing reducing equivalents (NADH and FADH2) and ATP precursors (GTP). The cycle generates NADH and FADH2, which donate electrons to the electron transport chain (ETC).\nElectron Transport Chain (ETC): The electron transport chain is located in the inner mitochondrial membrane. It consists of a series of protein complexes (I-IV) and coenzyme Q and cytochrome c as electron carriers. As electrons move through the ETC, they release energy, which is used to pump protons (H+) across the inner mitochondrial membrane, establishing an electrochemical gradient.\nATP Synthesis: The proton gradient generated by the ETC drives ATP synthesis through ATP synthase, an enzyme complex located in the inner mitochondrial membrane. Protons flow back into the mitochondrial matrix through ATP synthase, driving the synthesis of ATP from adenosine diphosphate (ADP) and inorganic phosphate (Pi). This process is known as oxidative phosphorylation.\n\n\n\n\n\n\n\n\n\nNADH Generation\n\n\n\n\nGlucose undergoes several metabolic reactions to produce NADH during cellular respiration. The process begins with glycolysis, where glucose is converted into pyruvate. Here’s a simplified breakdown of the steps involved:\n\nGlycolysis: Glucose (a 6-carbon molecule) is phosphorylated and split into two molecules of glyceraldehyde-3-phosphate (G3P), each containing three carbons. These G3P molecules are further oxidized and phosphorylated, ultimately yielding two molecules of pyruvate (a 3-carbon molecule). Along the way, glycolysis produces a net gain of 2 ATP molecules and 2 NADH molecules per glucose molecule.\nPyruvate Oxidation: Each pyruvate molecule produced during glycolysis enters the mitochondria, where it undergoes oxidation to produce acetyl-CoA. This process generates reducing equivalents in the form of NADH. While pyruvate oxidation does not directly produce NADH molecules, it generates NADH during subsequent steps of the citric acid cycle (Krebs cycle).\nKrebs Cycle (Citric Acid Cycle): Acetyl-CoA combines with oxaloacetate to form citrate, initiating the citric acid cycle. Through a series of enzymatic reactions, citrate is metabolized, ultimately regenerating oxaloacetate and producing reducing equivalents (NADH and FADH2). While the precise contribution of each pyruvate to NADH production in the Krebs cycle varies, each glucose molecule ultimately yields multiple NADH molecules through this pathway.\n\n\n\n\n\n\n\n\nNADH Usage\n\n\n\n\nNADH (nicotinamide adenine dinucleotide, reduced form) is a critical molecule in cellular metabolism, serving as a carrier of electrons during various biochemical reactions. Its primary role is to transfer high-energy electrons to the electron transport chain (ETC) in the mitochondria, where they are ultimately used to generate ATP through oxidative phosphorylation.\nHere’s how NADH is used in cellular metabolism:\n\nElectron Transport Chain (ETC): NADH donates its electrons to complex I (NADH dehydrogenase) of the electron transport chain in the inner mitochondrial membrane. These electrons then pass through a series of protein complexes (I-IV), including flavin mononucleotide (FMN), iron-sulfur clusters, and cytochromes, leading to the pumping of protons (H+) from the mitochondrial matrix to the intermembrane space. This creates an electrochemical gradient across the inner mitochondrial membrane.\nATP Synthesis: The flow of protons back into the mitochondrial matrix through complex V (ATP synthase) harnesses the energy released to drive the synthesis of ATP from adenosine diphosphate (ADP) and inorganic phosphate (Pi). This process, known as oxidative phosphorylation, is responsible for the majority of ATP production in aerobic cells.\nRegeneration of NAD+: After donating its electrons to the ETC, NADH is oxidized back to its original form, NAD+, allowing it to participate in subsequent rounds of metabolism. This regeneration of NAD+ is crucial for sustaining glycolysis, the citric acid cycle, and other metabolic pathways that rely on NAD+ as a cofactor.\n\n\n\n\n\n\n\n\n\n\nIllustration of the Electron Transport Chain\n\n\n\n\nThe Electron Transport Chain (ETC) is a critical component of cellular respiration, occurring in the inner mitochondrial membrane of eukaryotic cells and the plasma membrane of prokaryotic cells. It is responsible for the final stage of oxidative phosphorylation, the process by which cells generate adenosine triphosphate (ATP), the primary energy currency.\nHere’s how the Electron Transport Chain works:\n\nElectron Carriers: The ETC consists of a series of protein complexes and small molecules that serve as electron carriers. These include flavoproteins, iron-sulfur proteins, cytochromes, and coenzyme Q (ubiquinone).\nElectron Flow: Electrons donated by NADH and FADH2 (produced during glycolysis, pyruvate oxidation, and the citric acid cycle) enter the ETC at complex I (NADH dehydrogenase) and complex II (succinate dehydrogenase), respectively. These electrons are transferred sequentially from one carrier to another along the ETC, losing energy with each transfer.\nProton Pumping: As electrons flow through the ETC, energy released from their transfer is used to pump protons (H+) from the mitochondrial matrix to the intermembrane space, creating an electrochemical gradient across the inner mitochondrial membrane. Complexes I, III, and IV are involved in this process.\nChemiosmosis: The electrochemical gradient generated by proton pumping creates a proton motive force (PMF), which drives protons back into the mitochondrial matrix through complex V, also known as ATP synthase. As protons flow through ATP synthase, the energy released is used to convert adenosine diphosphate (ADP) and inorganic phosphate (Pi) into ATP, a process known as oxidative phosphorylation.\nOxygen as the Final Electron Acceptor: At the end of the ETC, electrons are transferred to molecular oxygen (O2), the final electron acceptor. Oxygen combines with protons to form water (H2O), completing the electron transport chain.\n\n\n\n\n\n\n\n\nDifferent Paths in the Electron Transport Chain\n\n\n\n\nIn the Electron Transport Chain (ETC), there are two main pathways for the flow of electrons:\n\nComplex I → Complex III → Complex IV: This pathway begins with complex I (NADH dehydrogenase) receiving electrons from NADH. Complex I transfers these electrons to coenzyme Q (ubiquinone), which then delivers them to complex III (cytochrome bc1 complex). Complex III passes the electrons to cytochrome c, and finally, they are transferred to complex IV (cytochrome c oxidase). Complex IV uses these electrons to reduce molecular oxygen (O2) to water (H2O).\nComplex II → Complex III → Complex IV: This pathway involves complex II (succinate dehydrogenase) receiving electrons directly from succinate in the citric acid cycle. Complex II transfers these electrons to coenzyme Q, which then follows the same path as in the previous pathway, delivering the electrons to complex III and then complex IV for the reduction of oxygen to water.\n\n\n\n\n\n\n\n\n\n\nDifferent Models of the ER\n\n\n\n\nThe Baffle Model and the Crista Junction Model are two proposed mechanisms that describe the organization of cristae, the internal membrane structures within mitochondria, and their role in mitochondrial function. Let’s delve into each model:\n\nBaffle Model:\nThe Baffle Model suggests that cristae are formed by invaginations of the inner mitochondrial membrane (IMM) that protrude into the mitochondrial matrix. These invaginations create a labyrinth-like structure, increasing the surface area of the inner membrane and providing more space for oxidative phosphorylation (ATP production). The term “baffles” refers to the folds or ridges formed by these invaginations.\nIn this model, the cristae junctions, which are the points where the inner membrane folds connect to the outer membrane, are considered to be relatively sparse and randomly distributed. The spaces between cristae (intercristae spaces) are thought to allow for efficient diffusion of metabolites and ions, facilitating metabolic processes within the mitochondria.\nCrista Junction Model:\nThe Crista Junction Model proposes a different organization of cristae within mitochondria. According to this model, cristae are interconnected by narrow tubular structures known as cristae junctions. These junctions serve as gateways that regulate the exchange of molecules between the intermembrane space and the mitochondrial matrix.\nIn the Crista Junction Model, the cristae are believed to be more tightly packed and organized compared to the Baffle Model. The presence of cristae junctions allows for compartmentalization of the inner mitochondrial membrane, segregating different metabolic processes and creating microenvironments within the mitochondria.\n\n\n\n\n\n\n\n\n\nElectron Transport in the Cristae\n\n\n\n\nThe electron transport chain (ETC) in mitochondria is a crucial process in cellular respiration, where electrons derived from the oxidation of nutrients are passed along a series of protein complexes embedded in the inner mitochondrial membrane (IMM). This process generates a proton gradient across the membrane, which is used to produce adenosine triphosphate (ATP) through oxidative phosphorylation. Cristae, the inward-folded structures of the IMM, play a critical role in facilitating the ETC and ATP synthesis. Here’s how the ETC functions within the cristae:\n\nOrganization within Cristae: Cristae provide an extensive surface area for the assembly and functioning of the ETC complexes. The proteins comprising the ETC, including complex I (NADH dehydrogenase), complex II (succinate dehydrogenase), complex III (cytochrome bc1 complex), complex IV (cytochrome c oxidase), and ATP synthase (complex V), are embedded within the cristae membranes.\nElectron Transfer: The ETC begins with the transfer of electrons from NADH or FADH2 to complex I or complex II, respectively. These electrons are then passed sequentially through the ETC complexes, with each complex accepting and donating electrons to the next in the chain. As electrons move along the chain, they release energy that is used to pump protons (H+) across the cristae membrane from the mitochondrial matrix to the intermembrane space.\nProton Gradient Formation: The pumping of protons from the mitochondrial matrix into the intermembrane space creates a proton gradient across the cristae membrane. This gradient represents stored energy that can be harnessed to drive ATP synthesis.\nATP Synthesis: The proton gradient established by the ETC drives the rotation of the rotor subunit within ATP synthase (complex V). This rotational motion catalyzes the synthesis of ATP from adenosine diphosphate (ADP) and inorganic phosphate (Pi) in a process known as chemiosmosis. ATP synthase is located within the cristae membrane and utilizes the energy from proton movement to generate ATP.\n\n\n\n\n\n\n\n\n\nOrigins of the Mitochondria\n\n\n\n\nAround 1.5 billion years ago, a remarkable event occurred in the history of life on Earth: the engulfment of a free-living bacterium by a primitive eukaryotic cell. This bacterium was likely an alpha-proteobacterium, a group of bacteria closely related to modern-day mitochondria. Instead of being digested by the host cell, this bacterium formed a symbiotic relationship with it, possibly providing additional energy in the form of ATP through aerobic respiration.\nOver time, this symbiotic relationship evolved, with the engulfed bacterium becoming increasingly integrated into the host cell. This integration involved a gradual transfer of genetic material from the bacterium to the host cell nucleus, resulting in the loss of many bacterial genes and the retention of only a small genome within the mitochondria. This genome is now known as mitochondrial DNA (mtDNA).\nAs this symbiosis continued, the host cell and the engulfed bacterium became interdependent, with the bacterium specializing in energy production through oxidative phosphorylation (aerobic respiration) while the host cell provided protection and resources. This symbiotic relationship proved to be highly advantageous, allowing eukaryotic cells to generate more energy and thus thrive in diverse environments.\nThrough natural selection and genetic drift, the symbiotic bacterium gradually evolved into the mitochondria we see in modern eukaryotic cells. Mitochondria retained their own distinct characteristics, such as a double membrane structure and their own genome (mtDNA), while also becoming integrated into the cellular machinery of the host cell.\n\n\n\n\n\n\n\n\nBiogenesis of Respiratory Chain Proteins\n\n\n\n\nThe biogenesis of respiratory chain proteins, which are essential components of the electron transport chain (ETC) in mitochondria, involves a complex process of synthesis, assembly, and insertion into the inner mitochondrial membrane (IMM). Here’s an overview of the steps involved:\n\nSynthesis of Mitochondrial Proteins: The majority of mitochondrial proteins, including those involved in the respiratory chain, are encoded by nuclear genes and synthesized in the cytoplasm as precursor proteins. These precursor proteins typically contain N-terminal targeting sequences, called mitochondrial targeting sequences (MTS) or presequences, that direct them to the mitochondria.\nImport into Mitochondria: Upon synthesis in the cytoplasm, mitochondrial precursor proteins are recognized by cytoplasmic chaperones and escorted to the translocase of the outer membrane (TOM) complex, which is responsible for the initial recognition and translocation of precursor proteins across the outer mitochondrial membrane (OMM). The MTS directs the precursor protein through the TOM complex into the intermembrane space (IMS).\nSorting and Processing: Once in the IMS, the MTS is cleaved by the mitochondrial processing peptidase (MPP), resulting in the removal of the targeting sequence and yielding the mature protein. Some proteins require further processing by additional proteases within the IMS.\nAssembly of Respiratory Complexes: Mature proteins synthesized in the cytoplasm or imported into the mitochondria are assembled into multi-subunit complexes that constitute the respiratory chain. These complexes include complex I (NADH dehydrogenase), complex II (succinate dehydrogenase), complex III (cytochrome bc1 complex), complex IV (cytochrome c oxidase), and ATP synthase (complex V).\nInsertion into the Inner Mitochondrial Membrane (IMM): The assembled respiratory chain complexes are inserted into the IMM with the assistance of various assembly factors and chaperones. The precise mechanisms of insertion and assembly vary for each complex but often involve interactions with specific lipid components of the IMM and assembly factors that facilitate proper folding and integration into the membrane.\nFormation of Supramolecular Structures: Once inserted into the IMM, individual respiratory chain complexes can interact with each other to form supramolecular structures known as supercomplexes or respirasomes. These structures optimize electron transfer efficiency and minimize reactive oxygen species (ROS) production by facilitating the rapid and efficient transfer of electrons through the ETC.\n\n\n\n\n\n\n\n\nTargeting Sequences\n\n\n\n\nThe mitochondrial targeting sequence (MTS), also known as a mitochondrial transit peptide or presequence, is a short, hydrophobic peptide sequence found at the N-terminus of proteins destined for import into mitochondria. The MTS serves as a molecular tag that directs precursor proteins from the cytoplasm to the mitochondria, where they undergo further processing and are ultimately integrated into the mitochondrial compartments.\nHere’s how the mitochondrial targeting sequence works:\n\nRecognition in the Cytoplasm: Newly synthesized precursor proteins containing an MTS are recognized by cytoplasmic chaperones and targeting factors. These factors prevent the premature folding of the precursor protein and help maintain its unfolded state, facilitating its recognition by the mitochondrial import machinery.\nTranslocation across the Outer Membrane: The precursor protein, bound to cytoplasmic chaperones, is guided to the translocase of the outer membrane (TOM) complex, which is located in the outer mitochondrial membrane (OMM). The TOM complex recognizes the MTS and facilitates the translocation of the precursor protein across the OMM into the intermembrane space (IMS) of the mitochondria.\nProcessing and Sorting: Once in the IMS, the MTS is cleaved by the mitochondrial processing peptidase (MPP), resulting in the removal of the targeting sequence. This cleavage event releases the mature protein, which may then be further sorted and directed to its specific destination within the mitochondria, such as the matrix, inner mitochondrial membrane (IMM), or intermembrane space.\nIntegration into Mitochondrial Compartments: The mature protein is then integrated into the appropriate mitochondrial compartment, where it performs its specific function. This integration process may involve additional folding, assembly into multi-subunit complexes, or insertion into the IMM, depending on the protein’s destination and function within the mitochondria.\n\n\n\n\n\n\n\n\n\nImporting Proteins into the Mitochondria\n\n\n\n\nMitochondrial protein import is a fundamental process by which proteins synthesized in the cytoplasm are transported into mitochondria, where they perform essential functions in various mitochondrial compartments. This import process is highly regulated and involves several steps, ensuring that proteins are correctly targeted to their specific destinations within mitochondria. Here’s an overview of mitochondrial protein import:\n\nRecognition of Mitochondrial Targeting Sequence (MTS): Proteins destined for import into mitochondria typically contain an N-terminal mitochondrial targeting sequence (MTS), also known as a mitochondrial transit peptide or presequence. The MTS is recognized by cytoplasmic chaperones and targeting factors, which prevent premature folding of the precursor protein and facilitate its recognition by the mitochondrial import machinery.\nTranslocation Across the Outer Membrane: The precursor protein, bound to cytoplasmic chaperones, is directed to the translocase of the outer membrane (TOM) complex, located in the outer mitochondrial membrane (OMM). The TOM complex recognizes the MTS and facilitates the translocation of the precursor protein across the OMM into the intermembrane space (IMS) of the mitochondria.\nSorting and Processing in the Intermembrane Space (IMS): Once in the IMS, the MTS is cleaved by the mitochondrial processing peptidase (MPP), resulting in the removal of the targeting sequence. This cleavage event releases the mature protein, which may then be further sorted and directed to its specific destination within the mitochondria, such as the matrix, inner mitochondrial membrane (IMM), or intermembrane space.\nTranslocation Across the Inner Membrane: Proteins targeted to the mitochondrial matrix or inner mitochondrial membrane (IMM) undergo additional translocation steps across the inner membrane. This process is facilitated by protein translocases, including the presequence translocase-associated motor (PAM) complex and the TIM22 and TIM23 complexes. These translocases recognize and transport proteins with specific targeting signals across the IMM into the matrix or inner membrane.\nIntegration into Mitochondrial Compartments: Once inside the mitochondrial matrix or IMM, proteins may undergo further folding, assembly into multi-subunit complexes, or insertion into the membrane, depending on their specific functions within mitochondria. Some proteins may also remain in the IMS, where they perform specialized roles in processes such as protein folding, oxidative protein folding, or apoptosis regulation.\n\n\n\n\n\n\n\n\n\nEnergy Requirements During Import\n\n\n\n\nEnergy plays a crucial role in mitochondrial protein import, facilitating the translocation of precursor proteins across the mitochondrial membranes and their subsequent sorting and processing within mitochondria. Here’s how energy is involved in various stages of mitochondrial protein import:\n\nTranslocation Across the Outer Membrane: The translocation of precursor proteins across the outer mitochondrial membrane (OMM) is facilitated by the translocase of the outer membrane (TOM) complex. While some precursor proteins are passively translocated through the TOM complex, others require energy in the form of ATP to overcome the electrochemical gradient across the membrane and enter the intermembrane space (IMS) of the mitochondria. ATP hydrolysis provides the energy needed for the initial translocation step.\nTranslocation Across the Inner Membrane: Precursor proteins targeted to the mitochondrial matrix or inner mitochondrial membrane (IMM) undergo additional translocation steps across the inner membrane. This process is facilitated by protein translocases, including the presequence translocase-associated motor (PAM) complex and the TIM22 and TIM23 complexes. ATP hydrolysis by the PAM complex provides the energy required for the translocation of proteins across the inner membrane into the matrix or inner membrane.\nFolding, Sorting, and Processing: Once inside the mitochondrial matrix or IMM, precursor proteins may undergo folding, assembly into multi-subunit complexes, or insertion into the membrane. These processes often require energy in the form of ATP to facilitate protein folding, conformational changes, and membrane insertion. ATP-dependent chaperones and protein folding enzymes within mitochondria utilize ATP hydrolysis to assist in protein folding and quality control.\nMaintenance of Membrane Potential: The maintenance of an electrochemical gradient across the mitochondrial membranes, driven by proton pumping by the electron transport chain (ETC), is essential for mitochondrial protein import. This proton gradient provides the driving force for the import of precursor proteins into mitochondria and the translocation of proteins across the inner membrane. ATP hydrolysis by the ATP synthase complex, located in the inner membrane, contributes to the maintenance of the proton gradient by consuming ATP to drive proton pumping."
  },
  {
    "objectID": "chapters/week5.html#reactive-oxygen-species",
    "href": "chapters/week5.html#reactive-oxygen-species",
    "title": "5  Mitochondria in Aging and Neurodegeneration",
    "section": "5.2 Reactive Oxygen Species",
    "text": "5.2 Reactive Oxygen Species\n\n\n\n\n\nSuperoxide Generation from the Mitochondria\n\n\n\n\nSuperoxide generation by mitochondria is a natural byproduct of the electron transport chain (ETC) during oxidative phosphorylation, the process by which cells produce adenosine triphosphate (ATP). While mitochondria play a crucial role in cellular energy production, they can also generate reactive oxygen species (ROS), including superoxide radicals (O2•−), as a result of electron leakage from the ETC. Here’s how superoxide is generated by mitochondria:\n\nElectron Leakage: During oxidative phosphorylation, electrons are transferred along the ETC through a series of protein complexes embedded in the inner mitochondrial membrane (IMM). While the majority of electrons flow smoothly through the ETC, some leakage can occur at various points along the chain, particularly at complexes I and III. This electron leakage leads to the partial reduction of molecular oxygen (O2) to form superoxide radicals (O2•−).\nSite of Generation: The primary sites of superoxide generation within mitochondria are believed to be complexes I and III of the ETC. Complex I (NADH dehydrogenase) and complex III (cytochrome bc1 complex) are known to produce superoxide radicals as a result of single-electron reduction of molecular oxygen by ubisemiquinone radicals (ubisemiquinone-O2 reaction) and cytochrome b, respectively.\nRegulation and Mitochondrial ROS Production: Mitochondrial superoxide generation is regulated by various factors, including the redox state of electron carriers within the ETC, the proton motive force across the inner mitochondrial membrane (IMM), and the availability of oxygen as a terminal electron acceptor. Changes in mitochondrial membrane potential, substrate availability, or ETC inhibitors can alter ROS production by mitochondria.\nPhysiological and Pathological Roles: While superoxide generation by mitochondria is a natural process essential for cellular signaling and redox homeostasis, excessive ROS production can have detrimental effects on cellular components, leading to oxidative damage, mitochondrial dysfunction, and cell death. Mitochondrial ROS have been implicated in various physiological processes, including cell signaling, apoptosis, and aging, as well as in the pathogenesis of numerous diseases, including neurodegenerative disorders, cardiovascular diseases, and cancer.\n\n\n5.2.1 Radical Theory\n\n\n\n\n\nRadical Theory of Aging\n\n\n\n\nThe mitochondrial free radical theory of aging proposes that aging and age-related diseases are, at least in part, driven by the cumulative damage caused by reactive oxygen species (ROS) generated by mitochondria during cellular respiration. Here’s an overview of the theory:\n\nROS Production by Mitochondria: Mitochondria are the primary producers of ROS within cells. During oxidative phosphorylation, electrons leaking from the electron transport chain (ETC) can react with molecular oxygen (O2), resulting in the formation of superoxide radicals (O2•−). Superoxide can then be converted into other ROS, including hydrogen peroxide (H2O2) and hydroxyl radicals (•OH), through various enzymatic and non-enzymatic reactions.\nDamage to Cellular Components: ROS generated by mitochondria can react with and damage cellular components, including lipids, proteins, and DNA. This oxidative damage can lead to disruptions in cellular homeostasis, impaired cellular function, and ultimately contribute to the aging process. For example, ROS-induced lipid peroxidation can lead to membrane damage, protein oxidation can impair enzymatic function, and DNA damage can result in mutations and cellular dysfunction.\nMitochondrial Dysfunction: Over time, the accumulation of oxidative damage to mitochondrial components can lead to mitochondrial dysfunction, including impaired ATP production, altered mitochondrial membrane potential, and increased production of ROS. This creates a vicious cycle whereby dysfunctional mitochondria produce even more ROS, exacerbating oxidative damage and further compromising cellular function.\nAge-Related Diseases: Mitochondrial ROS and oxidative stress have been implicated in the pathogenesis of various age-related diseases, including neurodegenerative disorders (e.g., Alzheimer’s disease, Parkinson’s disease), cardiovascular diseases, metabolic disorders, and cancer. Oxidative damage to cellular components contributes to the development and progression of these diseases, highlighting the role of mitochondrial dysfunction in aging-related pathologies.\nAntioxidant Defenses and Longevity: While ROS are inherently reactive and damaging, cells possess antioxidant defense mechanisms to neutralize and mitigate their effects. These include enzymatic antioxidants (e.g., superoxide dismutase, catalase, glutathione peroxidase) and non-enzymatic antioxidants (e.g., vitamin C, vitamin E, glutathione). Enhanced antioxidant defenses have been associated with increased longevity and reduced age-related pathologies in various model organisms.\n\n\n\n5.2.2 Superoxide Dismutase\n\n\n\n\n\nIllustration of Superoxide Dismutase’s Function\n\n\n\n\nSuperoxide dismutase (SOD) is an enzyme that catalyzes the conversion of superoxide radicals (O2•−) into hydrogen peroxide (H2O2) and molecular oxygen (O2). However, hydrogen peroxide itself is also a reactive oxygen species (ROS) that can cause cellular damage if not properly neutralized. To further detoxify hydrogen peroxide, cells utilize other enzymes such as catalase and glutathione peroxidase. Here’s how the conversion of hydrogen peroxide to water (H2O) occurs:\n\nCatalase: Catalase is an enzyme found in peroxisomes and certain other cellular compartments. It catalyzes the decomposition of hydrogen peroxide into water and molecular oxygen, as follows:\n\\(2H_2O_2 \\rightarrow 2H_2O + O_2\\)\nCatalase rapidly converts hydrogen peroxide into water and oxygen, thereby neutralizing its harmful effects on cells.\nGlutathione Peroxidase: Glutathione peroxidase is another enzyme involved in the detoxification of hydrogen peroxide. It utilizes reduced glutathione (GSH) as a cofactor to reduce hydrogen peroxide to water while oxidizing glutathione to its disulfide form. The reaction is as follows:\n\\(2GSH + H_2O_2 \\rightarrow GSSG + 2H_2O\\)\nIn this reaction, glutathione peroxidase reduces two molecules of hydrogen peroxide to two molecules of water while simultaneously oxidizing two molecules of glutathione."
  },
  {
    "objectID": "chapters/week5.html#mitochondria-and-apoptosis",
    "href": "chapters/week5.html#mitochondria-and-apoptosis",
    "title": "5  Mitochondria in Aging and Neurodegeneration",
    "section": "5.3 Mitochondria and Apoptosis",
    "text": "5.3 Mitochondria and Apoptosis\n\n\n\n\n\nDifferences Between Apoptosis and Necrosis\n\n\n\n\nApoptosis, often referred to as programmed cell death, is a highly regulated process that occurs in multicellular organisms. It is characterized by a series of biochemical events that lead to the controlled and orderly dismantling of cells. Apoptosis is initiated by either extrinsic (death receptor-mediated) or intrinsic (mitochondrial-mediated) pathways. In the intrinsic pathway, various stress signals trigger the release of cytochrome c from mitochondria, which activates caspase enzymes, leading to cell death. In the extrinsic pathway, binding of death ligands to death receptors on the cell surface activates caspase enzymes directly.\nApoptosis exhibits specific characteristics, including cell shrinkage and condensation of chromatin, as well as the formation of apoptotic bodies, which are small membrane-bound vesicles containing cellular contents. These apoptotic bodies are subsequently phagocytosed by neighboring cells or professional phagocytes, such as macrophages. In terms of its physiological role, apoptosis plays essential roles in various processes, including tissue development, immune system regulation, and the elimination of damaged or infected cells. It helps maintain tissue homeostasis and contributes to overall organismal health.\nNecrosis, in contrast to apoptosis, is a form of cell death characterized by rapid and uncontrolled cellular degradation, often resulting from acute injury, ischemia, or toxic insults. Unlike apoptosis, necrosis does not follow a programmed pathway and is associated with inflammation and tissue damage. Necrosis typically involves cellular swelling, organelle dysfunction, and rupture of the plasma membrane, leading to the release of cellular contents into the extracellular space.\nNecrosis is not a regulated process and can occur as a result of various insults, such as physical trauma, infection, or exposure to toxins. The inflammatory response triggered by necrotic cell death serves to remove the damaged tissue and initiate repair processes. However, excessive or prolonged necrosis can contribute to tissue damage and exacerbate pathological conditions. Unlike apoptosis, necrosis is generally considered detrimental to organismal health and is often associated with pathological states, including ischemic injury, neurodegenerative diseases, and cancer.\n\n5.3.1 Caspase Activation\n\n\n\n\n\nCaspase Activation\n\n\n\n\nDuring apoptosis, caspases, which are a family of cysteine–aspartic protease enzymes, play a central role in orchestrating the dismantling of the cell. The process begins with the initiation of apoptosis by various signals, such as DNA damage, cellular stress, or signaling molecules from neighboring cells. These signals trigger the activation of initiator caspases, such as caspase 8 and caspase 9.\nInitiator caspases exist in an inactive form within the cell until they are activated by apoptotic signals. Once activated, caspase 8 is involved in the extrinsic pathway of apoptosis, while caspase 9 is involved in the intrinsic pathway. Both pathways ultimately converge to activate downstream effector caspases, including caspase 3, caspase 6, and caspase 7.\nActivated initiator caspases cleave and activate effector caspases, leading to the amplification of the apoptotic signal and the execution of cell death. Effector caspases, in turn, cleave multiple cellular substrates, including structural proteins, DNA repair enzymes, and signaling molecules, ultimately leading to the characteristic morphological and biochemical changes associated with apoptosis.\n\n\n5.3.2 Phagocytosis of Apoptotic Cells\n\n\n\n\n\nPhagocytosis of Apoptotic Cells\n\n\n\n\nPhagocytosis of apoptotic cells is a vital process in the clearance of dying cells and the maintenance of tissue homeostasis. When cells undergo apoptosis, they display specific signals on their surface that mark them for recognition and engulfment by phagocytes, such as macrophages and dendritic cells. Here’s how phagocytosis of apoptotic cells occurs:\n\nRecognition of Apoptotic Cells: During apoptosis, dying cells undergo changes in their membrane composition and structure. This includes the exposure of “eat-me” signals, such as phosphatidylserine (PS), on the outer leaflet of the plasma membrane. These signals serve as ligands for receptors on phagocytic cells, facilitating the recognition and binding of apoptotic cells by phagocytes.\nEngulfment by Phagocytes: Once recognized, apoptotic cells are engulfed by phagocytes through a process known as phagocytosis. This involves the extension of pseudopodia around the apoptotic cell, leading to its internalization within a phagocytic vesicle called a phagosome. The phagosome then undergoes maturation, fusing with lysosomes to form a phagolysosome, where the engulfed apoptotic cell is degraded.\nAnti-inflammatory Response: Phagocytosis of apoptotic cells typically triggers an anti-inflammatory response in the phagocytic cell. This is mediated by the release of anti-inflammatory cytokines, such as transforming growth factor-beta (TGF-β), and the inhibition of pro-inflammatory cytokines, such as tumor necrosis factor-alpha (TNF-α) and interleukin-1 beta (IL-1β). This anti-inflammatory response helps to resolve inflammation and prevent tissue damage.\nProcessing and Clearance: Within the phagolysosome, the engulfed apoptotic cell is broken down by lysosomal enzymes, leading to the degradation of cellular components into their constituent molecules. These molecules, including amino acids, nucleotides, and lipids, can be recycled by the phagocyte or released back into the extracellular environment. Clearance of apoptotic cells by phagocytosis helps to maintain tissue homeostasis and prevent the release of potentially harmful cellular contents.\n\n\n\n5.3.3 Pathways of Apoptosis\n\n5.3.3.1 Extrinsic\n\n\n\n\n\nExtrinsic Pathway of Apoptosis\n\n\n\n\nThe extrinsic pathway of apoptosis, also known as the death receptor pathway, is one of the two main pathways by which apoptosis is initiated in multicellular organisms. This pathway is triggered by extracellular signals that bind to death receptors on the cell surface, leading to the activation of caspase enzymes and ultimately resulting in cell death. Here’s an overview of the extrinsic pathway:\n\nInitiation: The extrinsic pathway is initiated by the binding of extracellular death ligands, such as Fas ligand (FasL) or tumor necrosis factor-alpha (TNF-α), to specific death receptors on the cell surface. These death receptors belong to the tumor necrosis factor receptor (TNFR) superfamily and include Fas (CD95/APO-1), TNF receptor 1 (TNFR1), and TNF-related apoptosis-inducing ligand receptor (TRAIL-R).\nFormation of Death-Inducing Signaling Complex (DISC): Binding of the death ligand to its receptor induces conformational changes in the receptor, leading to the recruitment and clustering of adaptor proteins, such as Fas-associated death domain (FADD) and TNF receptor-associated death domain (TRADD), to the cytoplasmic domain of the receptor. These adaptor proteins then recruit procaspase-8 or procaspase-10 to form a multiprotein complex called the Death-Inducing Signaling Complex (DISC) at the cytoplasmic face of the plasma membrane.\nActivation of Caspases: Within the DISC, procaspase-8 or procaspase-10 molecules are brought into close proximity, facilitating their autoactivation by cleavage. Activated caspase-8 or caspase-10 then cleaves and activates downstream effector caspases, such as caspase-3, caspase-6, and caspase-7, initiating the execution phase of apoptosis.\nExecution of Apoptosis: Once activated, effector caspases cleave various cellular substrates, leading to characteristic morphological and biochemical changes associated with apoptosis, including DNA fragmentation, cytoskeletal reorganization, membrane blebbing, and formation of apoptotic bodies. These changes ultimately result in the dismantling of the cell and its phagocytic removal by neighboring cells or professional phagocytes.\n\n\n\n5.3.3.2 Intrinsic\n\n\n\n\n\nIntrinsic Pathway of Apoptosis\n\n\n\n\nThe intrinsic pathway of apoptosis, also known as the mitochondrial pathway, is a crucial mechanism by which cells initiate programmed cell death in response to internal stress signals, such as DNA damage, cellular injury, or nutrient deprivation. Unlike the extrinsic pathway, which is initiated by external death ligands binding to cell surface death receptors, the intrinsic pathway involves mitochondrial signaling events that lead to the release of pro-apoptotic proteins and the activation of caspase enzymes. Here’s an overview of the intrinsic pathway:\n\nMitochondrial Outer Membrane Permeabilization (MOMP): The intrinsic pathway is initiated by various intracellular stress signals, such as DNA damage or oxidative stress, which lead to the activation of pro-apoptotic proteins, including Bcl-2-associated X protein (BAX) and Bcl-2-antagonist/killer (BAK). These proteins undergo conformational changes and oligomerize on the outer mitochondrial membrane, leading to mitochondrial outer membrane permeabilization (MOMP).\nRelease of Pro-Apoptotic Proteins: MOMP results in the release of pro-apoptotic proteins from the intermembrane space of the mitochondria into the cytoplasm. These proteins include cytochrome c, Smac/DIABLO (Second mitochondria-derived activator of caspases/direct IAP-binding protein with low pI), and apoptosis-inducing factor (AIF). Cytochrome c binds to apoptotic protease-activating factor 1 (Apaf-1), forming the apoptosome complex, which activates caspase-9, an initiator caspase.\nActivation of Caspases: Activation of caspase-9 within the apoptosome complex leads to the activation of downstream effector caspases, such as caspase-3, caspase-6, and caspase-7. These effector caspases orchestrate the execution phase of apoptosis by cleaving various cellular substrates, leading to the characteristic morphological and biochemical changes associated with cell death.\nRegulation by Bcl-2 Family Proteins: The intrinsic pathway of apoptosis is tightly regulated by members of the Bcl-2 family of proteins, which include both pro-apoptotic (e.g., BAX, BAK, Bid) and anti-apoptotic (e.g., Bcl-2, Bcl-xL) members. The balance between pro-apoptotic and anti-apoptotic Bcl-2 family members determines the susceptibility of cells to undergo apoptosis in response to intracellular stress signals.\nPhysiological and Pathological Roles: The intrinsic pathway of apoptosis plays essential roles in various physiological processes, including tissue development, immune system regulation, and the elimination of damaged or infected cells. Dysregulation of this pathway can contribute to various diseases, including cancer, neurodegenerative disorders, and autoimmune diseases.\n\n\n\n\n5.3.4 Bak, Bax, and Cytochrome C Release\n\n\n\n\n\nBak and Bax Action\n\n\n\n\nBax and Bak are pro-apoptotic members of the Bcl-2 protein family that play a central role in initiating the intrinsic pathway of apoptosis. When cells undergo stress or receive apoptotic signals, inactive monomeric forms of Bax and Bak undergo a conformational change, leading to their activation and oligomerization. Here’s how the process unfolds:\n\nInactive Bax and Bak: Normally, Bax and Bak exist in an inactive monomeric state within the cytoplasm or associated with intracellular membranes, such as the outer mitochondrial membrane (OMM). In this state, they are unable to induce apoptosis.\nOligomerization of Bax and Bak: Upon receiving apoptotic signals, such as DNA damage or cellular stress, Bax and Bak undergo a conformational change that exposes their hydrophobic domains. This change allows multiple Bax and Bak molecules to interact and form oligomeric complexes on the OMM.\nPermeabilization of the Outer Mitochondrial Membrane (MOMP): The oligomerization of Bax and Bak leads to the permeabilization of the outer mitochondrial membrane (MOMP). This process allows the release of pro-apoptotic proteins, including cytochrome c, from the intermembrane space of the mitochondria into the cytoplasm.\nCytochrome c Release: Cytochrome c is a key protein involved in the intrinsic pathway of apoptosis. Once released into the cytoplasm following MOMP, cytochrome c binds to apoptotic protease-activating factor 1 (Apaf-1), leading to the formation of the apoptosome complex.\nActivation of Caspases: The apoptosome complex activates caspase-9, an initiator caspase, which in turn activates downstream effector caspases, such as caspase-3, caspase-6, and caspase-7. These effector caspases execute the apoptotic program by cleaving various cellular substrates, ultimately leading to cell death.\n\n\n\n5.3.5 Inactivating Bak and Bax with Bcl-2\n\n\n\n\n\nInactivation of Bak and Bax\n\n\n\n\nBcl-2 plays a crucial role in preventing apoptosis by inhibiting the activation of Bax and Bak. Here’s how Bcl-2 inhibits Bax and Bak:\n\nBinding and Sequestration: Bcl-2 can directly bind to Bax and Bak, preventing their activation and oligomerization. By sequestering Bax and Bak in an inactive state, Bcl-2 inhibits their ability to permeabilize the outer mitochondrial membrane (MOMP) and release pro-apoptotic proteins such as cytochrome c.\nMaintenance of Mitochondrial Integrity: Bcl-2 also helps maintain mitochondrial integrity by stabilizing the outer mitochondrial membrane and preventing its permeabilization. This stabilization further contributes to the inhibition of Bax and Bak activation and the prevention of cytochrome c release.\nInhibition of Apoptotic Signaling: By inhibiting Bax and Bak, Bcl-2 blocks the initiation of the intrinsic pathway of apoptosis. This prevents the downstream activation of caspases and the execution of the apoptotic program. As a result, cells are protected from undergoing apoptosis even in the presence of apoptotic stimuli.\nRegulation of Cell Fate: The balance between pro-apoptotic proteins like Bax and Bak and anti-apoptotic proteins like Bcl-2 determines the fate of the cell. In healthy cells, the presence of Bcl-2 maintains this balance, promoting cell survival. However, under conditions of cellular stress or damage, the balance may shift towards pro-apoptotic signaling, leading to the activation of Bax and Bak and the initiation of apoptosis.\n\n\n\n5.3.6 BH3-Only Proteins\nBH3-only proteins play a crucial role in regulating apoptosis by modulating the activity of Bcl-2 family proteins. These proteins are so named because they contain only the BH3 (Bcl-2 homology 3) domain, which is essential for their pro-apoptotic function. Here’s how BH3-only proteins function in the intrinsic pathway of apoptosis:\n\nProduction or Activation of BH3-only Protein: BH3-only proteins can be produced in response to various cellular stress signals, such as DNA damage, nutrient deprivation, or growth factor withdrawal. Alternatively, existing BH3-only proteins may become activated through post-translational modifications or changes in cellular localization. Once produced or activated, BH3-only proteins serve as sensors of cellular stress and initiate apoptotic signaling pathways.\nInactivation of Bcl-2: BH3-only proteins exert their pro-apoptotic effects by binding to and inhibiting the anti-apoptotic members of the Bcl-2 family, such as Bcl-2 itself. By binding to Bcl-2, BH3-only proteins disrupt its anti-apoptotic function, thereby promoting apoptosis. This frees up pro-apoptotic proteins like Bax and Bak to initiate the intrinsic pathway of apoptosis.\nBax, Bak Activation (Oligomerization): In the absence of inhibition by anti-apoptotic Bcl-2 proteins, pro-apoptotic proteins like Bax and Bak become activated and undergo oligomerization. Oligomerization refers to the formation of multimeric complexes of Bax and Bak proteins on the outer mitochondrial membrane. These oligomeric complexes lead to mitochondrial outer membrane permeabilization (MOMP), resulting in the release of pro-apoptotic proteins such as cytochrome c into the cytoplasm."
  },
  {
    "objectID": "chapters/week6.html",
    "href": "chapters/week6.html",
    "title": "6  Autophagy of Protein Aggregates and Mitochondria",
    "section": "",
    "text": "Autophagy Mechanism Illustrated\n\n\n\n\nAutophagy is a cellular process responsible for the degradation and recycling of damaged or unnecessary cellular components, including protein aggregates and dysfunctional organelles such as mitochondria. Here’s how autophagy mechanisms work in directing degradation targets to lysosomes:\n\nInitiation of Autophagy: Autophagy is initiated in response to various cellular stresses, such as nutrient deprivation, oxidative stress, or protein aggregation. The initiation phase involves the activation of key autophagy-related proteins, including the ULK1 (unc-51 like autophagy activating kinase 1) complex and the class III phosphatidylinositol 3-kinase (PI3K) complex.\nFormation of Autophagosome: Once initiated, autophagy progresses through several steps, including the formation of a specialized double-membrane structure called the autophagosome. The autophagosome sequesters cellular components targeted for degradation, including protein aggregates and dysfunctional organelles such as mitochondria.\nTargeting Degradation Targets: Selective autophagy mechanisms enable the specific targeting of degradation targets to autophagosomes. In the case of protein aggregates, selective autophagy receptors, such as p62/SQSTM1 (sequestosome 1), recognize ubiquitinated proteins and bind to both the cargo and the autophagosomal membrane, facilitating their engulfment into autophagosomes. Similarly, dysfunctional mitochondria are targeted for degradation through selective autophagy receptors, such as NIX (also known as BNIP3L) and FUNDC1, which recognize damaged mitochondria and recruit them to autophagosomes.\nFusion with Lysosomes: Following sequestration of cargo, autophagosomes undergo fusion with lysosomes to form autolysosomes. Lysosomes contain acidic hydrolases that degrade the engulfed cargo, resulting in the breakdown of proteins, lipids, nucleic acids, and other cellular components. This process releases the breakdown products, such as amino acids and fatty acids, for reuse by the cell.\nDegradation and Recycling: Within autolysosomes, the cargo undergoes degradation by lysosomal enzymes. Proteins are degraded into amino acids, which can be recycled for protein synthesis or used as an energy source. Lipids are broken down into fatty acids, while nucleic acids are degraded into nucleotides. This degradation process ensures the removal of damaged or unnecessary cellular components and contributes to cellular homeostasis and survival.\n\n\n\n\n\n\n\n\nFrom Cytosol to Lysosome\n\n\n\n\nThe journey of autophagy from the cytosol to the lysosome involves several key steps:\n\nInitiation: Autophagy is initiated in response to various cellular stresses, such as nutrient deprivation, oxidative stress, or protein aggregation. The initiation phase involves the activation of autophagy-related proteins, including the ULK1 (unc-51 like autophagy activating kinase 1) complex and the class III phosphatidylinositol 3-kinase (PI3K) complex.\nFormation of Phagophore: Once initiated, autophagy progresses with the formation of a phagophore, a crescent-shaped membrane structure derived from the endoplasmic reticulum (ER) or other membrane sources. The phagophore expands and engulfs cellular components targeted for degradation, including protein aggregates and dysfunctional organelles.\nFormation of Autophagosome: The edges of the phagophore seal to form a double-membrane vesicle called the autophagosome. The autophagosome encloses the cargo, sequestering it from the cytoplasm and creating a protective environment for degradation.\nLysosomal Fusion: The autophagosome then undergoes fusion with lysosomes, which are membrane-bound organelles containing acidic hydrolases. This fusion forms a structure called the autolysosome, where degradation occurs. Lysosomes provide the enzymes necessary for breaking down the engulfed cargo.\nCargo Degradation: Within the autolysosome, the cargo is exposed to the acidic pH and the enzymatic activity of lysosomal hydrolases. Proteins are degraded into amino acids, lipids into fatty acids, and nucleic acids into nucleotides. These breakdown products are then released back into the cytoplasm for reuse by the cell.\nRecycling and Reuse: The degraded components are recycled and can be used for various cellular processes, such as protein synthesis, energy production, or the maintenance of cellular membranes. This recycling process ensures the efficient utilization of cellular resources and contributes to cellular homeostasis.\n\n\n\n\n\n\n\n\n\n\n\nDiscovery of ATG Genes\n\n\n\n\nAutophagy was first discovered in yeast, particularly Saccharomyces cerevisiae, by Dr. Yoshinori Ohsumi, who was awarded the Nobel Prize in Physiology or Medicine in 2016 for his groundbreaking work. Dr. Ohsumi’s research led to the identification of a set of genes essential for autophagy, known as autophagy-related genes or ATG genes.\nThe discovery of ATG genes provided key insights into the molecular mechanisms underlying autophagy and paved the way for understanding the process in other organisms, including humans. By systematically studying yeast mutants defective in autophagy, Dr. Ohsumi and his team identified a series of genes involved in autophagosome formation, cargo recognition, and lysosomal degradation.\nSome of the key ATG genes identified in yeast include ATG1, ATG5, ATG6 (also known as VPS30), ATG8, and ATG12. These genes encode proteins that play crucial roles in different stages of the autophagy pathway, from the initiation of autophagosome formation to the fusion of autophagosomes with lysosomes.\nATG1 is a protein kinase involved in the initiation of autophagy, while ATG5 and ATG12 are involved in the conjugation of Atg8 (LC3 in mammals) to phosphatidylethanolamine, a critical step in autophagosome formation. ATG6/VPS30 is a subunit of the phosphatidylinositol 3-kinase (PI3K) complex, which regulates the nucleation of autophagosomal membranes.\n\n\n\n\n\n\n\n\n\nAutophagosome Formation\n\n\n\n\nThe autophagosome is a double-membraned vesicle that plays a central role in the process of autophagy, serving as the primary structure for sequestering and transporting cellular components destined for degradation within the lysosome. Here’s a closer look at the structure and function of the autophagosome:\n\nDouble-Membraned Structure: The autophagosome is characterized by its double-membraned structure, comprising an inner membrane and an outer membrane. These membranes are derived from various cellular sources, including the endoplasmic reticulum (ER), Golgi apparatus, plasma membrane, and mitochondria, among others.\nFormation: The formation of autophagosomes begins with the nucleation of a small membrane structure, known as the phagophore or isolation membrane. The phagophore expands and engulfs cytoplasmic components, including protein aggregates, damaged organelles, and invading pathogens, to form the autophagosome.\nSequestration of Cargo: As the phagophore expands, it sequesters cytoplasmic cargo within its lumen, encapsulating it within the double-membraned vesicle. This sequestration process allows for the selective targeting and isolation of cellular components destined for degradation, while excluding essential cellular structures from degradation.\nMaturation: Once formed, autophagosomes undergo maturation through a series of fusion events. They fuse with endosomes to form amphisomes, which subsequently fuse with lysosomes to form autolysosomes. These fusion events enable the delivery of autophagosomal cargo to lysosomes for degradation.\nDegradation of Cargo: Within autolysosomes, the acidic environment and the presence of lysosomal hydrolases facilitate the degradation of the sequestered cargo. Proteins, lipids, nucleic acids, and other cellular components are broken down into their constituent molecules, which can then be recycled by the cell.\nRole in Cellular Homeostasis: The autophagosome serves as a critical component of the cellular quality control system, allowing cells to eliminate damaged or unnecessary cellular components and maintain cellular homeostasis. Dysregulation of autophagosome formation and function has been implicated in various diseases, including neurodegenerative disorders, cancer, and metabolic diseases.\n\n\n\n\n\n\n\n\n\nSelective and Non-Selective Autophagy\n\n\n\n\nAutophagy is a highly regulated process that can be categorized into two main types based on the specificity of the cargo targeted for degradation: selective autophagy and non-selective autophagy.\n\nSelective Autophagy: Selective autophagy involves the targeted degradation of specific cellular components, such as damaged organelles, protein aggregates, or invading pathogens. Selective autophagy receptors recognize and bind to cargo destined for degradation, facilitating their engulfment into autophagosomes. Examples of selective autophagy include:\n\nMitophagy: Selective degradation of damaged or dysfunctional mitochondria.\nAggrephagy: Clearance of protein aggregates and inclusion bodies.\nPexophagy: Elimination of peroxisomes.\nLipophagy: Degradation of lipid droplets.\nXenophagy: Removal of intracellular pathogens, such as bacteria or viruses.\n\nNon-Selective Autophagy (Bulk Autophagy): Non-selective autophagy, also known as bulk autophagy, involves the indiscriminate degradation of cytoplasmic components to maintain cellular homeostasis during nutrient deprivation or other stress conditions. In non-selective autophagy, autophagosomes engulf cytoplasmic material randomly without specific cargo recognition. This form of autophagy is essential for recycling cellular constituents and generating nutrients and energy for cell survival during periods of stress.\n\n\n\n\n\n\n\n\nThree Different Kinds of Autophagy\n\n\n\n\nThe three different types of autophagy are:\n\nMacroautophagy: Macroautophagy, often simply referred to as autophagy, involves the sequestration of cytosolic components within double-membraned organelles called autophagosomes. These autophagosomes then fuse with lysosomes to form autolysosomes, where the engulfed cargo is degraded by lysosomal enzymes. Macroautophagy plays a fundamental role in the turnover of cellular components and the maintenance of cellular homeostasis.\nMicroautophagy: Microautophagy involves the direct engulfment of cytosolic components by lysosomes through invagination of the lysosomal membrane. Unlike macroautophagy, which involves the formation of autophagosomes, microautophagy occurs through direct membrane rearrangements at the lysosomal surface. Microautophagy contributes to the selective degradation of cytoplasmic constituents and plays a role in nutrient recycling and cellular quality control.\nChaperone-Mediated Autophagy (CMA): Chaperone-Mediated Autophagy (CMA) is a selective form of autophagy that targets specific cytosolic proteins for degradation. In CMA, chaperone proteins such as heat shock cognate 70 (HSC-70) recognize and bind to target proteins bearing a specific targeting motif. The chaperone-protein complex then interacts with lysosomal-associated membrane protein-2A (LAMP2A) on the lysosomal membrane, leading to the translocation of the unfolded target protein into the lysosome for degradation. CMA is essential for the removal of damaged or misfolded proteins and plays a role in cellular quality control and protein homeostasis.\n\n\n\n\n\n\n\n\n\n\nPhospholipid Structure\n\n\n\n\nPhospholipids are a crucial component of the lipid bilayer, the fundamental structure of cell membranes. Here’s how phospholipids contribute to the structure and function of the lipid bilayer:\n\nBasic Structure: Phospholipids consist of a hydrophilic (water-attracting) head region and two hydrophobic (water-repelling) tail regions. The hydrophilic head contains a phosphate group, which is polar and interacts with water molecules, while the hydrophobic tails consist of fatty acid chains that are nonpolar and repel water.\nArrangement in the Bilayer: In the lipid bilayer, phospholipids arrange themselves in a double layer with their hydrophilic heads facing outward toward the aqueous environment (extracellular space or cytoplasm) and their hydrophobic tails facing inward, away from water. This arrangement creates a hydrophobic core within the membrane, which acts as a barrier to the passage of water-soluble molecules.\nFluidity and Flexibility: Phospholipids confer fluidity and flexibility to the lipid bilayer. The presence of unsaturated fatty acid chains in some phospholipids introduces kinks in the hydrophobic tails, preventing them from packing tightly together. This results in a more fluid and flexible membrane that allows for lateral movement of phospholipids and membrane proteins.\nSelective Permeability: The lipid bilayer, composed primarily of phospholipids, exhibits selective permeability, allowing certain molecules to pass through while restricting the passage of others. Small, nonpolar molecules such as oxygen and carbon dioxide can diffuse freely through the lipid bilayer, while larger or charged molecules require specific transport proteins or channels for passage.\n\n\n\n\n\n\n\n\nFigures Pertaining to Phosphatidylinositol\n\n\n\n\nPhosphatidylinositol (PI) is a type of phospholipid that plays essential roles in cell signaling, membrane structure, and various cellular processes. Here are some key aspects of phosphatidylinositol:\n\nStructure: Phosphatidylinositol consists of a glycerol backbone, two fatty acid chains, and a phosphate group linked to the inositol head group. The inositol head group can be phosphorylated at different positions, leading to the formation of various phosphoinositides.\nCell Signaling: Phosphatidylinositol lipids are crucial components of cell signaling pathways. Phosphorylation of the inositol head group at the 3, 4, and 5 positions generates specific phosphoinositides, such as phosphatidylinositol 3-phosphate (PI3P), phosphatidylinositol 4,5-bisphosphate (PI(4,5)P2), and phosphatidylinositol 3,4,5-trisphosphate (PIP3). These phosphoinositides serve as signaling molecules that regulate diverse cellular processes, including cell growth, proliferation, survival, and vesicle trafficking.\nMembrane Trafficking: Phosphatidylinositol lipids play critical roles in membrane trafficking and vesicle formation. They act as docking sites for proteins involved in vesicle budding, fusion, and trafficking between cellular compartments, such as the endoplasmic reticulum (ER), Golgi apparatus, endosomes, and lysosomes.\nCytoskeleton Regulation: Phosphatidylinositol lipids contribute to the regulation of the cytoskeleton, which is essential for cell shape, movement, and intracellular transport. Phosphoinositides interact with cytoskeletal proteins, such as actin-binding proteins and microtubule-associated proteins, to coordinate cytoskeletal dynamics and cellular processes such as cell migration and cytokinesis.\nMembrane Identity and Function: Phosphatidylinositol lipids help define the identity and function of cellular membranes. By interacting with specific proteins and other lipids, phosphoinositides contribute to membrane curvature, organization, and protein recruitment, thereby regulating membrane structure and function.\nImplications in Disease: Dysregulation of phosphatidylinositol signaling has been implicated in various human diseases, including cancer, neurodegenerative disorders, and metabolic diseases. Mutations in enzymes involved in phosphatidylinositol metabolism and signaling pathways can disrupt cellular homeostasis and contribute to disease pathogenesis.\n\n\n\n\n\n\n\n\n\n\nRegulating Autophagy\n\n\n\n\nThe initiation of autophagy involves a complex series of molecular events orchestrated by several key proteins and signaling pathways. Here’s an overview of the mechanism of autophagy initiation:\n\nActivation of Autophagy-Related Proteins: Autophagy initiation is regulated by a conserved protein kinase complex called the ULK1 (unc-51 like autophagy activating kinase 1) complex, which consists of ULK1, FIP200, ATG13, and ATG101. Under nutrient-rich conditions, the mammalian target of rapamycin complex 1 (mTORC1) phosphorylates ULK1 and inhibits its activity, thereby suppressing autophagy initiation. However, during nutrient deprivation or other stress conditions, mTORC1 is inhibited, leading to the activation of the ULK1 complex.\nNucleation of the Phagophore: Upon activation, the ULK1 complex phosphorylates and activates the class III phosphatidylinositol 3-kinase (PI3K) complex, which includes BECN1 (Beclin 1), VPS34 (vacuolar protein sorting 34), VPS15 (vacuolar protein sorting 15), and ATG14L. The activated PI3K complex generates phosphatidylinositol 3-phosphate (PI3P) on the endoplasmic reticulum (ER) membrane, promoting the nucleation of the phagophore or isolation membrane.\nPhagophore Expansion and Cargo Sequestration: The phagophore expands and engulfs cytoplasmic components, including protein aggregates, damaged organelles, and invading pathogens. This process involves the recruitment of ATG proteins, such as ATG12-ATG5-ATG16L1 complex, and the lipidation of LC3 (microtubule-associated protein 1A/1B-light chain 3) to form LC3-II, which is essential for phagophore elongation and cargo sequestration.\nClosure of the Autophagosome: As the phagophore expands and engulfs cytoplasmic cargo, it eventually closes to form a double-membraned vesicle called the autophagosome. The outer membrane of the autophagosome fuses with vesicles derived from the ER or other membrane sources, while the inner membrane sequesters the cargo destined for degradation.\nFusion with Lysosomes: After closure, autophagosomes undergo fusion with lysosomes, forming autolysosomes. This fusion event is mediated by proteins such as Rab7 and SNARE proteins. The lysosomal hydrolases within autolysosomes degrade the sequestered cargo, releasing breakdown products for recycling and reuse by the cell.\n\n\n\n\n\n\n\n\nModifying PE During Autophagy\n\n\n\n\nThe modification of Atg8 in yeast or LC3 in humans with phosphatidylethanolamine (PE) is a crucial step in the autophagy process. This modification plays a key role in autophagosome formation and cargo sequestration. Here’s how the PE modification of Atg8/LC3 occurs and its significance in autophagy:\n\nConjugation Process: Atg8 in yeast or LC3 in humans undergo a conjugation process to become lipidated with phosphatidylethanolamine (PE). This process involves a series of enzymatic reactions mediated by several autophagy-related proteins. First, Atg8/LC3 is cleaved at its C-terminus by the cysteine protease Atg4, exposing a glycine residue. Then, the exposed glycine residue is conjugated to the amino group of PE through a ubiquitin-like conjugation system. The conjugation of Atg8/LC3 to PE is catalyzed by the sequential action of Atg7 (E1-like enzyme) and Atg3 (E2-like enzyme). This results in the formation of the lipidated form of Atg8/LC3, known as Atg8-PE or LC3-II, which is associated with the autophagosomal membrane.\nMembrane Association: The lipidation of Atg8/LC3 with PE facilitates its association with the autophagosomal membrane. Atg8-PE or LC3-II is recruited to the expanding phagophore, the precursor structure of the autophagosome, where it plays a critical role in membrane elongation and closure. The lipidated form of Atg8/LC3 anchors the autophagosomal membrane to the cytosolic cargo, facilitating cargo sequestration within the autophagosome.\nCargo Sequestration: Atg8/LC3 lipidation with PE is essential for cargo sequestration during autophagy. The lipidated form of Atg8/LC3 acts as a molecular scaffold that binds to specific autophagy receptors, which in turn recognize and tether cargo molecules (such as protein aggregates, damaged organelles, or pathogens) to the autophagosomal membrane. This selective targeting and sequestration of cargo within the autophagosome are crucial for the degradation and recycling of cellular components.\nAutophagosome Maturation: The lipidation of Atg8/LC3 with PE also plays a role in autophagosome maturation and fusion with lysosomes. Once formed, autophagosomes undergo fusion with lysosomes to form autolysosomes, where the sequestered cargo is degraded by lysosomal enzymes. Atg8-PE or LC3-II remains associated with the autophagosomal membrane during this process and is eventually recycled upon autolysosome formation.\n\n\n\n\n\n\n\n\n\nMechanism of Autophagy Initiation\n\n\n\n\nThe initiation of autophagy involves various signaling pathways and regulatory proteins, one of which is the phosphatidylinositol 3-kinase (PI3K) complex. Here’s an overview of how PI3K contributes to autophagy initiation:\n\nFormation of the PI3K Complex: The PI3K complex involved in autophagy initiation consists of several subunits, including the class III PI3K, also known as VPS34 (vacuolar protein sorting 34), and its regulatory subunits such as VPS15 (vacuolar protein sorting 15) and Beclin 1 (BECN1). Under basal conditions or during nutrient-rich states, the activity of the PI3K complex is inhibited.\nActivation by Stress Signals: Autophagy initiation is often triggered by various stress signals, such as nutrient deprivation, oxidative stress, or accumulation of damaged proteins or organelles. These stress signals lead to the inhibition of the mTOR (mechanistic target of rapamycin) pathway, a negative regulator of autophagy, which in turn relieves the suppression of the PI3K complex.\nPhosphatidylinositol 3-Phosphate (PI3P) Production: Upon activation, the PI3K complex catalyzes the phosphorylation of phosphatidylinositol (PI) to generate phosphatidylinositol 3-phosphate (PI3P) on the membranes of various cellular compartments, including the endoplasmic reticulum (ER), Golgi apparatus, and endosomes. PI3P serves as a critical signaling lipid that recruits downstream autophagy-related proteins to initiate autophagosome formation.\nRecruitment of Autophagy Machinery: PI3P-enriched membranes act as nucleation sites for the assembly of the autophagy machinery. Autophagy-related proteins containing PI3P-binding domains, such as WIPI proteins (WD-repeat protein interacting with phosphoinositides), DFCP1 (double FYVE-containing protein 1), and FYCO1 (FYVE and coiled-coil domain-containing protein 1), are recruited to these membranes, where they initiate the formation of the phagophore, the precursor structure of the autophagosome.\nPhagophore Elongation and Cargo Sequestration: The recruitment of autophagy-related proteins to PI3P-enriched membranes promotes the elongation and expansion of the phagophore, leading to the formation of the autophagosomal membrane. Meanwhile, cargo molecules such as protein aggregates, damaged organelles, or intracellular pathogens are selectively recognized and sequestered within the growing autophagosomal membrane.\nAutophagosome Maturation and Fusion with Lysosomes: Following cargo sequestration, the autophagosome matures through membrane fusion events and eventually fuses with lysosomes, forming autolysosomes. Within autolysosomes, the sequestered cargo is degraded by lysosomal hydrolases, and the breakdown products are recycled back into the cytoplasm for reuse.\n\n\n\n\n\n\n\n\n\nCargo Selection\n\n\n\n\nCargo selection in autophagy is a highly regulated process that ensures the selective degradation of specific cellular components, such as damaged organelles, protein aggregates, and intracellular pathogens, while preserving essential cellular structures. Here’s how cargo selection occurs in autophagy:\n\nRecognition by Autophagy Receptors: Cargo selection begins with the recognition of specific cellular components by autophagy receptors. These receptors contain specific domains that recognize and bind to the cargo molecules destined for degradation. Autophagy receptors often contain LC3-interacting region (LIR) motifs, which allow them to interact with Atg8/LC3 proteins on the autophagosomal membrane.\nTargeting Signals and Tags: Cargo molecules destined for degradation may contain specific targeting signals or post-translational modifications that mark them for recognition by autophagy receptors. For example, damaged organelles may expose specific surface markers or undergo modifications that make them recognizable by autophagy receptors.\nInteraction with Autophagy Machinery: Once bound to autophagy receptors, cargo molecules are targeted to the expanding phagophore, the precursor structure of the autophagosome. The autophagy machinery, including Atg proteins and the lipidated form of Atg8/LC3 (such as Atg8-PE or LC3-II), facilitates the sequestration of cargo within the growing autophagosomal membrane.\nCargo Sequestration and Encapsulation: The autophagosomal membrane engulfs the cargo molecules, forming a double-membraned vesicle known as the autophagosome. The lipidated form of Atg8/LC3 anchors the autophagosomal membrane to the cargo, facilitating cargo sequestration within the autophagosome. This process ensures that only selected cargo molecules are enclosed within the autophagosomal vesicle.\nSelective Degradation in Autolysosomes: Autophagosomes subsequently fuse with lysosomes, forming autolysosomes, where the sequestered cargo is degraded by lysosomal hydrolases. The degradation products are then recycled back into the cytoplasm for reuse by the cell. Selective cargo degradation ensures the removal of damaged or unnecessary cellular components while preserving essential cellular structures and functions.\n\n\n\n\n\n\n\n\n\nReceptors in Autophagy\n\n\n\n\nAggrephagy and mitophagy are specialized forms of autophagy that target protein aggregates and damaged mitochondria, respectively, for degradation. The selective recognition and targeting of cargo in these processes involve specific receptors that play crucial roles in cargo recognition and autophagosome formation. Here are the receptors involved in aggrephagy and mitophagy:\n\nReceptors in Aggrephagy: Aggrephagy refers to the selective degradation of protein aggregates by autophagy. Several receptors have been identified to mediate the recognition and targeting of protein aggregates for autophagic degradation. Some of the key receptors involved in aggrephagy include:\n\np62/SQSTM1 (Sequestosome 1): p62 is a multifunctional protein that contains several domains, including an LC3-interacting region (LIR) motif. p62 binds to ubiquitinated protein aggregates via its ubiquitin-binding domain (UBA) and interacts with LC3 on the autophagosomal membrane, facilitating the sequestration of protein aggregates into autophagosomes.\nNBR1 (Neighbor of BRCA1 Gene 1): NBR1 is another autophagy receptor that contains LIR motifs and UBA domains. Similar to p62, NBR1 binds to ubiquitinated protein aggregates and recruits autophagy machinery components to promote their degradation by autophagy.\nOptineurin: Optineurin is a protein involved in various cellular processes, including autophagy. It contains LIR motifs and interacts with both ubiquitin and LC3, facilitating the selective targeting of protein aggregates for autophagic degradation.\n\nReceptors in Mitophagy: Mitophagy specifically targets damaged or dysfunctional mitochondria for degradation to maintain cellular homeostasis. The selective recognition and targeting of mitochondria for degradation involve specific receptors that recognize mitochondrial damage or stress signals. Some of the key receptors involved in mitophagy include:\n\nPINK1 (PTEN-induced putative kinase 1): PINK1 is a mitochondrial kinase that accumulates on the outer mitochondrial membrane (OMM) of damaged mitochondria. Upon mitochondrial depolarization, PINK1 is stabilized and phosphorylates both Parkin and mitochondrial substrates. This recruits Parkin to the depolarized mitochondria, where it ubiquitinates mitochondrial proteins, marking them for selective degradation.\nParkin: Parkin is an E3 ubiquitin ligase that is recruited to depolarized mitochondria by PINK1. Once recruited, Parkin ubiquitinates proteins on the OMM, leading to the recruitment of autophagy receptors such as p62/SQSTM1 and optineurin. These receptors bind to ubiquitinated mitochondrial proteins and interact with LC3 on the autophagosomal membrane, facilitating the engulfment of damaged mitochondria into autophagosomes for degradation.\nBNIP3 (BCL2/adenovirus E1B 19 kDa protein-interacting protein 3): BNIP3 is a mitochondrial outer membrane protein that contains an LC3-interacting region (LIR) motif. During hypoxia or other stress conditions, BNIP3 binds to LC3 on the autophagosomal membrane, mediating the selective engulfment of damaged mitochondria for degradation."
  },
  {
    "objectID": "chapters/week6.html#autophagy-and-neurodegeneration",
    "href": "chapters/week6.html#autophagy-and-neurodegeneration",
    "title": "6  Autophagy of Protein Aggregates and Mitochondria",
    "section": "6.2 Autophagy and Neurodegeneration",
    "text": "6.2 Autophagy and Neurodegeneration\n\n\n\n\n\nMitochondrial Dynamics\n\n\n\n\nMitochondrial dynamics, which include processes such as fusion, fission, and mitochondrial movement, play a crucial role in maintaining mitochondrial function and cellular homeostasis. Here’s how mitochondrial dynamics contribute to protecting mitochondrial function:\n\nMitochondrial Quality Control: Mitochondrial dynamics participate in quality control mechanisms by regulating the turnover of damaged or dysfunctional mitochondria. Fusion facilitates the mixing of mitochondrial contents, allowing damaged mitochondria to exchange components with healthy ones, which may help dilute damaged proteins or DNA. Fission, on the other hand, segregates damaged portions of mitochondria, facilitating their selective removal by mitophagy.\nEnergy Production and Metabolism: Mitochondrial fusion promotes the exchange of mitochondrial DNA, proteins, and metabolites, optimizing mitochondrial function and energy production. By creating interconnected mitochondrial networks, fusion helps to maintain efficient electron transport chain complexes, ensuring proper ATP production and metabolic homeostasis. Additionally, fusion can rescue partially dysfunctional mitochondria by complementing missing or defective components.\nDistribution of Mitochondria: Mitochondrial movement and distribution are essential for ensuring a balanced distribution of mitochondria throughout the cell, particularly in cells with high energy demands or polarized structures. Dynamic positioning of mitochondria allows them to respond rapidly to local energy needs, such as ATP production near sites of high metabolic activity or calcium buffering in regions with elevated calcium levels.\nMitochondrial Adaptation to Stress: Mitochondrial dynamics enable rapid responses to cellular stressors by modulating mitochondrial morphology and function. Under stress conditions such as nutrient deprivation, oxidative stress, or changes in energy demand, mitochondrial dynamics can shift towards fusion or fission to optimize mitochondrial function and promote cellular survival. For example, fusion can mitigate stress-induced mitochondrial fragmentation and maintain mitochondrial integrity.\nApoptosis Regulation: Mitochondrial dynamics also play a role in regulating apoptosis, a programmed cell death process. Alterations in mitochondrial fusion and fission dynamics can influence mitochondrial morphology and membrane permeability, affecting the release of apoptotic factors such as cytochrome c. Balanced mitochondrial dynamics contribute to cell survival by preventing excessive mitochondrial fragmentation and apoptosis induction.\n\n\n6.2.1 If Mitochondria Do Not Fuse or Divide\n\n\n\n\n\nMitochondria Without Fusion or Division\n\n\n\n\nIf mitochondria are unable to fuse or divide properly, it can lead to various cellular dysfunctions and pathologies due to the disruption of mitochondrial dynamics. Here are some consequences of impaired mitochondrial fusion or fission:\n\nAccumulation of Damaged Mitochondria: Without fusion, damaged mitochondria cannot mix their contents with healthy mitochondria, leading to the accumulation of dysfunctional components such as damaged proteins, lipids, and DNA. Similarly, impaired fission prevents the segregation and removal of damaged portions of mitochondria, further exacerbating mitochondrial dysfunction.\nMitochondrial Fragmentation: In the absence of fusion, mitochondria may undergo excessive fission, leading to mitochondrial fragmentation and the formation of smaller, dysfunctional organelles. Fragmented mitochondria have reduced capacity for ATP production, compromised membrane potential, and increased susceptibility to oxidative stress and apoptosis.\nEnergy Deficiency: Mitochondrial fusion is essential for maintaining interconnected mitochondrial networks that facilitate efficient ATP production and metabolic coordination. Impaired fusion results in fragmented mitochondria with reduced respiratory capacity, leading to cellular energy deficits and metabolic dysfunction.\nCellular Stress Sensitivity: Proper mitochondrial dynamics play a crucial role in cellular stress responses by modulating mitochondrial morphology and function. Cells with impaired fusion or fission may exhibit heightened sensitivity to various stressors such as nutrient deprivation, oxidative stress, or changes in energy demand, leading to increased susceptibility to cell death or dysfunction.\nNeurological Disorders: Dysfunction in mitochondrial dynamics has been implicated in the pathogenesis of neurodegenerative diseases such as Parkinson’s disease, Alzheimer’s disease, and Huntington’s disease. Impaired mitochondrial fusion or fission can disrupt neuronal function, synaptic transmission, and neuronal survival, contributing to the progression of neurological disorders.\n\n\n\n6.2.2 Drp1-Mediated Fission\n\n\n\n\n\nMechanism of Drp1\n\n\n\n\nDynamin-related protein 1 (Drp1) is a key regulator of mitochondrial fission, a process that involves the division of mitochondria into smaller organelles. Here’s how Drp1-mediated fission of mitochondria occurs:\n\nLocalization to Mitochondria: Drp1 is primarily a cytosolic protein, but it translocates to the outer mitochondrial membrane (OMM) in response to signals that trigger mitochondrial fission. The recruitment and activation of Drp1 at the OMM are tightly regulated by various factors, including post-translational modifications and binding partners.\nFormation of Oligomeric Rings: Upon translocation to the OMM, Drp1 assembles into higher-order structures, forming spiral or ring-like oligomers around constricted regions of mitochondria. This oligomerization process is facilitated by the GTPase activity of Drp1 and is essential for the subsequent scission of mitochondria.\nConstriction of Mitochondria: As Drp1 oligomers assemble on the OMM, they constrict the mitochondrial membrane at specific sites, often at the points where ER-mitochondria contact sites are located. This constriction process involves the coordinated action of Drp1 and other proteins, such as mitochondrial fission factor (Mff) and mitochondrial dynamics proteins of 49 and 51 kDa (MiD49/51), which serve as receptors for Drp1 recruitment.\nFission Machinery Activation: Once the mitochondria are constricted by Drp1 oligomers, the fission machinery is activated to complete the division process. GTP hydrolysis by Drp1 induces a conformational change that triggers the mechanical force required for mitochondrial scission. This leads to the division of the mitochondria into two daughter organelles.\nRelease of Daughter Mitochondria: Following scission, the daughter mitochondria are released into the cytosol as individual organelles. Drp1 remains associated with the mitochondrial fragments for a short period before being recycled back to the cytosol. The daughter mitochondria undergo further remodeling and fusion with other mitochondria to maintain mitochondrial homeostasis and function.\n\n\n\n6.2.3 Mitochondrial Fusion\n\n\n\n\n\nSchemaitc of Mitochondria Fusion\n\n\n\n\nMitochondrial fusion is a complex process involving the merger of two individual mitochondria to form a single, interconnected organelle. This process is crucial for maintaining mitochondrial function, morphology, and cellular homeostasis. Here’s an overview of the mechanism of mitochondrial fusion:\n\nOuter Membrane Fusion: Mitochondrial fusion begins with the fusion of the outer mitochondrial membranes (OMMs) of two adjacent mitochondria. The initial step involves tethering and docking of the outer membranes through protein-protein interactions. Several protein complexes facilitate this process, including mitofusins (Mfn1 and Mfn2) in mammals and Fzo1 in yeast. These dynamin-like GTPases are anchored in the OMM and mediate the physical interaction between adjacent mitochondria.\nGTP Hydrolysis and Membrane Fusion: After tethering, mitofusins/Fzo1 proteins undergo GTP hydrolysis, leading to a conformational change that promotes the fusion of the outer membranes. This process involves the formation of hemifusion intermediates, where the outer leaflets of the lipid bilayers merge, followed by the fusion of the inner leaflets, resulting in the complete fusion of the outer membranes. The exact mechanism by which mitofusins/Fzo1 facilitate membrane fusion is still under investigation but likely involves changes in protein conformation and lipid rearrangement.\nIntermembrane Space Fusion: Following outer membrane fusion, the inner mitochondrial membranes (IMMs) of the fused mitochondria come into close proximity. Proteins such as OPA1 (optic atrophy 1) in mammals and Mgm1 in yeast are responsible for mediating fusion of the inner membranes. OPA1 is a dynamin-like GTPase that exists in multiple isoforms, some of which are anchored in the IMM and regulate cristae morphology, while others are released into the intermembrane space (IMS) during fusion. The exact role of OPA1/Mgm1 in inner membrane fusion is not fully understood but likely involves tethering, hemifusion, and lipid mixing similar to outer membrane fusion.\nMatrix Content Mixing: Once the outer and inner membranes are fused, the contents of the matrix, including proteins, lipids, and mitochondrial DNA, can mix between the fused mitochondria. This allows for the exchange of metabolites and mitochondrial components, contributing to the maintenance of mitochondrial function, genome integrity, and metabolic homeostasis.\nRegulation of Fusion Machinery: Mitochondrial fusion is tightly regulated by various factors, including post-translational modifications of fusion proteins, calcium signaling, mitochondrial dynamics proteins, and cellular energy status. These regulatory mechanisms ensure the proper coordination of fusion events and prevent excessive or aberrant fusion, which could lead to mitochondrial dysfunction and cellular pathology.\n\n\n\n6.2.4 PINK1, Parkin, and Mitophagy\n\n\n\n\n\nPINK1 and Parkin Mode of Action\n\n\n\n\nPINK1 (PTEN-induced putative kinase 1) and Parkin are two key proteins involved in the regulation of mitophagy, a selective form of autophagy that targets damaged or dysfunctional mitochondria for degradation. Here’s how PINK1 and Parkin cooperate to initiate and execute mitophagy:\n\nPINK1 Activation: Under normal conditions, PINK1 is continuously imported into healthy mitochondria through the translocase of the outer membrane (TOM) complex and the translocase of the inner membrane (TIM)23 complex. Once inside the mitochondria, PINK1 undergoes proteolytic processing by mitochondrial processing peptidase (MPP) and presenilin-associated rhomboid-like protease (PARL), leading to its degradation in the inner mitochondrial membrane (IMM). However, upon mitochondrial damage or depolarization, PINK1 import is impaired, leading to its accumulation on the outer mitochondrial membrane (OMM).\nPINK1 Stabilization and Phosphorylation: Accumulated PINK1 on the OMM becomes stabilized and undergoes autophosphorylation. This phosphorylation activates PINK1’s kinase activity, allowing it to phosphorylate various substrates on the OMM, including Miro and ubiquitin.\nRecruitment of Parkin: Phosphorylated ubiquitin on the OMM serves as a signal for Parkin recruitment. Parkin is an E3 ubiquitin ligase that is normally cytosolic but translocates to damaged mitochondria upon activation by PINK1. Parkin is recruited to mitochondria through its interaction with phosphorylated ubiquitin and other OMM proteins.\nUbiquitination of Mitochondrial Proteins: Once recruited to the mitochondria, Parkin catalyzes the ubiquitination of various OMM proteins, including voltage-dependent anion channel (VDAC) and mitofusins (Mfn1 and Mfn2). Ubiquitination of these proteins serves as a signal for the targeting of damaged mitochondria for degradation.\nRecognition by Autophagy Machinery: Ubiquitinated proteins on the surface of damaged mitochondria are recognized by autophagy receptors such as p62/SQSTM1 and optineurin. These receptors bind to ubiquitin chains via their ubiquitin-binding domains (UBDs) and interact with LC3 on the forming autophagosomal membrane, thereby linking the damaged mitochondria to the autophagy machinery.\nSequestration and Degradation: The autophagosome engulfs the damaged mitochondria, forming an autophagosome-enclosed structure called the mitophagosome. The mitophagosome subsequently fuses with lysosomes to form an autolysosome, where the engulfed mitochondria are degraded by lysosomal enzymes, leading to the removal of damaged components and recycling of nutrients."
  },
  {
    "objectID": "chapters/week7.html",
    "href": "chapters/week7.html",
    "title": "7  Singalling Pathways and Telomeres in Aging",
    "section": "",
    "text": "Mechanism of mTORC1\n\n\n\n\nmTORC1 (mechanistic target of rapamycin complex 1) is a central regulator of cell growth, metabolism, and proliferation in response to various environmental cues, including nutrient availability, energy status, growth factors, and stress signals. Here’s how mTORC1 regulates cell growth:\n\nNutrient Sensing: mTORC1 acts as a nutrient sensor, integrating signals from amino acids, glucose, lipids, and other metabolites to regulate cellular metabolism and growth. Amino acids, particularly leucine and arginine, are potent activators of mTORC1, promoting its translocation to the lysosomal membrane where it becomes activated.\nActivation by Growth Factors: Growth factors such as insulin, insulin-like growth factor 1 (IGF-1), and epidermal growth factor (EGF) activate mTORC1 signaling through the phosphoinositide 3-kinase (PI3K)/Akt pathway. Upon growth factor stimulation, Akt phosphorylates and inhibits tuberous sclerosis complex 2 (TSC2), relieving its inhibitory effect on mTORC1 and promoting its activation.\nCellular Energy Status: mTORC1 activity is also influenced by cellular energy levels, particularly through the AMP-activated protein kinase (AMPK) pathway. AMPK, a sensor of cellular energy depletion, inhibits mTORC1 by phosphorylating TSC2 and raptor, leading to mTORC1 inhibition and energy conservation during metabolic stress.\nRegulation of Protein Synthesis: mTORC1 promotes protein synthesis by phosphorylating and activating key downstream effectors, including ribosomal protein S6 kinase 1 (S6K1) and eukaryotic initiation factor 4E-binding protein 1 (4E-BP1). Activation of S6K1 leads to the phosphorylation of ribosomal proteins and the initiation factors involved in mRNA translation, while phosphorylation of 4E-BP1 releases it from eukaryotic initiation factor 4E (eIF4E), allowing it to initiate cap-dependent translation.\nLipid Biosynthesis and Lipogenesis: mTORC1 promotes lipid biosynthesis and lipogenesis by activating sterol regulatory element-binding proteins (SREBPs) and promoting the transcription of genes involved in fatty acid and cholesterol synthesis. This supports the increased demand for membrane biogenesis and lipid storage during cell growth and proliferation.\nCell Cycle Progression: mTORC1 signaling promotes cell cycle progression by regulating the expression of cyclins, cyclin-dependent kinases (CDKs), and cell cycle inhibitors. Activation of mTORC1 promotes entry into the cell cycle and progression through the G1 phase, facilitating cell growth and proliferation.\n\n\n\n\n\n\n\n\nDifferences Between mTORC1 and mTORC2\n\n\n\n\nmTOR (mechanistic target of rapamycin) exists in two distinct complexes: mTORC1 and mTORC2. While both complexes share the mTOR kinase as a core component, they have different compositions, substrates, and cellular functions. Here’s an overview of mTORC1 and mTORC2:\n\nmTORC1 (mechanistic target of rapamycin complex 1):\n\nComposition: mTORC1 consists of mTOR, regulatory-associated protein of mTOR (RAPTOR), mammalian lethal with SEC13 protein 8 (mLST8), proline-rich Akt substrate 40 kDa (PRAS40), and DEP domain-containing mTOR-interacting protein (DEPTOR).\nActivation: mTORC1 is primarily activated by growth factors, amino acids, energy status, and stress signals. Growth factors such as insulin and insulin-like growth factor 1 (IGF-1) activate mTORC1 through the PI3K/Akt pathway, while amino acids, particularly leucine, activate mTORC1 by promoting its translocation to the lysosomal membrane.\nSubstrates and Functions: mTORC1 regulates protein synthesis, lipid metabolism, autophagy, and cell growth by phosphorylating downstream effectors such as ribosomal protein S6 kinase 1 (S6K1) and eukaryotic initiation factor 4E-binding protein 1 (4E-BP1). Activation of mTORC1 promotes protein synthesis, lipid biosynthesis, and cell proliferation, while inhibiting autophagy.\n\nmTORC2 (mechanistic target of rapamycin complex 2):\n\nComposition: mTORC2 consists of mTOR, rapamycin-insensitive companion of mTOR (RICTOR), mammalian stress-activated protein kinase-interacting protein 1 (mSIN1), protein observed with RICTOR 1 and 2 (PROTOR1/2), and mLST8.\nActivation: mTORC2 is less well understood than mTORC1, but it is activated by growth factors and regulates cell survival, cytoskeletal organization, and metabolism. Growth factor stimulation activates mTORC2 through PI3K/Akt pathway-dependent mechanisms.\nSubstrates and Functions: mTORC2 phosphorylates downstream effectors such as Akt at Serine 473 (Ser473), protein kinase C (PKC), and serum- and glucocorticoid-inducible kinase 1 (SGK1). Akt phosphorylation by mTORC2 at Ser473 enhances its kinase activity and promotes cell survival, proliferation, and metabolism. Additionally, mTORC2 regulates cytoskeletal dynamics and cell migration through its effects on PKC and SGK1.\n\n\n\n\n\n\n\n\n\n\nmTORC1 Inhibiting Autophagy\n\n\n\n\nYes, mTORC1 (mechanistic target of rapamycin complex 1) is a potent inhibitor of autophagy, a cellular process responsible for the degradation and recycling of damaged or unnecessary cellular components. Here’s how mTORC1 inhibits autophagy:\n\nRegulation of Autophagy Initiation: mTORC1 negatively regulates the initiation of autophagy by phosphorylating and inhibiting key components of the autophagy machinery, including the Unc-51-like kinase 1 (ULK1) complex. ULK1 is a key initiator of autophagy, and its activity is inhibited by phosphorylation by mTORC1. When mTORC1 is active, it phosphorylates ULK1 and inhibits its kinase activity, thereby suppressing the initiation of autophagy.\nInhibition of Autophagy Induction: mTORC1 also inhibits autophagy induction by regulating the activity of transcription factors involved in the expression of autophagy-related genes. For example, mTORC1 phosphorylates and inhibits the transcription factor EB (TFEB), a master regulator of lysosomal and autophagy gene expression. Inhibition of TFEB by mTORC1 prevents the transcriptional upregulation of genes involved in lysosome biogenesis and autophagy, thereby suppressing autophagy induction.\nRegulation of Autophagosome Formation: In addition to its effects on autophagy initiation and induction, mTORC1 also regulates the formation of autophagosomes, the double-membraned vesicles responsible for sequestering cellular cargo for degradation. mTORC1 inhibits the formation of autophagosomes by phosphorylating and inhibiting components of the phosphatidylinositol 3-kinase (PI3K) complex, which is required for the nucleation of the autophagosomal membrane.\n\n\n\n\n\n\n\n\n\nActivation at Lysosomes\n\n\n\n\nmTORC1 (mechanistic target of rapamycin complex 1) activation at lysosomes is a critical step in the regulation of cell growth, metabolism, and autophagy. Lysosomes serve as signaling platforms for mTORC1 activation in response to various environmental cues, including amino acids, growth factors, and cellular energy status. Here’s how mTORC1 is activated at lysosomes:\n\nAmino Acid Sensing: Amino acids, particularly essential amino acids such as leucine, arginine, and glutamine, are potent activators of mTORC1 signaling. Upon amino acid stimulation, a series of events occur at the lysosomal surface to promote mTORC1 activation.\nRag GTPases: The Rag GTPases, consisting of RagA/B and RagC/D heterodimers, play a central role in amino acid sensing and mTORC1 activation at lysosomes. Rag GTPases are anchored to the lysosomal membrane and function as molecular switches that regulate the recruitment of mTORC1 to lysosomes in response to amino acid availability.\nRagulator Complex: The Rag GTPases are regulated by the Ragulator complex, a pentameric protein complex associated with the lysosomal surface. The Ragulator complex acts as a guanine nucleotide exchange factor (GEF) for RagA/B, promoting their activation in the presence of amino acids.\nRag-mTORC1 Interaction: Activated Rag GTPases recruit mTORC1 to the lysosomal surface by interacting with the RAPTOR subunit of mTORC1. The interaction between Rag GTPases and mTORC1 is facilitated by the cytosolic scaffold protein folliculin-interacting protein 1 (FNIP1) and its homolog FNIP2.\nRheb-GTP Loading: Once recruited to the lysosomes, mTORC1 becomes activated by the small GTPase Ras homolog enriched in brain (Rheb). Rheb is a potent activator of mTORC1 and is localized to the lysosomal membrane in its active, GTP-bound state. Rheb-GTP directly binds to and activates mTORC1, leading to its phosphorylation and activation.\nDownstream Signaling: Activated mTORC1 phosphorylates a multitude of downstream targets involved in protein synthesis, lipid metabolism, and autophagy regulation, thereby coordinating cellular responses to nutrient availability and growth signals.\n\n\n\n\n\n\n\n\n\nRTK Activation\n\n\n\n\nReceptor tyrosine kinases (RTKs) are cell surface receptors that play crucial roles in signal transduction by initiating intracellular signaling cascades in response to extracellular stimuli such as growth factors, hormones, and cytokines. RTK activation typically occurs through dimerization, a process where two receptor molecules come together to form a functional complex. Here’s how RTK activation by dimerization works:\n\nLigand Binding: RTKs have an extracellular ligand-binding domain that interacts with specific ligands, such as growth factors or hormones, in the extracellular space. Ligand binding induces a conformational change in the receptor, leading to the formation of an active signaling state.\nReceptor Dimerization: Ligand binding promotes the association of two RTK monomers, either by bringing pre-existing receptors into close proximity or by inducing receptor clustering on the cell surface. This dimerization event can occur in various configurations, including homodimerization (two identical receptor monomers) or heterodimerization (two different receptor monomers).\nTransphosphorylation: Upon dimerization, the intracellular tyrosine kinase domains of the RTK monomers become juxtaposed, allowing for cross-phosphorylation of specific tyrosine residues within the kinase activation loop of the opposing receptor. This transphosphorylation event leads to the activation of the RTK’s intrinsic kinase activity.\nRecruitment of Signaling Molecules: Phosphorylated tyrosine residues on the activated RTK serve as docking sites for various cytoplasmic signaling molecules containing Src homology 2 (SH2) or phosphotyrosine-binding (PTB) domains. These signaling molecules, such as adaptor proteins and enzymes, are recruited to the phosphorylated RTKs, where they become activated or modulate downstream signaling cascades.\nInitiation of Downstream Signaling: The recruitment and activation of downstream signaling molecules at the activated RTKs initiate intracellular signaling cascades that propagate the signal from the cell surface to the nucleus. These signaling pathways regulate diverse cellular processes, including cell proliferation, survival, differentiation, and metabolism, depending on the specific RTK and its associated signaling partners.\n\n\n\n\n\n\n\n\n\nPI3K-AKT-mTOR Signalling Pathway\n\n\n\n\nThe PI3K-AKT-mTOR signaling pathway is a key intracellular signaling pathway involved in the regulation of various cellular processes, including cell growth, proliferation, survival, metabolism, and protein synthesis. Here’s an overview of how this pathway operates:\n\nActivation of PI3K: The pathway is initiated by the activation of phosphoinositide 3-kinase (PI3K) in response to extracellular stimuli such as growth factors (e.g., insulin, insulin-like growth factor 1, epidermal growth factor). Upon ligand binding to their respective receptor tyrosine kinases (RTKs), PI3K is recruited to the plasma membrane, where it phosphorylates phosphatidylinositol 4,5-bisphosphate (PIP2) to generate phosphatidylinositol 3,4,5-trisphosphate (PIP3).\nActivation of AKT: PIP3 serves as a second messenger that recruits AKT (also known as protein kinase B) to the plasma membrane via its pleckstrin homology (PH) domain. Once localized to the membrane, AKT is phosphorylated and activated by phosphoinositide-dependent kinase 1 (PDK1) at threonine 308. Full activation of AKT also requires phosphorylation at serine 473, which can be mediated by mTOR complex 2 (mTORC2) or other kinases.\nAKT-Mediated Signaling: Activated AKT phosphorylates and regulates numerous downstream targets involved in various cellular processes. Some of the key targets of AKT include:\n\nmTORC1: AKT activates mTORC1 by phosphorylating and inhibiting tuberous sclerosis complex 2 (TSC2), leading to the activation of mTORC1 and subsequent stimulation of protein synthesis and cell growth.\nGlycogen synthase kinase 3 (GSK3): AKT phosphorylates and inhibits GSK3, which regulates glycogen synthesis, protein translation, and cell survival.\nBad: AKT phosphorylates and inactivates the pro-apoptotic protein Bad, preventing its association with anti-apoptotic Bcl-2 family members and promoting cell survival.\nFOXO transcription factors: AKT phosphorylates FOXO transcription factors, leading to their cytoplasmic sequestration and inhibition of their transcriptional activity, which regulates genes involved in apoptosis, cell cycle arrest, and oxidative stress response.\n\nmTOR Signaling: The activation of mTORC1 by AKT leads to the phosphorylation and activation of downstream effectors such as ribosomal protein S6 kinase 1 (S6K1) and eukaryotic initiation factor 4E-binding protein 1 (4E-BP1). Activation of these effectors promotes protein synthesis, ribosome biogenesis, and cell growth.\nCellular Responses: The PI3K-AKT-mTOR signaling pathway regulates various cellular processes in response to extracellular cues, including cell growth, proliferation, survival, metabolism, and protein synthesis. Dysregulation of this pathway is implicated in numerous diseases, including cancer, diabetes, and neurological disorders.\n\n\n\n\n\n\n\n\n\nCells With and Without Glucose\n\n\n\n\nInsulin plays a central role in the regulation of glucose uptake by cells, particularly in skeletal muscle, adipose tissue, and liver. Here’s how insulin facilitates glucose uptake:\n\nInsulin Secretion: After a meal, blood glucose levels rise, triggering the secretion of insulin from pancreatic beta cells. Insulin acts as a hormone that signals cells to take up glucose from the bloodstream.\nInsulin Receptor Activation: Insulin binds to its receptor, the insulin receptor (IR), which is a receptor tyrosine kinase located on the cell surface of target cells. Binding of insulin to the IR leads to autophosphorylation and activation of the receptor’s tyrosine kinase activity.\nInsulin Signaling Cascade: Activated insulin receptors phosphorylate intracellular substrates, including insulin receptor substrate proteins (IRS), which serve as docking sites for downstream signaling molecules. Phosphorylated IRS proteins recruit and activate phosphoinositide 3-kinase (PI3K), initiating a signaling cascade.\nActivation of GLUT4 Translocation: PI3K activation leads to the phosphorylation and activation of protein kinase B (AKT), which in turn phosphorylates and activates AS160 (Akt substrate of 160 kDa). Phosphorylated AS160 facilitates the translocation of glucose transporter 4 (GLUT4) vesicles from intracellular storage compartments to the cell membrane.\nGlucose Uptake: Upon translocation to the cell membrane, GLUT4 facilitates the uptake of glucose from the extracellular space into the cytoplasm of target cells. In skeletal muscle and adipose tissue, this process significantly increases glucose uptake, allowing cells to utilize glucose for energy production or storage as glycogen or fat.\nGlucose Metabolism: Once inside the cell, glucose undergoes metabolism through glycolysis, the tricarboxylic acid (TCA) cycle, and oxidative phosphorylation to produce ATP, the cell’s primary energy source. Additionally, glucose can be stored as glycogen in the liver and muscle or converted to fatty acids for storage in adipose tissue."
  },
  {
    "objectID": "chapters/week7.html#telomeres-and-aging",
    "href": "chapters/week7.html#telomeres-and-aging",
    "title": "7  Singalling Pathways and Telomeres in Aging",
    "section": "7.2 Telomeres and Aging",
    "text": "7.2 Telomeres and Aging\n\n\n\n\n\nEnd-Replication Problem\n\n\n\n\nCellular senescence is a phenomenon where cells undergo irreversible growth arrest in response to various stressors, such as DNA damage, telomere shortening, oxidative stress, or oncogenic signaling. One of the key mechanisms underlying cellular senescence is the “end-replication problem.”\nThe end-replication problem refers to the inability of DNA polymerases to fully replicate the ends of linear chromosomes during DNA replication. In eukaryotic cells, chromosomes are capped by structures called telomeres, which consist of repetitive DNA sequences and associated proteins. Telomeres play a crucial role in protecting the integrity of chromosomes and preventing the loss of genetic information during DNA replication.\nDuring each round of DNA replication, the DNA polymerase complex synthesizes new DNA strands in the 5’ to 3’ direction. However, due to the nature of DNA polymerases and the absence of a primer at the end of the template strand, the replication machinery is unable to replicate the extreme ends of linear chromosomes completely. As a result, with each round of cell division, telomeres progressively shorten.\nTelomere shortening serves as a “mitotic clock” that limits the replicative lifespan of cells. When telomeres become critically short, they lose their protective function, leading to the activation of DNA damage response pathways and triggering cellular senescence. Additionally, dysfunctional telomeres can undergo inappropriate DNA repair mechanisms, resulting in genomic instability and promoting oncogenic transformation.\nCellular senescence mediated by the end-replication problem serves as a tumor suppressive mechanism by preventing the proliferation of cells with damaged or unstable genomes. However, excessive accumulation of senescent cells over time contributes to aging and age-related diseases, as senescent cells secrete pro-inflammatory cytokines, growth factors, and proteases collectively known as the senescence-associated secretory phenotype (SASP), which can disrupt tissue homeostasis and promote chronic inflammation.\n\n7.2.1 End Replication by Telomerase\n\n\n\n\n\nTelomerase Replication\n\n\n\n\nTelomerase is a specialized enzyme that counteracts the end-replication problem by adding repetitive DNA sequences to the ends of linear chromosomes, known as telomeres. Telomerase activity is particularly important in cells with high proliferative capacity, such as stem cells and cancer cells, as it helps maintain telomere length and ensures genomic stability during repeated rounds of cell division.\nHere’s how telomerase mediates the end-replication process:\n\nTelomere Structure: Telomeres consist of repetitive DNA sequences (TTAGGG in humans) and associated proteins that cap the ends of linear chromosomes. Telomeres protect chromosome ends from degradation and prevent them from being recognized as DNA breaks by the cellular DNA repair machinery.\nTelomerase Enzyme: Telomerase is a ribonucleoprotein complex composed of two main components: a catalytic protein subunit called telomerase reverse transcriptase (TERT) and an RNA component called telomerase RNA (TERC). TERC serves as a template for the synthesis of telomeric DNA by TERT.\nExtension of Telomeres: During DNA replication, the lagging strand of the chromosome cannot be fully replicated due to the end-replication problem. Telomerase acts to extend the telomeres by adding repetitive DNA sequences to the 3’ end of the lagging strand.\nTelomerase Action: Telomerase extends telomeres in a processive manner by using the RNA template within TERC to synthesize repetitive telomeric DNA sequences onto the chromosome ends. This elongation process compensates for the telomere shortening that occurs during each round of DNA replication.\nTelomere Length Maintenance: By counteracting telomere shortening, telomerase helps maintain telomere length and prevents telomeres from becoming critically short. This ensures the stability of linear chromosomes and promotes cell proliferation and genomic integrity.\nRole in Stem Cells and Cancer: Telomerase activity is particularly high in stem cells and cancer cells, where it helps maintain telomere length and sustains the replicative capacity of these cells. In cancer cells, upregulation of telomerase activity allows for unlimited cell proliferation, contributing to tumor growth and progression.\n\n\n\n7.2.2 DNA Damage Response\n\n\n\n\n\nIllustration of the DNA Damage Response\n\n\n\n\nThe DNA damage response (DDR) is a complex network of signaling pathways that detects and repairs damaged DNA, maintaining genomic stability and preventing the accumulation of mutations that can lead to diseases such as cancer. The DDR involves a series of coordinated molecular events that are activated in response to various types of DNA damage, including DNA double-strand breaks (DSBs), single-strand breaks (SSBs), cross-links, and base modifications. Here’s an overview of the key components and processes involved in the DDR:\n\nDetection of DNA Damage: DNA damage is detected by sensor proteins that recognize specific types of lesions or abnormalities in the DNA structure. These sensor proteins include the MRN complex (MRE11-RAD50-NBS1), Ku70/Ku80 heterodimer, PARP1 (poly(ADP-ribose) polymerase 1), and various DNA damage checkpoint proteins.\nActivation of Checkpoint Signaling: Upon detection of DNA damage, sensor proteins activate checkpoint signaling pathways to halt the cell cycle and prevent the propagation of damaged DNA to daughter cells. Key checkpoint kinases involved in this process include ATM (ataxia telangiectasia mutated), ATR (ataxia telangiectasia and Rad3-related), and DNA-PK (DNA-dependent protein kinase).\nTransduction of DNA Damage Signals: Activated checkpoint kinases phosphorylate downstream effector proteins, including CHK1 and CHK2, which in turn phosphorylate a variety of target proteins involved in cell cycle regulation, DNA repair, and apoptosis. Phosphorylation of these effector proteins leads to the activation of DNA damage response pathways and the initiation of appropriate cellular responses.\nDNA Repair Pathways: The DDR coordinates several DNA repair pathways to remove or repair damaged DNA lesions, including:\n\nNon-homologous end joining (NHEJ): Repairs DNA DSBs by directly ligating broken DNA ends together. NHEJ is error-prone and can lead to the introduction of small insertions or deletions.\nHomologous recombination (HR): Repairs DNA DSBs using an undamaged sister chromatid or homologous DNA sequence as a template. HR is a high-fidelity repair pathway that restores the original DNA sequence.\nBase excision repair (BER): Repairs damaged DNA bases and single-strand breaks by excising the damaged nucleotide and replacing it with a new one.\nNucleotide excision repair (NER): Repairs bulky DNA lesions, such as UV-induced thymine dimers or chemical adducts, by removing a short stretch of nucleotides surrounding the lesion and replacing it with newly synthesized DNA.\n\nCellular Responses: Depending on the extent and type of DNA damage, cells may undergo various responses, including cell cycle arrest, DNA repair, senescence, or apoptosis. These responses are critical for maintaining genomic integrity and preventing the propagation of damaged DNA to daughter cells.\n\n\n\n7.2.3 Shelterin\n\n\n\n\n\nShelterin\n\n\n\n\nShelterin is a protein complex that plays a critical role in protecting and regulating the structure of telomeres, the repetitive DNA sequences located at the ends of linear chromosomes. Telomeres function to maintain chromosome stability by preventing the ends of chromosomes from being recognized as DNA breaks and undergoing inappropriate DNA repair or degradation processes. Shelterin proteins bind to telomeric DNA and help to form a specialized nucleoprotein structure that shields telomeres from being recognized as damaged DNA.\nThe Shelterin complex consists of several key protein components, each with specific functions:\n\nTRF1 (Telomeric Repeat-binding Factor 1) and TRF2 (Telomeric Repeat-binding Factor 2): TRF1 and TRF2 are DNA-binding proteins that specifically recognize and bind to double-stranded telomeric DNA. They play essential roles in forming and maintaining the structure of telomeres by facilitating the formation of higher-order telomeric loops, known as T-loops. TRF2 is particularly important for protecting telomeres from being recognized as DNA double-strand breaks and promoting telomere end-capping.\nTIN2 (TRF1-interacting Nuclear factor 2): TIN2 serves as a central scaffold protein within the Shelterin complex, interacting with TRF1, TRF2, and other Shelterin components. TIN2 helps to stabilize the Shelterin complex and regulate its interactions with other proteins involved in telomere maintenance and DNA repair.\nRAP1 (Repressor/activator Protein 1): RAP1 binds to the telomeric DNA sequence in a sequence-specific manner and interacts with TRF2. RAP1 plays a role in regulating telomere length and function, as well as in coordinating telomere maintenance with other cellular processes such as transcriptional regulation and DNA repair.\nPOT1 (Protection of Telomeres 1): POT1 binds specifically to the single-stranded DNA overhang present at the 3’ end of telomeres. POT1 protects telomeres from inappropriate DNA damage responses and regulates telomere length by interacting with telomerase and regulating its access to telomeric DNA.\nTPP1 (Adrenocortical Dysplasia Homolog (ACD) Protein 1): TPP1 interacts with POT1 and TIN2 within the Shelterin complex and plays a crucial role in stabilizing POT1 binding to telomeric DNA. TPP1 also facilitates the recruitment and activation of telomerase at telomeres, promoting telomere elongation and maintenance.\n\n\n7.2.3.1 Telomerase and Shelterin\n\n\n\n\n\nTelomere Loop\n\n\n\n\nThe telomere loop, or T-loop, is a specialized nucleoprotein structure that forms at the ends of linear chromosomes, where telomeric DNA sequences are located. The T-loop plays a crucial role in protecting chromosome ends from being recognized as DNA double-strand breaks and from undergoing inappropriate DNA repair processes. It consists of the single-stranded 3’ overhang of telomeric DNA invading and pairing with double-stranded telomeric DNA upstream, creating a looped structure.\nTelomerase and Shelterin proteins work together to solve the end-replication problem and maintain telomere integrity:\n\nTelomerase: Telomerase is a specialized enzyme that adds repetitive DNA sequences to the ends of chromosomes, compensating for the loss of telomeric DNA during each round of DNA replication. Telomerase contains an RNA component (TERC) that serves as a template for synthesizing telomeric DNA and a catalytic protein component (TERT) that carries out the DNA synthesis reaction. By adding telomeric repeats to chromosome ends, telomerase helps counteract the gradual shortening of telomeres and ensures their stability.\nShelterin Complex: The Shelterin complex is a group of proteins that bind to telomeric DNA and help maintain the structural integrity of telomeres. Key components of the Shelterin complex include TRF1, TRF2, TIN2, RAP1, POT1, and TPP1. Shelterin proteins play essential roles in protecting telomeres from being recognized as DNA damage sites, regulating telomere length, and coordinating telomere maintenance with other cellular processes.\n\nTogether, telomerase and Shelterin proteins collaborate to solve the end-replication problem and maintain telomere stability. Telomerase adds telomeric repeats to chromosome ends, counteracting telomere shortening, while Shelterin proteins help form and stabilize the T-loop structure, preventing chromosome ends from being recognized as DNA breaks and protecting them from inappropriate DNA repair mechanisms.\n\n\n\n7.2.4 Cellular Senescence\n\n\naging.png){fig-align=‘center’ width=506}\n\n\nCellular senescence is a process in which cells undergo irreversible growth arrest in response to various stressors, such as DNA damage, telomere shortening, oncogene activation, or oxidative stress. Senescent cells display distinct phenotypic changes, including altered gene expression patterns, increased secretion of inflammatory cytokines and growth factors (known as the senescence-associated secretory phenotype or SASP), and changes in cell morphology.\nOne of the key triggers for cellular senescence is telomere shortening. Telomeres are repetitive DNA sequences located at the ends of linear chromosomes, and they protect chromosome ends from degradation and fusion with neighboring chromosomes. During each round of cell division, telomeres undergo gradual shortening due to the end-replication problem, where DNA polymerases are unable to fully replicate the ends of linear chromosomes.\nIn normal somatic cells, telomerase activity is typically repressed or downregulated, leading to progressive telomere shortening with each cell division. Eventually, telomeres become critically short, triggering a DNA damage response and cellular senescence. This downregulation of telomerase expression in somatic cells serves as a tumor suppressive mechanism, as it limits the proliferative potential of cells and prevents the accumulation of genetic mutations that could lead to cancer.\nThe regulation of telomerase expression in somatic cells is complex and involves multiple factors, including epigenetic modifications, transcriptional regulation, and telomere-associated proteins. Various signaling pathways, such as the p53/p21 and p16INK4a/Rb pathways, play important roles in controlling telomerase expression and cellular senescence. For example, activation of the p53 tumor suppressor pathway in response to DNA damage or other stress signals can lead to transcriptional repression of the TERT gene, which encodes the catalytic subunit of telomerase.\n\n\n7.2.5 Shelterin and Non-Homologous End Joining\n\n\n\n\n\nNHEJ and Shelterin\n\n\n\n\nTelomeres play a critical role in maintaining genomic stability by protecting chromosome ends from being recognized as DNA double-strand breaks (DSBs) and undergoing inappropriate DNA repair mechanisms. Dysfunctional telomeres, resulting from excessive shortening or loss of telomeric proteins, can lead to genome instability and contribute to the development of cancer.\nThe Shelterin complex, comprised of several key proteins including TRF1, TRF2, TIN2, RAP1, POT1, and TPP1, is essential for maintaining telomere integrity and function. Shelterin proteins bind to telomeric DNA and help form a specialized nucleoprotein structure that protects chromosome ends. One of the critical functions of Shelterin is to prevent non-homologous end joining (NHEJ) at telomeres.\nNHEJ is an error-prone DNA repair pathway that directly ligates broken DNA ends together, often resulting in the loss or addition of nucleotides and potentially leading to chromosomal rearrangements or deletions. At dysfunctional telomeres, NHEJ-mediated repair can result in telomere fusion, chromosome end-to-end fusions, or other chromosomal abnormalities, all of which contribute to genome instability and promote tumorigenesis.\nShelterin proteins help prevent NHEJ at telomeres through several mechanisms:\n\nTRF2-Mediated Protection: TRF2 plays a key role in protecting telomeres from being recognized as DSBs and inhibiting the activation of the DNA damage response (DDR) at chromosome ends. By forming a protective cap at telomeres, TRF2 prevents the binding of NHEJ factors and blocks the initiation of inappropriate DNA repair processes.\nInhibition of Ku70/Ku80: The Ku70/Ku80 heterodimer is a critical component of the NHEJ pathway and is involved in DNA end recognition and tethering during repair. Shelterin proteins, particularly TRF2, have been shown to inhibit the recruitment and function of Ku70/Ku80 at telomeres, thereby preventing NHEJ-mediated repair.\nShelterin-Mediated Sequestration: Shelterin proteins help maintain the structural integrity of telomeres and promote the formation of higher-order nucleoprotein structures, such as the T-loop. These structures sequester the chromosome end and prevent it from being recognized as a DNA break, thereby minimizing the likelihood of NHEJ-mediated repair."
  },
  {
    "objectID": "chapters/week8.html",
    "href": "chapters/week8.html",
    "title": "8  Mechanism of Intracellular Protein Deposition",
    "section": "",
    "text": "Hsp104 Action\nProtein disaggregation is a critical cellular process that helps maintain protein homeostasis by resolving protein aggregates and misfolded proteins. One key player in this process is the heat shock protein 104 (Hsp104), a molecular chaperone found in certain organisms such as yeast.\nHsp104 functions as a disaggregase, meaning it is capable of dissociating and solubilizing protein aggregates, thereby restoring proteins to their functional, native state. Here’s how Hsp104 accomplishes this task:"
  },
  {
    "objectID": "chapters/week8.html#cystic-fibrosis",
    "href": "chapters/week8.html#cystic-fibrosis",
    "title": "8  Mechanism of Intracellular Protein Deposition",
    "section": "8.1 Cystic Fibrosis",
    "text": "8.1 Cystic Fibrosis\n\n\n\n\n\nCFTR Gene\n\n\n\n\nCystic fibrosis (CF) is a genetic disorder characterized by the buildup of thick, sticky mucus in the lungs, digestive system, and other organs. It is caused by mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene, which encodes a protein that regulates the flow of salt and fluids in and out of cells.\nThe CFTR protein is a chloride channel found primarily in the epithelial cells lining the respiratory, digestive, and reproductive tracts. It plays a crucial role in maintaining the balance of salt and water across cell membranes, which is essential for normal fluid secretion and mucus clearance in various organs.\nMutations in the CFTR gene can lead to dysfunction or absence of the CFTR protein, resulting in impaired chloride transport and dysregulated fluid secretion. This leads to the buildup of thick, sticky mucus in the airways, pancreas, liver, intestines, and other organs, leading to a range of symptoms and complications characteristic of cystic fibrosis.\nSome common symptoms of cystic fibrosis include:\n\nPersistent coughing with thick mucus\nFrequent lung infections, such as pneumonia and bronchitis\nDifficulty breathing and shortness of breath\nPoor growth and weight gain despite a good appetite\nSalty-tasting skin\nDigestive problems, including pancreatic insufficiency and intestinal blockages\nMale infertility due to congenital absence of the vas deferens\n\nTreatment for cystic fibrosis aims to manage symptoms, prevent complications, and improve quality of life. This may include medications to help thin mucus, antibiotics to treat infections, airway clearance techniques, nutritional support, and, in some cases, lung transplantation. Emerging therapies, such as CFTR modulators, target specific defects in the CFTR protein and aim to correct or improve chloride transport function, offering promising new treatment options for individuals with cystic fibrosis.\n\n8.1.1 Mucous Production in Cystic Fibrosis\n\n\n\n\n\nMucous Production in Cystic Fibrosis\n\n\n\n\nThe CFTR gene encodes the cystic fibrosis transmembrane conductance regulator protein, which plays a crucial role in regulating the flow of salt and fluids across cell membranes. Mutations in the CFTR gene result in dysfunctional or absent CFTR protein, leading to impaired chloride transport and dysregulated fluid secretion in various organs.\nOne of the hallmark features of cystic fibrosis is the buildup of thick, sticky mucus in the airways, digestive tract, and other organs. This mucus accumulation impairs mucociliary clearance, which is a key defense mechanism of the lungs. Mucociliary clearance involves the coordinated movement of mucus and its contents, including potentially harmful substances like bacteria and debris, out of the lungs via ciliary action.\nIn individuals with cystic fibrosis, the impaired clearance of mucus from the airways leads to the retention of mucus, along with trapped bacteria and other pathogens. This creates an environment conducive to recurrent lung infections, inflammation, and progressive damage to lung tissue, ultimately resulting in respiratory symptoms such as persistent coughing, difficulty breathing, and recurrent lung infections.\n\n\n8.1.2 CFTR Aggregation\n\n\n\n\n\nCFTR Aggregation\n\n\n\n\nIn cystic fibrosis (CF), the cystic fibrosis transmembrane conductance regulator (CFTR) protein undergoes both degradation and aggregation, contributing to the pathophysiology of the disease.\n\nDegradation of CFTR: CFTR protein degradation occurs when mutated CFTR proteins are recognized as misfolded or defective by the cellular quality control machinery. This recognition typically leads to the targeting of mutant CFTR proteins for degradation through the cellular degradation pathways, such as the ubiquitin-proteasome system or the lysosomal degradation pathway.\n\nUbiquitin-Proteasome System (UPS): Misfolded or defective CFTR proteins may be tagged with ubiquitin molecules, marking them for degradation by the proteasome, a cellular complex responsible for degrading unwanted or damaged proteins. Defective CFTR proteins that fail to pass quality control are ubiquitinated and targeted for degradation by the proteasome.\nLysosomal Degradation Pathway: Alternatively, misfolded CFTR proteins may be trafficked to lysosomes, where they are degraded by lysosomal enzymes. Lysosomes are cellular organelles containing enzymes capable of breaking down proteins, lipids, and other macromolecules. CFTR proteins that are misfolded or fail to properly fold may be targeted to lysosomes for degradation.\n\nAggregation of CFTR: In addition to degradation, misfolded or defective CFTR proteins may also form aggregates or clumps within cells. Aggregation occurs when mutated CFTR proteins, unable to fold properly, accumulate and interact with each other, leading to the formation of insoluble protein aggregates.\n\nImpact on Cellular Function: The aggregation of CFTR proteins can disrupt cellular processes and impair cellular function. Aggregated CFTR proteins may interfere with intracellular trafficking pathways, impair protein folding and assembly, and disrupt normal cellular signaling processes. Additionally, protein aggregates can trigger cellular stress responses and contribute to cellular toxicity.\nContribution to Disease Pathology: The accumulation of misfolded CFTR proteins and protein aggregates is thought to contribute to the pathogenesis of cystic fibrosis by impairing CFTR function, disrupting cellular homeostasis, and promoting cellular dysfunction and tissue damage. The presence of protein aggregates may also exacerbate inflammation and oxidative stress, further contributing to disease progression.\n\n\n\n8.1.2.1 APP\n\n\n\n\n\nAPP Forming Aggresomes\n\n\n\n\nAnother membrane protein known to form aggresomes is the amyloid precursor protein (APP). APP is a type I transmembrane protein that plays a role in synaptic function and has been implicated in the pathogenesis of Alzheimer’s disease (AD) when processed aberrantly.\n\nAmyloid Precursor Protein (APP): APP is primarily known for its involvement in the pathogenesis of Alzheimer’s disease, where abnormal processing of APP leads to the production and accumulation of amyloid-beta (Aβ) peptides. However, under certain conditions, misfolded or aggregated forms of APP can accumulate in cells and contribute to the formation of aggresomes.\nAggresome Formation: Similar to CFTRΔF508, misfolded or aggregated forms of APP can overwhelm the cellular quality control machinery, leading to the formation of aggresomes. Aggresomes serve as sites for sequestering and concentrating misfolded proteins, preventing their toxic effects and facilitating their subsequent degradation.\nConsequences for Cellular Function: The accumulation of misfolded APP in aggresomes can disrupt cellular homeostasis and impair cellular function. Aggresome formation may interfere with normal cellular processes, such as protein trafficking, organelle dynamics, and cellular signaling pathways. Additionally, the sequestration of misfolded APP in aggresomes may prevent its proper localization and function at the cell membrane, where it is involved in synaptic transmission and neuronal signaling.\nPathological Implications: In the context of Alzheimer’s disease, the aggregation of APP and the accumulation of Aβ peptides are key pathological features associated with the formation of amyloid plaques in the brain. Aggresome formation may represent a cellular response to the accumulation of misfolded APP and Aβ peptides, serving as a protective mechanism to mitigate their toxic effects.\nTherapeutic Considerations: Understanding the mechanisms underlying APP aggregation and aggresome formation is important for developing therapeutic strategies to alleviate protein misfolding and aggregation in Alzheimer’s disease and related neurodegenerative disorders. Approaches aimed at promoting proper protein folding, enhancing protein degradation pathways, or disaggregating protein aggregates may hold promise for treating Alzheimer’s disease and mitigating its progression."
  },
  {
    "objectID": "chapters/week8.html#cytoskeleton-organization-during-cell-division",
    "href": "chapters/week8.html#cytoskeleton-organization-during-cell-division",
    "title": "8  Mechanism of Intracellular Protein Deposition",
    "section": "8.2 Cytoskeleton Organization During Cell Division",
    "text": "8.2 Cytoskeleton Organization During Cell Division\n\n\n\n\n\nChanges in Cytoskeleton Organization During Mitosis\n\n\n\n\nDuring cell division, the cytoskeletal organization undergoes dynamic changes to facilitate various processes such as chromosome segregation and cytokinesis.\n\nActin Filaments Reorganization: Actin filaments, which determine the shape of the cell’s surface and are involved in cellular locomotion, undergo reorganization during cell division. Initially, actin filaments are reorganized, and the cell assumes a spherical shape. Subsequently, after chromosome segregation, actin filaments form a contractile ring at the center of the cell, which pinches the cell in two during cytokinesis.\nMicrotubule Rearrangement: The polarized microtubule array undergoes rearrangement to form a bipolar mitotic spindle. This mitotic spindle is responsible for aligning and segregating duplicated chromosomes during cell division. Microtubules determine the positions of organelles and facilitate intracellular transport.\nDaughter Cell Cytoskeletal Reorganization: After cell division is complete, the two daughter cells reorganize their microtubule and actin cytoskeletons into smaller versions of those present in the mother cell. This reorganization ensures that each daughter cell has the necessary cytoskeletal components for cellular functions such as maintaining cell shape, facilitating intracellular transport, and supporting cellular movement.\n\n\n8.2.1 Microtubules and Centromeres\nThe centrosome and microtubules play essential roles in organizing the cell’s cytoskeleton and facilitating various cellular processes.\n\nCentrosome: The centrosome is a cellular organelle that serves as the main microtubule-organizing center (MTOC) in animal cells. It consists of a pair of centrioles surrounded by pericentriolar material (PCM). The centrosome is involved in nucleating, anchoring, and organizing microtubules within the cell.\nMicrotubules: Microtubules are dynamic protein filaments composed of tubulin subunits. They extend outward from the centrosome throughout the cell, forming a network of tracks along which molecular motors and vesicles can move. Microtubules have a polarity, with one end referred to as the “plus end” and the other end as the “minus end.”\nOrganization of Microtubules: Within the cell, the centrosome serves as the primary site for microtubule nucleation. Microtubules extend outward from the centrosome, with their plus ends pointing toward the cell periphery. This radial array of microtubules provides structural support to the cell and facilitates intracellular transport, cell division, and cell motility.\nCellular Functions: Microtubules are involved in various cellular processes, including:\n\nIntracellular transport: Microtubules serve as tracks for molecular motors such as dynein and kinesin, facilitating the movement of organelles, vesicles, and proteins within the cell.\nCell division: Microtubules form the mitotic spindle during cell division, facilitating the alignment and segregation of chromosomes.\nCell shape and motility: Microtubules contribute to cell shape maintenance and are involved in processes such as cell migration and ciliary/flagellar movement.\n\n\n\n\n8.2.2 Mitotic Spindle\nThe mitotic spindle is a dynamic structure composed of microtubules that forms during cell division (mitosis) and is essential for the accurate segregation of chromosomes into daughter cells. Microtubules are long, cylindrical polymers made up of tubulin protein subunits arranged in a helical fashion. Each tubulin subunit consists of an α-tubulin and a β-tubulin molecule, which assemble end-to-end to form the microtubule filament.\nThe structure of a microtubule can be described as follows:\n\nPolarity: Microtubules exhibit polarity, with one end referred to as the “plus end” and the other end as the “minus end.” The plus end is characterized by the addition of tubulin subunits, while the minus end is associated with the removal of subunits.\nGrowth and Shrinking: Microtubules undergo dynamic instability, a process in which they alternate between periods of growth (polymerization) and shrinking (depolymerization). During polymerization, tubulin subunits are added to the growing plus end of the microtubule, while during depolymerization, subunits are removed from the plus end.\nStructural Features: Microtubules have a hollow cylindrical structure, with an outer diameter of approximately 25 nanometers. The tubulin subunits assemble longitudinally along the microtubule axis, forming a protofilament. Thirteen protofilaments are arranged in parallel to form the wall of the microtubule.\nDynamic Instability: The dynamic instability of microtubules allows them to explore space within the cell and rapidly reorganize their structure. This property is crucial for the formation and function of the mitotic spindle during cell division."
  },
  {
    "objectID": "chapters/week9.html",
    "href": "chapters/week9.html",
    "title": "9  Alzheimer’s Disease",
    "section": "",
    "text": "Alzheimer’s disease (AD) is a prevalent neurodegenerative disorder characterized by progressive cognitive decline and memory loss. Here are some key points about the prevalence, duration, and onset of Alzheimer’s disease:\nIn AD, hippocampal and cortical atrophy are prominent structural changes that occur in the brain and are associated with cognitive decline and memory loss. Here’s how these changes manifest:"
  },
  {
    "objectID": "chapters/week9.html#structure-of-the-brain",
    "href": "chapters/week9.html#structure-of-the-brain",
    "title": "9  Alzheimer’s Disease",
    "section": "9.1 Structure of the Brain",
    "text": "9.1 Structure of the Brain\nThe structure of the human brain is complex and highly organized, consisting of various regions and interconnected networks that govern cognitive, emotional, sensory, and motor functions. Here’s an overview of the key structures and their functions:\n\nCerebrum:\n\nThe largest and most prominent part of the brain.\nDivided into two hemispheres (left and right) and further subdivided into four lobes: frontal, parietal, temporal, and occipital.\nResponsible for higher cognitive functions such as reasoning, problem-solving, language, and voluntary movement.\nContains the cerebral cortex, the outer layer of gray matter where most information processing occurs.\n\nCerebellum:\n\nLocated below the cerebrum at the back of the brain.\nPlays a crucial role in coordinating voluntary movements, maintaining balance, and posture.\nInvolved in motor learning and skill acquisition.\n\nBrainstem:\n\nConnects the brain to the spinal cord and serves as a relay center for sensory and motor pathways.\nComprises the midbrain, pons, and medulla oblongata.\nRegulates essential functions such as heart rate, breathing, sleep-wake cycles, and basic arousal.\n\nThalamus:\n\nLocated deep within the brain, above the brainstem.\nActs as a relay station for sensory information, transmitting signals from sensory organs to the cerebral cortex.\nPlays a role in regulating consciousness, attention, and sleep.\n\nHypothalamus:\n\nLies below the thalamus and above the pituitary gland.\nRegulates various physiological processes such as body temperature, hunger, thirst, and circadian rhythms.\nControls the release of hormones from the pituitary gland.\n\nHippocampus:\n\nLocated within the temporal lobes, deep within the cerebrum.\nPlays a crucial role in memory formation and spatial navigation.\nParticularly involved in the consolidation of short-term memories into long-term memories.\n\nAmygdala:\n\nSituated in the temporal lobes, adjacent to the hippocampus.\nInvolved in the processing of emotions, particularly fear and aggression.\nPlays a role in emotional memory and social behavior.\n\nBasal Ganglia:\n\nCollection of nuclei located deep within the cerebral hemispheres.\nInvolved in motor control, voluntary movement, and procedural learning.\nDysfunction of the basal ganglia can lead to movement disorders such as Parkinson’s disease and Huntington’s disease.\n\n\n\n9.1.1 Hallmarks of AD\nAD is characterized by several hallmark features that contribute to its progressive neurodegenerative nature. These hallmarks include:\n\nAmyloid Beta (Aβ) Plaques:\n\nAccumulation of extracellular deposits of amyloid beta protein.\nAβ peptides are derived from the cleavage of amyloid precursor protein (APP).\nAggregation of Aβ peptides forms insoluble plaques, which are a hallmark pathological feature of AD.\nDisruption of synaptic function and neuronal toxicity are associated with Aβ plaques.\n\nNeurofibrillary Tangles (NFTs):\n\nIntracellular aggregates of hyperphosphorylated tau protein.\nTau protein normally stabilizes microtubules within neurons.\nHyperphosphorylation of tau leads to its misfolding and aggregation into insoluble filaments.\nNFTs disrupt neuronal structure and function, leading to cell death and neurodegeneration.\n\nNeuronal Loss and Atrophy:\n\nProgressive loss of neurons, particularly in brain regions associated with memory and cognitive function, such as the hippocampus and cortex.\nAtrophy (shrinkage) of affected brain regions due to neuronal loss and synaptic dysfunction.\nNeuronal loss contributes to cognitive decline and dementia in AD patients.\n\nInflammation and Neuroinflammation:\n\nActivation of immune cells, including microglia and astrocytes, in response to Aβ plaques and NFTs.\nRelease of pro-inflammatory cytokines and chemokines, leading to chronic neuroinflammation.\nNeuroinflammation exacerbates neuronal damage and contributes to disease progression.\n\nSynaptic Dysfunction:\n\nImpairment of synaptic transmission and plasticity.\nDisruption of neurotransmitter systems, including acetylcholine, glutamate, and gamma-aminobutyric acid (GABA).\nLoss of synapses precedes neuronal loss and correlates with cognitive decline in AD.\n\nVascular Changes:\n\nAccumulation of vascular amyloid deposits in cerebral blood vessels (cerebral amyloid angiopathy).\nVascular dysfunction, including impaired cerebral blood flow and blood-brain barrier integrity.\nVascular pathology contributes to cognitive impairment and increases the risk of hemorrhagic stroke in AD patients.\n\n\n\n\n9.1.2 Amyloid Cascade Hypothesis\n\n\n\n\n\nIllustration of the Amyloid Hypothesis\n\n\n\n\nThe amyloid cascade hypothesis proposes that the accumulation of amyloid beta (Aβ) protein is the primary trigger for the development of Alzheimer’s disease pathology. According to this hypothesis, the deposition of Aβ in the brain leads to a cascade of events that ultimately result in neurofibrillary tangles, neuronal cell loss, vascular damage, and dementia characteristic of Alzheimer’s disease.\nKey points of the amyloid cascade hypothesis include:\n\nAβ Deposition: The hypothesis posits that the initial step in Alzheimer’s disease pathogenesis is the abnormal accumulation of Aβ peptides, which aggregate to form insoluble plaques in the brain.\nNeurofibrillary Tangles: The presence of Aβ plaques is believed to trigger the hyperphosphorylation and aggregation of tau protein, leading to the formation of neurofibrillary tangles within neurons. These tangles disrupt neuronal structure and function, contributing to neurodegeneration.\nNeuronal Cell Loss: As the disease progresses, widespread neuronal cell loss occurs, particularly in brain regions crucial for memory and cognitive function, such as the hippocampus and cortex. This neuronal loss correlates with the severity of cognitive impairment in Alzheimer’s patients.\nVascular Damage: Aβ deposition is also associated with vascular changes, including the accumulation of amyloid in cerebral blood vessels (cerebral amyloid angiopathy) and impaired cerebral blood flow. Vascular dysfunction contributes to cognitive decline and increases the risk of stroke in Alzheimer’s disease.\nDementia: Ultimately, the cumulative effects of Aβ deposition, neurofibrillary tangles, neuronal loss, and vascular damage lead to the clinical manifestation of dementia, characterized by progressive cognitive decline, memory loss, and impaired daily functioning.\n\n\n\n9.1.3 Amyloid Precursor Protein (i.e., APP)\nAmyloid precursor protein (APP) is a transmembrane protein that is abundantly produced in neurons, although its precise function in the brain is not fully understood. Interestingly, studies in mice lacking APP have shown minimal observable effects, suggesting that APP may not be essential for basic neuronal function.\nHowever, APP is known to undergo proteolytic processing through multiple alternative pathways, some of which result in the generation of amyloid beta (Aβ) peptides, while others do not. Aβ peptides are central to the amyloid cascade hypothesis of Alzheimer’s disease, as their accumulation is believed to contribute to the pathogenesis of the disease.\nThe metabolism of APP involves several proteolytic enzymes, including α-secretase, β-secretase, and γ-secretase. Cleavage of APP by α-secretase within the Aβ region results in the generation of soluble APP fragments that have neuroprotective properties. However, cleavage by β-secretase followed by γ-secretase leads to the production of Aβ peptides, particularly Aβ42, which are prone to aggregation and form insoluble plaques in the brain, a hallmark of Alzheimer’s disease.\nWhile the exact physiological function of APP remains elusive, its involvement in Aβ production and the pathogenesis of Alzheimer’s disease has garnered significant attention in research aimed at understanding and treating the disease. Further investigation into the molecular pathways and regulatory mechanisms governing APP metabolism may provide insights into its role in normal brain function and neurodegenerative disorders.\n\n9.1.3.1 Transmembrane Protein Biosynthesis\n\n\n\n\n\nIllustration of Transmembrane Protein Biosynthesis\n\n\n\n\nTransmembrane protein biogenesis refers to the process by which transmembrane proteins, which span the lipid bilayer of cellular membranes, are synthesized, folded, and inserted into their appropriate cellular membranes. This process is essential for the proper functioning of cells, as transmembrane proteins play crucial roles in various cellular processes, including cell signaling, transport of molecules across membranes, and cell-cell communication.\nThe biogenesis of transmembrane proteins involves several steps:\n\nProtein Synthesis: Transmembrane proteins are synthesized on ribosomes in the cytosol as precursor proteins. These precursor proteins typically contain an N-terminal signal sequence that directs them to the endoplasmic reticulum (ER), where transmembrane protein biogenesis primarily occurs.\nTargeting to the Endoplasmic Reticulum (ER): The N-terminal signal sequence of the precursor protein interacts with the signal recognition particle (SRP), which targets the ribosome-nascent chain complex to the ER membrane. The ribosome then docks onto the ER membrane, and protein synthesis continues into the ER lumen.\nTranslocation into the ER Lumen: As the nascent polypeptide chain is synthesized, it is translocated across the ER membrane through a proteinaceous channel called the translocon. The signal sequence is typically cleaved by signal peptidase as the protein is translocated into the ER lumen.\nProtein Folding and Quality Control: Once in the ER lumen, transmembrane proteins undergo folding and assembly into their native three-dimensional structures. Chaperone proteins assist in the folding process, while quality control mechanisms monitor protein folding and ensure that misfolded proteins are targeted for degradation by the ER-associated degradation (ERAD) pathway.\nInsertion into the Membrane: Integral transmembrane proteins contain hydrophobic regions (transmembrane domains) that span the lipid bilayer of the ER membrane. These hydrophobic regions facilitate the insertion of the protein into the membrane, where they adopt their final topology.\nPost-Translational Modifications: Transmembrane proteins may undergo various post-translational modifications in the ER, including glycosylation, disulfide bond formation, and proteolytic cleavage, which can further modulate their structure and function.\nTransport to Destination Organelles: Once synthesized and properly folded in the ER, transmembrane proteins may be transported to their final destination organelles, such as the Golgi apparatus, plasma membrane, or other cellular compartments, via vesicular transport pathways.\n\n\n\n\n9.1.4 Presinilin and \\(\\gamma\\)-secretase\n\n\n\n\n\nGamma Secretase in Action\n\n\n\n\nGamma-secretase is a multisubunit enzyme complex responsible for the cleavage of transmembrane proteins within the lipid bilayer, including amyloid precursor protein (APP) and Notch receptors. The catalytic core of gamma-secretase is composed of presenilin, which exists in two isoforms: presenilin 1 (PSEN1) and presenilin 2 (PSEN2). Both isoforms are integral membrane proteins that contain multiple transmembrane domains and are essential components of the gamma-secretase complex.\nKey points about gamma-secretase and its association with presenilin 1 or presenilin 2 include:\n\nCleavage of Substrates: Gamma-secretase mediates the proteolytic cleavage of a variety of transmembrane proteins, including APP and Notch receptors, which are involved in critical cellular processes such as neuronal signaling and development. The cleavage of these substrates by gamma-secretase generates intracellular signaling fragments and extracellular protein fragments, such as amyloid beta (Aβ) peptides derived from APP.\nPresenilin as the Catalytic Component: Presenilin serves as the catalytic subunit of the gamma-secretase complex, responsible for the enzymatic activity that cleaves substrates within their transmembrane domains. Presenilin contains essential aspartate residues within its transmembrane domains, which are involved in the proteolytic cleavage reaction.\nAssociation with Alzheimer’s Disease: Mutations in the genes encoding presenilin 1 (PSEN1) and presenilin 2 (PSEN2) are associated with familial forms of Alzheimer’s disease (FAD), a rare, early-onset form of the disease. These mutations lead to alterations in gamma-secretase activity, resulting in an imbalance in the production of Aβ peptides and an increased accumulation of neurotoxic Aβ42 peptides, which are believed to contribute to the pathogenesis of Alzheimer’s disease.\nTherapeutic Target: Due to its central role in the generation of Aβ peptides, gamma-secretase has been considered a promising target for therapeutic intervention in Alzheimer’s disease. However, targeting gamma-secretase poses challenges due to its involvement in the processing of multiple substrates, including Notch receptors, which play critical roles in cellular signaling and development. Selective inhibition of Aβ production while preserving Notch signaling presents a significant hurdle in the development of gamma-secretase inhibitors as Alzheimer’s disease therapies.\n\n\n\n9.1.5 Generating A\\(\\beta\\) Peptides\n\n\n\n\n\nAPP Processing and A\\(\beta\\) Peptides\n\n\n\n\nThe processing of amyloid precursor protein (APP) by proteolytic enzymes results in the generation of amyloid beta (Aβ) peptides, which play a central role in the pathogenesis of Alzheimer’s disease. Here’s an overview of how APP processing leads to the production of Aβ peptides:\n\nSynthesis of APP:\n\nAmyloid precursor protein (APP) is a type I transmembrane protein synthesized in neurons and other cells.\nIt is produced in the endoplasmic reticulum (ER) and transported to the Golgi apparatus for further processing and trafficking to the cell surface.\n\nProteolytic Processing of APP:\n\nAPP undergoes proteolytic cleavage by two major pathways: the amyloidogenic pathway and the non-amyloidogenic pathway.\n\nAmyloidogenic Pathway:\n\nIn the amyloidogenic pathway, APP is sequentially cleaved by β-secretase (beta-site amyloid precursor protein cleaving enzyme, BACE1) and γ-secretase.\nβ-secretase cleaves APP at the N-terminus of the Aβ domain, releasing a soluble fragment called soluble APPβ (sAPPβ) and a membrane-bound C-terminal fragment (CTFβ or C99).\nCTFβ/C99 fragment is then cleaved by γ-secretase within the transmembrane domain, resulting in the release of Aβ peptides of various lengths, including Aβ40 and Aβ42.\nAβ42 is particularly prone to aggregation and is implicated in the formation of amyloid plaques in the brain, a hallmark pathological feature of Alzheimer’s disease.\n\nNon-amyloidogenic Pathway:\n\nIn the non-amyloidogenic pathway, APP is cleaved by α-secretase within the Aβ domain, precluding the generation of Aβ peptides.\nα-secretase cleavage results in the release of a soluble fragment called soluble APPα (sAPPα) and a membrane-bound C-terminal fragment (CTFα or C83).\nCTFα/C83 fragment can be further processed by γ-secretase to produce p3 peptides, which are shorter and less prone to aggregation compared to Aβ peptides.\n\nFunctional Roles of Aβ Peptides:\n\nThe physiological functions of Aβ peptides are not fully understood, but they may play roles in synaptic function, neuronal plasticity, and regulation of neurotransmitter release.\nHowever, the accumulation and aggregation of Aβ peptides, particularly Aβ42, in the brain are believed to contribute to the neurodegenerative processes underlying Alzheimer’s disease, leading to synaptic dysfunction, neuronal loss, and cognitive decline."
  },
  {
    "objectID": "chapters/week9.html#neurons",
    "href": "chapters/week9.html#neurons",
    "title": "9  Alzheimer’s Disease",
    "section": "9.2 Neurons",
    "text": "9.2 Neurons\n\n\n\n\n\nIllustration of a Neuron\n\n\n\n\nNeurons, the fundamental units of the nervous system, possess a unique structure specialized for the transmission of electrical and chemical signals. Here’s an overview of the structure of a typical neuron and the role of glial cells:\n\nNeuron Structure:\n\nCell Body (Soma): The main part of the neuron containing the nucleus and organelles responsible for cellular metabolism and protein synthesis.\nDendrites: Branch-like extensions protruding from the cell body that receive incoming signals (neurotransmitters) from other neurons or sensory receptors.\nAxon: A long, slender projection extending from the cell body that transmits electrical impulses (action potentials) away from the cell body toward other neurons, muscles, or glands.\nAxon Terminals (Axon Endings): Specialized structures at the end of the axon that release neurotransmitters to communicate with other neurons or target cells.\nMyelin Sheath: A fatty, insulating layer surrounding the axon formed by glial cells (oligodendrocytes in the central nervous system and Schwann cells in the peripheral nervous system). The myelin sheath enhances the speed and efficiency of electrical signal conduction along the axon.\n\nGlia (Glial Cells):\n\nOligodendrocytes: Glial cells in the central nervous system (CNS) that produce myelin sheaths, which wrap around axons to insulate and support them.\nAstrocytes: Star-shaped glial cells that provide structural support to neurons, regulate the extracellular environment by maintaining ion balance and neurotransmitter levels, and contribute to the blood-brain barrier.\nMicroglia: Small, specialized immune cells in the CNS that act as the primary immune defense and perform functions such as phagocytosis (removal of cellular debris and pathogens) and immune response regulation.\n\n\n\n9.2.1 APP Trafficking in Neurons\n\n\n\n\n\nAPP Trafficking in Neurons\n\n\n\n\nThe trafficking of amyloid precursor protein (APP) in neurons involves a complex series of cellular processes that regulate the localization, processing, and function of APP within the cell. Here’s an overview of APP trafficking in neurons:\n\nSynthesis and Localization:\n\nAPP is synthesized in the endoplasmic reticulum (ER) and transported through the secretory pathway to the Golgi apparatus, where it undergoes post-translational modifications.\nFrom the Golgi apparatus, APP is transported in vesicles to various cellular compartments, including the plasma membrane and endosomes.\n\nPlasma Membrane Localization:\n\nA fraction of newly synthesized APP is transported to the plasma membrane, where it functions in cell adhesion, neurite outgrowth, and synaptic transmission.\nAt the plasma membrane, APP may interact with other cell surface receptors and undergo proteolytic processing by secretases, leading to the production of amyloid beta (Aβ) peptides.\n\nEndocytic Trafficking:\n\nAPP is internalized from the plasma membrane via endocytosis, leading to its trafficking through endosomal compartments.\nEndosomes serve as sorting platforms where APP can be sorted for recycling back to the plasma membrane, targeted for degradation in lysosomes, or transported to other cellular compartments.\n\nIntracellular Trafficking:\n\nWithin neurons, APP-containing vesicles can undergo retrograde transport along microtubules toward the cell body or anterograde transport toward axonal or dendritic compartments.\nMotor proteins, such as kinesins and dyneins, mediate the movement of APP-containing vesicles along microtubules.\n\nAxonal Transport:\n\nAPP is transported along axons to reach distal synaptic terminals, where it plays roles in synaptic function and plasticity.\nThe axonal trafficking of APP is crucial for the production and release of Aβ peptides at synapses.\n\nRegulation of Trafficking:\n\nVarious cellular factors and signaling pathways regulate the trafficking of APP in neurons, including protein kinases, phosphatases, and cytoskeletal elements.\nDysregulation of APP trafficking can lead to aberrant processing and accumulation of Aβ peptides, contributing to the pathogenesis of Alzheimer’s disease.\n\n\n\n\n9.2.2 Structure of A$$42\n\n\n\n\n\nStructure of A$\beta$42\n\n\n\n\nThe fibril structure of amyloid beta 42 (Aβ42) is characterized by its ability to form insoluble aggregates known as amyloid fibrils, which are a hallmark pathological feature of Alzheimer’s disease. Here’s an overview of the fibril structure of Aβ42:\n\nPeptide Sequence: Aβ42 is a peptide consisting of 42 amino acid residues, derived from the proteolytic cleavage of amyloid precursor protein (APP). It is characterized by its hydrophobicity and propensity to aggregate.\nBeta-Sheet Conformation: Aβ42 peptides undergo a conformational change from random coil to beta-sheet structure during fibril formation. Beta-sheet structures are characterized by the alignment of peptide strands in a parallel or antiparallel fashion, forming a cross-beta structure.\nCross-Beta Architecture: The assembly of Aβ42 peptides into amyloid fibrils results in the formation of a cross-beta architecture, where individual peptide strands run perpendicular to the long axis of the fibril. This arrangement creates a characteristic pattern of beta-strands stacked along the fibril axis, with intermolecular hydrogen bonding between adjacent peptide strands.\nProtofilament Formation: Aβ42 peptides assemble into protofilaments, which are linear aggregates of peptides arranged in a parallel fashion. Protofilaments can further associate laterally to form mature amyloid fibrils, which can vary in length and thickness.\nTwisted Ribbon Structure: Mature Aβ42 fibrils often exhibit a twisted ribbon morphology, where individual protofilaments twist around the fibril axis, giving rise to a helical or helical-like structure. This twisted ribbon architecture is a common feature observed in many amyloid fibrils.\nAmyloid Core: Within the fibril structure, the amyloid core consists of densely packed regions of beta-sheet structure formed by the aggregation of Aβ42 peptides. These regions are highly stable and resistant to proteolytic degradation.\nStructural Polymorphism: Aβ42 fibrils can exhibit structural polymorphism, meaning they can adopt different conformations and morphologies depending on factors such as peptide concentration, solution conditions, and the presence of cofactors or ligands.\n\n\n9.2.2.1 Amyloid Fibrilation\n\n\n\n\n\nAmyloid Fibriliation Steps\n\n\n\n\nThe amyloid fibrillation process of amyloid beta (Aβ) peptides, particularly Aβ42, involves a series of steps leading to the formation of insoluble aggregates known as amyloid fibrils. Here are the key steps involved in the fibrillation of Aβ peptides:\n\nNucleation Phase:\n\nThe fibrillation process begins with the nucleation phase, where monomeric Aβ peptides undergo a conformational change from a soluble, random coil structure to a partially folded intermediate state.\nSeveral monomeric Aβ peptides associate to form small, stable aggregates known as oligomers or nuclei. These nuclei serve as templates for the further growth of fibrils.\nNucleation is often considered the rate-limiting step of amyloid fibrillation and can be influenced by factors such as peptide concentration, pH, temperature, and the presence of cofactors.\n\nElongation Phase:\n\nOnce nuclei are formed, additional monomeric Aβ peptides bind to the existing aggregates, elongating them and promoting fibril growth.\nThe elongation phase involves the addition of Aβ peptides to the ends of existing fibrils, leading to the formation of protofilaments, which are linear aggregates of peptides arranged in a parallel or antiparallel fashion.\nThe elongation process proceeds through a mechanism of monomer addition, where soluble Aβ peptides bind to exposed ends of protofilaments, incorporating into the growing fibril structure.\n\nMaturation Phase:\n\nAs fibrils continue to grow, they undergo structural rearrangements and maturation, leading to the formation of mature amyloid fibrils.\nMature fibrils are characterized by their stable, cross-beta architecture, with individual peptide strands aligned perpendicular to the long axis of the fibril.\nThe maturation phase may involve the lateral association of protofilaments and the twisting of fibrils to form higher-order structures with a twisted ribbon morphology.\n\nSecondary Nucleation and Fragmentation:\n\nIn addition to elongation, secondary processes such as secondary nucleation and fibril fragmentation can also contribute to the overall kinetics of amyloid fibrillation.\nSecondary nucleation involves the generation of new nuclei from existing fibril surfaces, leading to the formation of new fibrils and the amplification of fibril growth.\nFibril fragmentation occurs when mature fibrils break apart into smaller fragments, which can serve as seeds for the formation of new fibrils or promote the growth of existing fibrils.\n\nFibril Aggregation and Toxicity:\n\nAs amyloid fibrils continue to accumulate, they can aggregate further to form higher-order structures, such as amyloid plaques, which are pathological hallmarks of neurodegenerative diseases like Alzheimer’s disease.\nOligomeric intermediates formed during the fibrillation process are thought to be particularly toxic to neurons, contributing to neuronal dysfunction and cell death in neurodegenerative disorders.\n\n\n\n\n9.2.2.2 A\\(\\beta\\) Aggregation and Clearance\n\n\n\n\n\nA\\(\beta\\) Aggregation and Clearance\n\n\n\n\nThe clearance and aggregation of amyloid beta (Aβ) peptides are key processes that influence their accumulation and toxicity in the brain, particularly in the context of Alzheimer’s disease. Here’s an overview of Aβ clearance mechanisms and factors contributing to its aggregation:\n\nAβ Clearance Mechanisms:\n\nEnzymatic Degradation: Aβ peptides can be enzymatically degraded by proteases, such as neprilysin, insulin-degrading enzyme (IDE), and matrix metalloproteinases (MMPs), which cleave Aβ into smaller, soluble fragments that can be cleared from the brain.\nMicroglial Phagocytosis: Microglial cells, the resident immune cells of the brain, can engulf and clear Aβ peptides through phagocytosis. Microglia express various cell surface receptors, including scavenger receptors, that recognize and internalize Aβ aggregates for degradation within lysosomes.\nTransport Across the Blood-Brain Barrier (BBB): Aβ peptides can be transported across the BBB from the brain to the bloodstream, where they can be cleared by systemic mechanisms, including renal clearance and uptake by the liver.\nCerebrospinal Fluid (CSF) Clearance: Aβ peptides in the brain interstitial fluid can diffuse into the CSF and be cleared from the central nervous system (CNS) via bulk flow mechanisms, including drainage into the lymphatic system.\n\nFactors Influencing Aβ Aggregation:\n\nAβ Production Rate: The rate of Aβ production, determined by the proteolytic processing of amyloid precursor protein (APP), influences the concentration of soluble Aβ peptides available for aggregation. Increased production or impaired clearance of Aβ can lead to its accumulation and aggregation.\nAβ Oligomerization: Aβ peptides can form soluble oligomeric intermediates during the early stages of aggregation, which are thought to be particularly toxic to neurons and synapses. Oligomers can further assemble into larger aggregates, including protofibrils and mature amyloid fibrils.\nSeeding and Nucleation: The presence of pre-existing Aβ aggregates, or seeds, can promote the nucleation and aggregation of soluble Aβ peptides by providing templates for fibril growth. Seeding can accelerate the aggregation process and contribute to the propagation of Aβ pathology in the brain.\nCellular Environment: Factors within the cellular microenvironment, such as pH, metal ions (e.g., copper, zinc), lipid membranes, and chaperone proteins, can influence the conformation and stability of Aβ peptides, affecting their propensity to aggregate."
  },
  {
    "objectID": "chapters/week9.html#tau-protein",
    "href": "chapters/week9.html#tau-protein",
    "title": "9  Alzheimer’s Disease",
    "section": "9.3 Tau Protein",
    "text": "9.3 Tau Protein\n\n\n\n\n\nPhosphorylation and Aggregation of the Tau Protein\n\n\n\n\nPhosphorylation and aggregation of the Tau protein are central events in the pathogenesis of several neurodegenerative diseases, collectively referred to as tauopathies, including Alzheimer’s disease. Here’s an overview of the relationship between phosphorylation and aggregation of Tau:\n\nTau Protein Structure:\n\nTau is a microtubule-associated protein (MAP) that plays a crucial role in stabilizing microtubules and facilitating axonal transport in neurons.\nTau is primarily expressed in neurons and undergoes alternative splicing to generate six isoforms in the adult human brain, ranging from 352 to 441 amino acids in length.\nTau contains multiple serine and threonine residues that can be phosphorylated by various protein kinases, regulating its physiological function and cellular localization.\n\nPhosphorylation of Tau:\n\nUnder normal physiological conditions, Tau is subject to dynamic phosphorylation and dephosphorylation events, which regulate its interaction with microtubules and other cellular components.\nPhosphorylation of Tau is tightly regulated by multiple protein kinases, including glycogen synthase kinase 3β (GSK3β), cyclin-dependent kinase 5 (CDK5), and protein kinase A (PKA), among others.\nPhosphorylation of Tau at specific sites can disrupt its binding to microtubules, leading to microtubule destabilization and impairing axonal transport.\nAberrant hyperphosphorylation of Tau is a hallmark pathological feature of tauopathies, resulting in the accumulation of hyperphosphorylated Tau in the form of intracellular neurofibrillary tangles (NFTs) and neuropil threads.\n\nAggregation of Tau:\n\nHyperphosphorylated Tau has a reduced affinity for microtubules and an increased propensity to self-aggregate into insoluble fibrillar structures.\nThe aggregation process of Tau involves the formation of soluble oligomeric intermediates, protofibrils, and mature paired helical filaments (PHFs) and straight filaments (SFs), which constitute the core of NFTs.\nTau aggregation disrupts neuronal function, impairs synaptic transmission, and promotes neurotoxicity, ultimately leading to neuronal dysfunction and cell death.\nThe spread of pathological Tau aggregates throughout the brain correlates with disease progression in tauopathies and contributes to the characteristic pattern of neurodegeneration observed in affected brain regions.\n\nRole in Disease Pathogenesis:\n\nAccumulation of hyperphosphorylated and aggregated Tau is thought to disrupt neuronal homeostasis, impair cellular processes, and trigger neuroinflammatory responses, ultimately leading to neuronal degeneration and cognitive decline in tauopathies.\nTherapeutic strategies targeting Tau phosphorylation and aggregation represent promising avenues for the development of disease-modifying treatments for Alzheimer’s disease and related tauopathies.\n\n\n\n9.3.1 Structure of the Tau Protein\n\n\n\n\n\nStructure of the Tau Protein\n\n\n\n\nThe structure of tau filaments, particularly those found in neurofibrillary tangles (NFTs) in the brains of individuals with Alzheimer’s disease and other tauopathies, is characterized by its intricate arrangement of protein subunits and its contribution to neuronal dysfunction and cell death. Here’s an overview of the structure of tau filaments:\n\nComposition:\n\nTau filaments are composed primarily of hyperphosphorylated tau protein, a microtubule-associated protein that normally stabilizes microtubules in neurons.\nHyperphosphorylated tau undergoes conformational changes and self-aggregates into insoluble fibrillar structures, forming the core of NFTs.\n\nCore Structure:\n\nTau filaments have a characteristic cross-beta structure, where individual tau molecules assemble into beta-sheet-rich fibrils arranged perpendicular to the long axis of the filament.\nThe core of tau filaments consists of repeating units of tau protein arranged in a helical or straight configuration, depending on the isoform of tau and the specific disease state.\n\nSubunit Arrangement:\n\nThe arrangement of tau subunits within filaments can vary, giving rise to different morphological subtypes of tau filaments, including paired helical filaments (PHFs) and straight filaments (SFs).\nPHFs are characterized by a twisted ribbon-like morphology, where individual tau molecules twist around the filament axis, forming paired helices.\nSFs, on the other hand, have a straight, unbranched morphology, with tau molecules aligned parallel to the filament axis.\n\nCross-Beta Architecture:\n\nWithin tau filaments, tau molecules interact through intermolecular hydrogen bonds between beta-strands, forming a stable cross-beta architecture.\nThe cross-beta structure confers stability to tau filaments and renders them resistant to proteolytic degradation and clearance mechanisms.\n\nPost-Translational Modifications:\n\nIn addition to hyperphosphorylation, tau filaments may undergo other post-translational modifications, such as acetylation, glycation, and truncation, which can further modulate their structure and stability.\nThese modifications may influence the aggregation propensity and neurotoxicity of tau filaments and contribute to the heterogeneity observed in tauopathies.\n\nPathological Implications:\n\nThe accumulation of tau filaments, along with other pathological changes, such as amyloid beta plaques, neuroinflammation, and synaptic dysfunction, contributes to neuronal degeneration and cognitive decline in tauopathies.\nTau filaments disrupt cellular processes, impair axonal transport, and promote synaptic dysfunction, ultimately leading to neurodegeneration and cell death.\n\n\n\n\n9.3.2 Spread of Amyloid Plaques\n\n\n\n\n\nSpread of Amyloid Plaques\n\n\n\n\nThe spread of amyloid plaques and neurofibrillary tangles (NFTs) in the brain is a hallmark feature of Alzheimer’s disease and related tauopathies. Here’s an overview of how these pathological structures spread throughout the brain:\n\nAmyloid Plaque Spread:\n\nAmyloid plaques primarily consist of aggregated amyloid beta (Aβ) peptides and are typically found in the extracellular space surrounding neurons.\nThe spread of amyloid plaques in the brain follows a stereotypical pattern, with initial deposition occurring in specific regions and spreading to interconnected brain regions over time.\nThe earliest deposits of amyloid plaques often occur in the neocortex, particularly in regions involved in higher cognitive functions such as the hippocampus and association cortices.\nAs the disease progresses, amyloid plaques spread to additional cortical areas and subcortical structures, including the basal forebrain, thalamus, and eventually the brainstem and cerebellum.\nThe spread of amyloid plaques is thought to occur through a combination of neuronal transport, synaptic transmission, and diffusion of soluble Aβ species, as well as seeding and templating mechanisms.\n\nNeurofibrillary Tangle Spread:\n\nNeurofibrillary tangles (NFTs) are intracellular aggregates primarily composed of hyperphosphorylated tau protein, which forms paired helical filaments and straight filaments within neurons.\nSimilar to amyloid plaques, the spread of NFTs in the brain follows a hierarchical pattern, with initial deposition in specific brain regions and subsequent spread to interconnected areas.\nThe earliest NFT pathology is often observed in the entorhinal cortex and hippocampus, regions crucial for memory formation and consolidation.\nNFTs then spread to adjacent cortical areas and subcortical structures, including the amygdala, basal forebrain, and neocortex, as the disease progresses.\nThe spread of NFTs is thought to occur through neuronal connectivity pathways, with pathological tau species propagating from neuron to neuron via axonal transport, synaptic transmission, and trans-synaptic spread.\n\nInteraction Between Amyloid and Tau Pathology:\n\nThere is evidence to suggest that amyloid pathology may precede and drive the accumulation of tau pathology in Alzheimer’s disease.\nSoluble forms of Aβ peptides may trigger tau hyperphosphorylation and aggregation, leading to the formation of NFTs and subsequent neurodegeneration.\nConversely, pathological forms of tau may exacerbate amyloid pathology by impairing Aβ clearance mechanisms and promoting amyloid plaque deposition."
  },
  {
    "objectID": "chapters/week9.html#apoe4",
    "href": "chapters/week9.html#apoe4",
    "title": "9  Alzheimer’s Disease",
    "section": "9.4 ApoE4",
    "text": "9.4 ApoE4\n\n\n\n\n\nApoE Illustration\n\n\n\n\nApolipoprotein E4 (ApoE4) is a well-established genetic risk factor for late-onset Alzheimer’s disease (AD), contributing to an increased susceptibility to developing the disease compared to other isoforms of apolipoprotein E (ApoE). Here’s an overview of ApoE4 and its association with AD risk:\n\nApolipoprotein Structure:\n\nApolipoproteins are essential components of lipoproteins, which are lipid-protein complexes involved in transporting cholesterol and other lipids through the bloodstream.\nThe structure of lipoproteins includes triacylglycerol, cholesterol, phospholipids, and amphipathic proteins known as apolipoproteins.\nApoE is one of the major apolipoproteins found in the brain and peripheral tissues, playing a crucial role in lipid metabolism and transport.\n\nApoE Isoforms:\n\nThere are three common isoforms of ApoE: ApoE2, ApoE3, and ApoE4, encoded by different alleles of the APOE gene.\nApoE3 is the most prevalent isoform in the general population, followed by ApoE4 and then ApoE2.\nEach ApoE isoform differs in its amino acid sequence, leading to variations in its structure and function.\n\nAD Risk:\n\nNumerous studies have shown that carrying the ApoE4 allele is associated with an increased risk of developing late-onset AD, the most common form of Alzheimer’s disease.\nIndividuals who inherit one copy of the ApoE4 allele (heterozygous) have a higher risk of developing AD compared to those with two copies of the ApoE3 allele (homozygous).\nThe risk of developing AD is further elevated in individuals who inherit two copies of the ApoE4 allele (homozygous).\n\nMechanisms of AD Risk:\n\nThe exact mechanisms by which ApoE4 increases the risk of AD are not fully understood but may involve multiple pathways.\nApoE4 has been implicated in various processes associated with AD pathogenesis, including amyloid beta aggregation, tau pathology, neuroinflammation, synaptic dysfunction, and impaired lipid metabolism.\nApoE4 may modulate the clearance and metabolism of amyloid beta peptides, leading to their accumulation and the formation of amyloid plaques, a hallmark pathological feature of AD.\n\nReceptor Recognition and Lipid Transport:\n\nApoE isoforms can interact with cell surface receptors, such as the low-density lipoprotein receptor (LDLR) and the apolipoprotein E receptor 2 (ApoER2), mediating the uptake and clearance of lipoprotein particles.\nDysfunction in the receptor-mediated clearance of lipoproteins, particularly those containing ApoE4, may contribute to the accumulation of pathological proteins and lipid dysregulation in the brain, promoting AD pathogenesis."
  },
  {
    "objectID": "chapters/week9.html#microglia",
    "href": "chapters/week9.html#microglia",
    "title": "9  Alzheimer’s Disease",
    "section": "9.5 Microglia",
    "text": "9.5 Microglia\n\n\n\n\n\nMicroglia\n\n\n\n\nMicroglia, comprising approximately 10% of the cells in our brain, are resident phagocytic immune cells critical for maintaining brain homeostasis and responding to pathological insults. They play a pivotal role in immune surveillance, synaptic pruning, and neuroinflammatory responses.\nRecent studies have identified mutations in the TREM2 gene as a risk factor for Alzheimer’s disease. TREM2, or Triggering Receptor Expressed on Myeloid cells 2, is a gene predominantly expressed in microglia, indicating the crucial involvement of these cells in Alzheimer’s pathology.\nThe association between TREM2 mutations and Alzheimer’s disease underscores the importance of microglia in the disease process. Microglia, activated by factors such as amyloid beta accumulation and tau pathology, can exhibit both neuroprotective and neurotoxic functions. Understanding the role of microglia in Alzheimer’s disease may provide insights into potential therapeutic strategies aimed at modulating microglial responses to mitigate neurodegeneration and cognitive decline.\n\n\n\n\n\nRoles of Microglia\n\n\n\n\nMicroglia, the resident immune cells of the brain, play complex roles in Alzheimer’s disease (AD), contributing to both disease progression and potential therapeutic interventions. Here’s an overview of their multifaceted involvement:\n\nImmune Response: Microglia are activated in response to pathological insults in AD, including the accumulation of amyloid beta (Aβ) plaques and tau tangles. Initially, microglia may attempt to clear these protein aggregates through phagocytosis, aiming to maintain brain homeostasis and limit neuronal damage.\nInflammatory Response: While microglial activation is crucial for immune surveillance, excessive or dysregulated activation can lead to neuroinflammation, contributing to neuronal dysfunction and neurodegeneration in AD. Activated microglia release pro-inflammatory cytokines, reactive oxygen species (ROS), and other neurotoxic molecules, exacerbating neuronal damage.\nSynaptic Pruning: Microglia play a role in synaptic pruning, the process of eliminating unnecessary or dysfunctional synapses during brain development and in adulthood. In AD, microglia may aberrantly prune synapses in response to Aβ accumulation, leading to synaptic loss and cognitive impairment.\nPhagocytosis and Clearance: While microglia initially attempt to clear Aβ plaques and tau tangles, their phagocytic capacity may become impaired with disease progression. Dysfunctional microglia may fail to efficiently clear protein aggregates, allowing them to accumulate and contribute to neurotoxicity.\nModulation of Neuroinflammation: Microglia exhibit phenotypic heterogeneity, with both pro-inflammatory (M1-like) and anti-inflammatory (M2-like) states. Modulating microglial polarization toward an anti-inflammatory phenotype may have therapeutic potential in AD, dampening neuroinflammation and promoting neuroprotection.\nGenetic Risk Factors: Genetic studies have identified mutations in microglia-specific genes, such as TREM2, as risk factors for AD. These mutations can impair microglial function, compromising their ability to respond to pathological stimuli and clear protein aggregates.\nTherapeutic Target: Despite their dual roles in neuroprotection and neurotoxicity, microglia represent a promising therapeutic target in AD. Strategies aimed at modulating microglial activation, promoting phagocytosis, and dampening neuroinflammation are under investigation as potential disease-modifying therapies."
  },
  {
    "objectID": "chapters/week9.html#treating-ad",
    "href": "chapters/week9.html#treating-ad",
    "title": "9  Alzheimer’s Disease",
    "section": "9.6 Treating AD",
    "text": "9.6 Treating AD\nInterventions for Alzheimer’s disease (AD) aim to target various pathological mechanisms underlying the disease process. Here are some promising opportunities for AD intervention:\n\nInhibitors of β-Secretase and γ-Secretase:\n\nβ-secretase and γ-secretase are enzymes involved in the production of amyloid beta (Aβ) peptides, which aggregate to form plaques in the brain, a hallmark of AD.\nInhibitors targeting β-secretase or γ-secretase aim to reduce the production of Aβ peptides, thereby potentially slowing down the accumulation of amyloid plaques.\nHowever, targeting γ-secretase may have potential side effects due to its involvement in the processing of other proteins essential for normal cellular function.\n\nImmunotherapies and Tau Inhibitors:\n\nImmunotherapies involve the use of antibodies or vaccines to target and clear abnormal proteins, such as Aβ or tau, from the brain.\nAntibodies targeting Aβ have shown some success in reducing amyloid plaque burden in clinical trials, although results have been mixed.\nSmall molecules that inhibit the aggregation and spread of tau protein may also be promising therapeutic candidates, as tau pathology correlates closely with cognitive decline in AD.\n\nAnti-Inflammatory Drugs:\n\nNeuroinflammation, mediated by activated microglia and astrocytes, is a prominent feature of AD and may contribute to disease progression.\nAnti-inflammatory drugs aim to dampen neuroinflammation and reduce the release of pro-inflammatory cytokines and reactive oxygen species, potentially slowing down neuronal damage.\nHowever, the timing and extent of inflammation in AD are complex, and targeting inflammation may require careful modulation to avoid disrupting beneficial immune responses."
  },
  {
    "objectID": "chapters/week10.html",
    "href": "chapters/week10.html",
    "title": "10  Parkinson’s Disease",
    "section": "",
    "text": "Parkinson’s disease (PD) is the second most prevalent neurodegenerative disorder, following Alzheimer’s disease (AD). It affects an estimated 2-3% of the population over the age of 65. While the mean age of onset is around 70 years, approximately 4% of patients develop early-onset PD before the age of 50.\nPD is characterized by a progressive loss of dopaminergic neurons in the substantia nigra region of the brain, leading to motor symptoms such as tremors, rigidity, bradykinesia (slowed movement), and postural instability. Non-motor symptoms, including cognitive impairment, mood disturbances, and autonomic dysfunction, may also occur.\nThe etiology of PD is complex and multifactorial, involving a combination of genetic predisposition and environmental factors. Genetic mutations, such as those in the SNCA, LRRK2, and Parkin genes, have been implicated in familial forms of PD, while environmental factors such as pesticide exposure, head trauma, and certain medications may increase the risk of developing PD.\nDespite advances in understanding PD pathophysiology, there is currently no cure for the disease. Treatment strategies primarily focus on managing symptoms and improving quality of life for patients. These may include dopamine replacement therapy, deep brain stimulation, physical therapy, and supportive care.\nOngoing research efforts aim to identify novel therapeutic targets and develop disease-modifying treatments that can slow or halt the progression of PD. This includes investigating neuroprotective strategies to prevent neuronal degeneration, exploring the role of inflammation and oxidative stress in PD pathogenesis, and developing personalized medicine approaches based on genetic and biomarker profiling."
  },
  {
    "objectID": "chapters/week10.html#symptoms-and-causes-of-pd",
    "href": "chapters/week10.html#symptoms-and-causes-of-pd",
    "title": "10  Parkinson’s Disease",
    "section": "10.1 Symptoms and Causes of PD",
    "text": "10.1 Symptoms and Causes of PD\n\n\n\n\n\nSymptoms and Progression of Parkinson’s Disease\n\n\n\n\nParkinson’s disease (PD) manifests through a variety of motor and non-motor symptoms. Here’s an overview of the key symptoms associated with PD:\nMotor Symptoms:\n\nRigidity (Stiffness): Patients experience muscle stiffness, making it difficult to initiate or carry out movements smoothly.\nBradykinesia (Slowness): This refers to a general decrease in spontaneous and voluntary movement. Patients may have difficulty initiating movements, resulting in slower walking, reduced arm swinging while walking, or decreased blinking and facial expressions.\nResting Tremor: A characteristic symptom of PD, a resting tremor is a rhythmic, involuntary shaking that occurs in a limb, typically when it is relaxed and at rest. The tremor often disappears or decreases significantly during purposeful movement.\nAction Tremor: In addition to resting tremors, some individuals with PD may experience tremors while performing voluntary movements, such as reaching for an object or holding a utensil.\nPostural Instability: Patients may experience difficulties with balance and coordination, leading to walking problems and an increased risk of falls. Postural instability is often more pronounced in the later stages of the disease.\n\nNon-Motor Symptoms:\n\nConstipation: Many individuals with PD experience gastrointestinal symptoms, including constipation, which may occur years before motor symptoms appear.\nDecreased Sense of Smell (Hyposmia or Anosmia): A reduced ability to detect odors is common in PD and may precede the onset of motor symptoms.\nDepression and Anxiety: Mental health issues such as depression and anxiety are prevalent in individuals with PD and can significantly impact quality of life.\nSleep Disorders: PD can disrupt sleep patterns, leading to insomnia, restless legs syndrome, rapid eye movement (REM) sleep behavior disorder, and excessive daytime sleepiness.\nOther Non-Motor Symptoms: Additional non-motor symptoms may include cognitive impairment, dementia, fatigue, urinary urgency or incontinence, sexual dysfunction, and speech and swallowing difficulties.\n\n\n10.1.1 Causes of PD\n\n\n\n\n\nCauses of PD\n\n\n\n\nParkinson’s disease (PD) is a multifactorial disorder with a complex interplay of genetic and environmental factors contributing to its development. Here’s an overview of the main causes associated with PD:\nGenetic Factors: 1. LRRK2 (Leucine-Rich Repeat Kinase 2): Mutations in the LRRK2 gene are among the most common genetic causes of familial PD, accounting for a small percentage of cases. Variants in the LRRK2 gene can increase the risk of developing PD. 2. SNCA (Alpha-Synuclein): Mutations or multiplications of the SNCA gene, which encodes the alpha-synuclein protein, are associated with rare familial forms of PD. Alpha-synuclein is a key component of Lewy bodies, abnormal protein aggregates found in the brains of individuals with PD. 3. PRKN (Parkin): Mutations in the PRKN gene are associated with autosomal recessive juvenile-onset PD. Parkin plays a role in protein degradation pathways and mitochondrial function. 4. GBA (Glucocerebrosidase): Mutations in the GBA gene, which codes for the enzyme glucocerebrosidase, are a significant genetic risk factor for PD. GBA mutations are more common in individuals of Ashkenazi Jewish descent and are associated with an increased risk of developing PD.\nEnvironmental Factors: 1. Head Injury: Traumatic brain injury, particularly repeated head trauma, has been linked to an increased risk of developing PD later in life. 2. Pesticide Exposure: Exposure to certain pesticides and herbicides, such as paraquat and rotenone, has been implicated as potential environmental risk factors for PD. 3. Heavy Metal Exposure: Some studies suggest that exposure to heavy metals, including manganese and lead, may increase the risk of PD, although the evidence is less conclusive. 4. Age: Age is the single greatest risk factor for PD. As individuals age, their cells may become more susceptible to damage, and changes in gene expression over time could trigger cellular events that contribute to the development of PD.\n\n\n10.1.2 Basal Ganglia\n\n\n\n\n\nIllustration of the Basal Ganglia\n\n\n\n\nThe basal ganglia are clusters of nerve cells located deep within the cerebrum, a part of the brain. They play a crucial role in regulating voluntary motor movements, as well as various cognitive and emotional functions. The basal ganglia consist of several key structures, including:\n\nStriatum: The largest component of the basal ganglia, comprising the caudate nucleus and the putamen. The striatum receives input from various regions of the brain and is involved in motor control, reward processing, and learning.\nGlobus Pallidus: Divided into two segments, the globus pallidus consists of the external segment (GPe) and the internal segment (GPi). It serves as a major output nucleus of the basal ganglia, regulating motor activity by sending inhibitory signals to the thalamus and brainstem.\nSubstantia Nigra: Divided into two regions, the substantia nigra consists of the pars compacta (SNc) and the pars reticulata (SNr). The SNc is involved in the production of dopamine, a neurotransmitter crucial for motor control and reward processing. Dysfunction of the substantia nigra, particularly the loss of dopamine-producing neurons in the SNc, is associated with Parkinson’s disease (PD).\nSubthalamic Nucleus: Located beneath the thalamus, the subthalamic nucleus plays a role in modulating motor functions and is involved in the regulation of movement through its connections with other basal ganglia nuclei.\n\nParkinson’s disease (PD) and Huntington’s disease (HD) are neurodegenerative disorders that primarily affect the basal ganglia, leading to motor impairments and other neurological symptoms. In PD, the degeneration of dopamine-producing neurons in the substantia nigra disrupts the balance of neurotransmitters within the basal ganglia, resulting in characteristic motor symptoms such as tremors, rigidity, and bradykinesia. HD, on the other hand, is characterized by the progressive degeneration of neurons in the striatum, leading to involuntary movements (chorea), cognitive decline, and psychiatric symptoms.\n\n\n10.1.3 Death of Dopaminergic Neurons\n\n\n\n\n\nDeath of Dopaminergic Neurons\n\n\n\n\nThe death of dopaminergic neurons refers to the loss or degeneration of nerve cells in the brain that produce dopamine, a neurotransmitter involved in regulating movement, emotions, and cognition. This phenomenon is particularly relevant in the context of neurodegenerative disorders such as Parkinson’s disease (PD), where the progressive loss of dopaminergic neurons in the substantia nigra region of the brain leads to the characteristic motor symptoms associated with the disease.\nIn Parkinson’s disease, the exact cause of dopaminergic neuron death is not fully understood, but it is believed to result from a combination of genetic, environmental, and age-related factors. Several mechanisms have been proposed to contribute to the death of dopaminergic neurons, including:\n\nAlpha-Synuclein Aggregation: Abnormal accumulation and aggregation of alpha-synuclein protein into Lewy bodies, which are characteristic pathological hallmarks of PD, may lead to cellular toxicity and neuronal death.\nOxidative Stress: Dopaminergic neurons are particularly vulnerable to oxidative stress due to the high metabolic demands associated with dopamine synthesis and metabolism. Oxidative stress can result from an imbalance between the production of reactive oxygen species (ROS) and antioxidant defense mechanisms, leading to cellular damage and eventual neuronal death.\nMitochondrial Dysfunction: Dysfunction of mitochondria, the cellular organelles responsible for energy production, has been implicated in PD pathogenesis. Mitochondrial dysfunction can impair energy metabolism, increase oxidative stress, and trigger apoptotic cell death pathways in dopaminergic neurons.\nInflammation: Neuroinflammation, characterized by the activation of microglia and the release of pro-inflammatory cytokines, may contribute to the death of dopaminergic neurons in PD. Chronic inflammation in the brain can exacerbate neuronal damage and disrupt normal cellular functions.\nProtein Misfolding and Proteostasis Dysfunction: Impaired protein folding and clearance mechanisms, leading to the accumulation of misfolded proteins and disruption of proteostasis, may contribute to dopaminergic neuron death in PD."
  },
  {
    "objectID": "chapters/week10.html#pd-pathology",
    "href": "chapters/week10.html#pd-pathology",
    "title": "10  Parkinson’s Disease",
    "section": "10.2 PD Pathology",
    "text": "10.2 PD Pathology\n\n\n\n\n\nPD Pathology\n\n\n\n\nLewy bodies are abnormal aggregates of protein that develop inside nerve cells, particularly in regions of the brain associated with movement and cognition. They are a hallmark pathological feature of Parkinson’s disease (PD) and other related neurodegenerative disorders, collectively known as Lewy body diseases.\nThe primary protein component of Lewy bodies is alpha-synuclein, a protein normally found in the brain that plays a role in neurotransmitter release and synaptic function. In Lewy body diseases, alpha-synuclein becomes abnormally folded and aggregates into insoluble clumps, forming the characteristic spherical structures known as Lewy bodies.\nThe presence of Lewy bodies in the brain is associated with the death of nerve cells, particularly dopaminergic neurons in the substantia nigra region, which leads to the motor symptoms of PD. Lewy bodies are also found in other areas of the brain, including the cerebral cortex and brainstem, contributing to a range of cognitive and non-motor symptoms observed in PD and related disorders, such as dementia with Lewy bodies (DLB).\nThe exact role of Lewy bodies in neurodegeneration and disease progression is still not fully understood. However, research suggests that Lewy bodies may disrupt cellular processes, impair protein clearance mechanisms, and induce toxic effects on nerve cells, ultimately contributing to their dysfunction and death.\nWhile Lewy bodies are a characteristic feature of PD pathology, their presence alone does not necessarily correlate with disease severity or progression. Other factors, including inflammation, mitochondrial dysfunction, and genetic predisposition, likely play a role in the complex pathogenesis of PD and related disorders.\n\n10.2.1 \\(\\alpha\\)-synuclein in Familial PD\n\n\n\n\n\n\\(\u0007lpha\\)-Synuclein Mutations\n\n\n\n\nMutations in the alpha-synuclein (α-synuclein) gene (SNCA) have been linked to familial forms of Parkinson’s disease (PD). While the majority of PD cases are sporadic, meaning they occur without a clear family history, approximately 5-10% of PD cases have a familial component, and mutations in the SNCA gene are among the genetic factors implicated in these cases.\nSeveral point mutations and gene multiplications (duplications or triplications) in the SNCA gene have been identified in families with inherited PD. These mutations are thought to alter the structure or function of the alpha-synuclein protein, leading to its abnormal aggregation and the formation of Lewy bodies, characteristic pathological features of PD.\nThe most well-known mutation in the SNCA gene associated with familial PD is the A53T mutation, where alanine is substituted with threonine at position 53 of the alpha-synuclein protein. Other mutations include A30P (alanine to proline at position 30) and E46K (glutamic acid to lysine at position 46), among others.\nIndividuals carrying mutations in the SNCA gene typically develop PD with clinical features similar to those of sporadic PD, including motor symptoms such as tremor, rigidity, bradykinesia, and postural instability. However, familial PD cases associated with SNCA mutations may exhibit earlier onset and more rapid disease progression compared to sporadic cases.\nThe precise mechanisms by which mutations in the SNCA gene lead to neurodegeneration and PD pathology are still under investigation. However, it is believed that mutant forms of alpha-synuclein have an increased propensity to misfold and aggregate into toxic oligomers and fibrils, which disrupt cellular function and ultimately lead to the death of dopaminergic neurons in the brain.\n\n\n10.2.2 Synaptic Vesicles\n\n\n\n\n\nVesicles\n\n\n\n\nSynaptic vesicles are small membrane-bound sacs found within nerve terminals (synaptic boutons) of neurons. These vesicles are essential components of the synaptic transmission process, facilitating the release of neurotransmitters from the presynaptic neuron into the synaptic cleft, where they can then bind to receptors on the postsynaptic neuron or other target cells.\nKey features of synaptic vesicles include:\n\nNeurotransmitter Storage: Synaptic vesicles contain high concentrations of neurotransmitter molecules, such as acetylcholine, dopamine, serotonin, glutamate, and gamma-aminobutyric acid (GABA), depending on the type of synapse. These neurotransmitters are synthesized and packaged into vesicles within the presynaptic neuron.\nMembrane Proteins: Synaptic vesicles are equipped with specific membrane proteins responsible for neurotransmitter uptake, storage, and release. For example, vesicular neurotransmitter transporters, such as vesicular acetylcholine transporter (VAChT) or vesicular glutamate transporter (VGLUT), actively transport neurotransmitters into the vesicle lumen.\nSynaptic Vesicle Cycle: Synaptic vesicles undergo a series of tightly regulated steps known as the synaptic vesicle cycle. This cycle involves vesicle docking and fusion at the presynaptic membrane, neurotransmitter release into the synaptic cleft, vesicle retrieval through endocytosis, and vesicle reformation and recycling.\nExocytosis and Neurotransmitter Release: Upon arrival of an action potential at the presynaptic terminal, synaptic vesicles undergo exocytosis, a process by which the vesicle fuses with the presynaptic membrane, releasing neurotransmitter molecules into the synaptic cleft. This neurotransmitter release triggers postsynaptic responses in the target neuron, leading to synaptic transmission.\nEndocytosis and Recycling: Following neurotransmitter release, synaptic vesicle membrane proteins are retrieved through endocytosis, allowing the vesicle to be recycled for subsequent rounds of neurotransmitter packaging and release. This process ensures efficient neurotransmission and maintains synaptic function.\n\n\n10.2.2.1 Exocytosis\n\n\n\n\n\nExocytosis of Vesicles\n\n\n\n\nExocytosis of synaptic vesicles is a crucial step in the process of synaptic transmission, where neurotransmitters stored within synaptic vesicles are released into the synaptic cleft to signal the postsynaptic neuron or target cell. This process involves several key steps:\n\nAction Potential Depolarization: When an action potential arrives at the presynaptic terminal, voltage-gated calcium channels open in response to membrane depolarization. This influx of calcium ions (Ca2+) into the presynaptic terminal triggers synaptic vesicle exocytosis.\nVesicle Docking and Priming: Prior to exocytosis, synaptic vesicles undergo a series of molecular interactions that allow them to dock and become primed at specialized sites on the presynaptic membrane called active zones. Proteins such as SNARE (soluble N-ethylmaleimide-sensitive factor attachment protein receptor) complexes mediate vesicle docking and priming, bringing the vesicle into close proximity with the presynaptic membrane and preparing it for fusion.\nMembrane Fusion: Upon calcium influx, synaptic vesicles undergo fusion with the presynaptic membrane at the active zone. This fusion process involves the formation of a fusion pore, allowing the contents of the vesicle, including neurotransmitter molecules, to be released into the synaptic cleft.\nNeurotransmitter Release: Once the fusion pore is formed, neurotransmitter molecules stored within the synaptic vesicle are released into the synaptic cleft through diffusion. Neurotransmitters then bind to receptors on the postsynaptic membrane, leading to changes in postsynaptic membrane potential and synaptic transmission.\nRecycling of Vesicle Components: Following exocytosis, the empty synaptic vesicle membrane is retrieved from the presynaptic membrane through endocytosis. This process allows for the recycling of vesicle components, including membrane proteins and lipids, and enables the vesicle to be refilled with neurotransmitter for subsequent rounds of synaptic transmission.\n\n\n\n\n10.2.3 \\(\\alpha\\)-Synuclein Binding to Vesicles\n\n\n\n\n\n\\(\u0007lpha\\)-Synuclein and Vesicles\n\n\n\n\nAlpha-synuclein (α-synuclein) is a protein that is abundant in the brain, particularly in presynaptic terminals, where it is thought to play a role in regulating neurotransmitter release and synaptic function. One of the intriguing aspects of α-synuclein biology is its ability to interact with cell membranes, including synaptic vesicle membranes, and to adopt different conformations depending on its environment.\nHere’s an overview of α-synuclein’s interaction with membranes:\n\nBinding to Lipid Membranes: α-synuclein is known to bind to lipid membranes, including synaptic vesicle membranes, through interactions with lipid bilayers. This binding is mediated by specific regions within the protein, such as its N-terminal domain, which contains positively charged residues that can interact with negatively charged phospholipids in the membrane.\nInduction of Membrane Curvature: α-synuclein has been shown to have the ability to induce curvature in lipid membranes, leading to changes in membrane morphology. This property is thought to be important for α-synuclein’s physiological functions, such as regulating synaptic vesicle trafficking and fusion.\nRole in Vesicle Trafficking: α-synuclein has been implicated in the regulation of synaptic vesicle dynamics and neurotransmitter release. By interacting with synaptic vesicle membranes, α-synuclein may modulate vesicle trafficking processes, such as vesicle docking, fusion, and recycling, which are essential for synaptic transmission.\nFormation of Membrane-associated Oligomers: Under certain conditions, α-synuclein can undergo conformational changes and form oligomeric structures that associate with lipid membranes. These membrane-associated oligomers have been implicated in the pathogenesis of neurodegenerative diseases such as Parkinson’s disease, where they may disrupt membrane integrity and neuronal function.\nRole in Neurodegenerative Disease: Abnormal accumulation and aggregation of α-synuclein are pathological hallmarks of Parkinson’s disease and other synucleinopathies. The interaction of α-synuclein with membranes, as well as its propensity to form toxic oligomers and fibrils, may contribute to neuronal dysfunction and cell death in these diseases.\n\n\n\n10.2.4 \\(\\alpha\\)-Synuclein Aggregations in Neurons\n\n\n\n\n\nAggregation of \\(\u0007lpha\\)-Synuclein in Neurons\n\n\n\n\nThe aggregation of alpha-synuclein (α-synuclein) within neurons is a central feature of several neurodegenerative diseases, including Parkinson’s disease (PD) and dementia with Lewy bodies (DLB). Here’s an overview of how α-synuclein aggregation occurs within neurons:\n\nNative Function of α-synuclein: In its native state, α-synuclein is thought to play a role in regulating synaptic function, neurotransmitter release, and vesicle trafficking within neurons. However, under certain conditions, α-synuclein can undergo conformational changes and form aggregates.\nMisfolding and Oligomerization: α-synuclein can misfold from its native, soluble conformation into β-sheet-rich structures that are prone to aggregation. Initially, monomeric α-synuclein molecules form smaller oligomeric species, which are thought to be highly toxic to neurons and disrupt cellular function.\nFormation of Protofibrils and Fibrils: Oligomeric α-synuclein species can further assemble into larger aggregates, including protofibrils and fibrils, which are insoluble and resistant to degradation. These aggregates accumulate within neurons, particularly in regions rich in dopamine-producing neurons, such as the substantia nigra in PD.\nCellular Consequences of Aggregation: The accumulation of α-synuclein aggregates within neurons can have several detrimental effects. It may disrupt cellular homeostasis, impair mitochondrial function, induce oxidative stress, interfere with protein degradation pathways (such as the ubiquitin-proteasome system and autophagy), and trigger inflammatory responses.\nNeuronal Dysfunction and Death: Ultimately, the aggregation of α-synuclein and the resulting cellular dysfunction contribute to the degeneration and death of neurons, particularly dopaminergic neurons in the substantia nigra. This neuronal loss underlies the motor and cognitive symptoms observed in PD and DLB.\nPropagation of Aggregates: Interestingly, α-synuclein aggregates can spread between neurons and propagate throughout the brain in a prion-like manner. This propagation may involve the release of α-synuclein aggregates from affected neurons, uptake by neighboring neurons, and seeding of new aggregates, leading to the progressive spread of pathology in the brain.\n\n\n\n10.2.5 \\(\\alpha\\)-Synuclein Amyloid Fibril\nAlpha-synuclein (α-synuclein) amyloid fibrils are insoluble, filamentous protein aggregates that are a hallmark pathological feature of several neurodegenerative diseases, including Parkinson’s disease (PD) and dementia with Lewy bodies (DLB). Here’s an overview of α-synuclein amyloid fibrils:\n\nComposition: α-synuclein amyloid fibrils are composed of misfolded and aggregated α-synuclein protein molecules. These aggregates adopt a β-sheet-rich conformation, which gives them stability and resistance to degradation.\nFormation: α-synuclein amyloid fibrils form through a complex process of nucleation, elongation, and fibril assembly. Monomeric α-synuclein molecules initially undergo conformational changes and self-associate to form small oligomeric intermediates. These oligomers then further assemble into larger structures, ultimately leading to the formation of mature amyloid fibrils.\nStructure: α-synuclein amyloid fibrils have a characteristic fibrillar structure, with a cross-β sheet architecture in which β-strands run perpendicular to the long axis of the fibril. The fibrils typically adopt a twisted, filamentous morphology, with a diameter of approximately 10-20 nanometers and variable lengths.\nPathological Role: Accumulation of α-synuclein amyloid fibrils in the brain is associated with neuronal dysfunction and cell death, contributing to the progressive neurodegeneration observed in PD and DLB. These fibrils can disrupt cellular processes, induce oxidative stress, impair mitochondrial function, and trigger inflammatory responses, ultimately leading to neuronal loss and clinical symptoms.\nPropagation: α-synuclein amyloid fibrils have the ability to propagate and spread between neurons in a prion-like manner. This propagation may involve the release of fibrils from affected neurons, uptake by neighboring neurons, and seeding of new fibrils, leading to the progressive spread of pathology throughout the brain.\nDiagnostic and Therapeutic Implications: Detection of α-synuclein amyloid fibrils in postmortem brain tissue or cerebrospinal fluid is used as a diagnostic marker for PD and related synucleinopathies. Targeting α-synuclein aggregation and fibril formation is a major focus of therapeutic strategies aimed at slowing or halting disease progression in these disorders.\n\n\n\n10.2.6 iPSC Stem Cell Therapy\n\n\n\n\n\nStem Cell Therapy\n\n\n\n\nPersonalized cell therapy using induced pluripotent stem cells (iPSCs) holds great promise for treating a wide range of diseases and conditions. Here’s an overview of how iPSCs can be used for personalized cell therapy:\n\nGeneration of iPSCs: iPSCs are derived from adult somatic cells, such as skin cells or blood cells, through a process called reprogramming. This involves introducing specific transcription factors that reprogram the cells to a pluripotent state, similar to embryonic stem cells. The resulting iPSCs have the ability to differentiate into virtually any cell type in the body.\nPatient-Specific iPSCs: One of the key advantages of iPSCs is that they can be generated from individual patients, allowing for the creation of patient-specific cell lines. This enables the development of personalized cell therapies tailored to the unique genetic and biological characteristics of each patient.\nDifferentiation into Desired Cell Types: iPSCs can be directed to differentiate into specific cell types relevant to the disease or condition being treated. For example, iPSCs can be differentiated into neurons for treating neurodegenerative diseases, cardiomyocytes for treating heart disease, or pancreatic beta cells for treating diabetes.\nCorrection of Genetic Defects: In cases where the patient’s cells carry genetic mutations contributing to the disease, gene editing techniques such as CRISPR-Cas9 can be used to correct these mutations in iPSCs prior to differentiation. This allows for the generation of healthy, genetically corrected cells for transplantation.\nIn Vitro Disease Modeling: iPSCs can also be used to model diseases in vitro, allowing researchers to study disease mechanisms, screen potential therapies, and test drug efficacy in a personalized manner. Patient-specific iPSC-derived disease models can provide valuable insights into disease pathology and help guide treatment strategies.\nCell Replacement Therapy: Once differentiated into the desired cell type, iPSC-derived cells can be transplanted back into the patient to replace damaged or dysfunctional tissues and restore normal function. For example, iPSC-derived dopaminergic neurons can be transplanted into the brains of Parkinson’s disease patients to replenish lost neurons and improve motor function.\nImmunocompatibility: By using the patient’s own cells to generate iPSCs, the risk of immune rejection upon transplantation is minimized, as the cells are genetically identical to the patient’s own tissues. This reduces the need for immunosuppressive drugs and improves the long-term safety and efficacy of cell-based therapies."
  },
  {
    "objectID": "chapters/week10.html#prion-diseases",
    "href": "chapters/week10.html#prion-diseases",
    "title": "10  Parkinson’s Disease",
    "section": "10.3 Prion Diseases",
    "text": "10.3 Prion Diseases\nThe Prion hypothesis, proposed by Stanley Prusiner and recognized with the Nobel Prize in Physiology or Medicine in 1997, introduced a groundbreaking concept in infectious diseases. Prions, short for proteinaceous infectious particles, challenged the traditional understanding of infectious agents by demonstrating that infectious properties could be attributed solely to proteins, without the involvement of nucleic acids like DNA or RNA.\n\nDefinition of Prions: Prions are abnormal forms of a naturally occurring cellular protein called PrP (prion protein). When PrP undergoes a conformational change and adopts a misfolded shape, it becomes infectious and can induce other PrP molecules to misfold as well. This abnormal accumulation of misfolded PrP is associated with a group of neurodegenerative diseases known as transmissible spongiform encephalopathies (TSEs), including Creutzfeldt-Jakob disease (CJD) in humans, scrapie in sheep, bovine spongiform encephalopathy (BSE or “mad cow disease”) in cattle, and Chronic Wasting Disease (CWD) in deer and other cervids.\nUnique Infectious Properties: Prions exhibit unique infectious properties that distinguish them from conventional pathogens like bacteria or viruses. Unlike viruses, which contain genetic material that directs their replication, prions lack nucleic acids and propagate by inducing conformational changes in normal cellular proteins. This process leads to the formation of insoluble aggregates and the accumulation of amyloid fibrils in the brain, resulting in neurodegeneration and the characteristic spongiform changes observed in affected tissues.\nCross-Species Transmission: One of the remarkable features of prion diseases is their ability to cross species barriers and infect organisms with different genetic backgrounds. For example, BSE in cattle can be transmitted to humans, causing variant Creutzfeldt-Jakob disease (vCJD), and CWD in cervids has raised concerns about potential transmission to humans or other animal species. The ability of prions to adapt to new host species and propagate in diverse biological environments underscores their unique biology and challenges traditional concepts of infectious disease.\nDiagnostic Challenges: The unique properties of prions pose significant challenges for disease diagnosis and surveillance. Conventional diagnostic techniques that rely on the detection of nucleic acids or microbial antigens are ineffective for prion diseases, as prions lack these traditional markers. Instead, diagnosis typically relies on the detection of abnormal PrP aggregates in brain tissue using specialized techniques such as immunohistochemistry or protein misfolding assays.\nImplications for Public Health: The discovery of prions has profound implications for public health, food safety, and wildlife conservation. Prion diseases represent a complex and poorly understood group of disorders with devastating consequences for affected individuals and populations. Efforts to mitigate the risks associated with prion diseases require interdisciplinary collaboration, innovative research, and evidence-based strategies for disease management and prevention.\n\n\n\n\n\n\nChronic Wasting Disease\n\n\n\n\nChronic Wasting Disease (CWD) is a progressive and fatal neurological disorder that affects members of the deer family, including deer, elk, reindeer, and moose. It belongs to a group of diseases known as transmissible spongiform encephalopathies (TSEs), which also include scrapie in sheep, bovine spongiform encephalopathy (BSE) in cattle, and Creutzfeldt-Jakob disease (CJD) in humans.\n\nEfficient Spread: CWD is characterized by its high efficiency in spreading among susceptible animal populations. It is believed to be transmitted through prions, misfolded proteins that can induce other proteins to adopt the same abnormal conformation. Prions are highly resistant to degradation and can persist in the environment for extended periods, contributing to the widespread transmission of CWD.\nNeurological Symptoms: CWD primarily affects the brain and nervous system of infected animals. It leads to a progressive degeneration of brain tissue, resulting in neurological symptoms such as behavioral changes, loss of coordination, emaciation, excessive salivation, and ultimately death. These symptoms typically manifest over an extended period, ranging from months to years, depending on the species and individual.\nConcerns for Wildlife and Management: CWD poses significant challenges for wildlife management and conservation efforts, particularly in regions where infected populations overlap with economically and ecologically important species. The disease can have serious implications for population dynamics, genetic diversity, and ecosystem health, as affected animals may experience reduced reproductive success and increased mortality.\nPotential Zoonotic Risk: While there is currently no evidence to suggest that CWD can infect humans, concerns have been raised about the potential for zoonotic transmission, particularly given the similarities between CWD and other TSEs that affect humans, such as variant Creutzfeldt-Jakob disease (vCJD). As a precautionary measure, public health agencies advise against consuming meat from CWD-infected animals and recommend proper handling and disposal of carcasses.\nResearch and Surveillance: Efforts to better understand and control CWD include ongoing research into the epidemiology, pathogenesis, and transmission dynamics of the disease, as well as the development of diagnostic tests and potential vaccines or treatments. Surveillance programs are also in place to monitor the spread of CWD and detect new cases in wildlife populations.\n\n\n10.3.1 Prions in Humans\nPrion infections in humans, such as Creutzfeldt-Jakob disease (CJD), variant Creutzfeldt-Jakob disease (vCJD), and Gerstmann-Sträussler-Scheinker syndrome (GSS), are rare but devastating neurodegenerative disorders caused by the misfolding and aggregation of the prion protein (PrP). Detecting prions in human tissues presents unique challenges due to the unconventional nature of these infectious agents. Here’s an overview of prion infection detection methods:\n\nClinical Evaluation: Diagnosis of prion diseases often begins with a thorough clinical evaluation, which includes assessing the patient’s medical history, symptoms, and neurological examinations. Prion diseases typically manifest with rapidly progressive dementia, cognitive decline, movement abnormalities, and other neurological symptoms.\nBrain Biopsy or Autopsy: Definitive diagnosis of prion diseases usually requires neuropathological examination of brain tissue obtained through biopsy or autopsy. Histopathological analysis of brain samples can reveal characteristic features such as spongiform degeneration, neuronal loss, and the presence of abnormal prion protein aggregates.\nCerebrospinal Fluid (CSF) Analysis: Analysis of cerebrospinal fluid (CSF) can provide valuable diagnostic information for prion diseases. Techniques such as protein misfolding cyclic amplification (PMCA) and real-time quaking-induced conversion (RT-QuIC) allow for the sensitive detection of abnormal prion protein aggregates in CSF samples, aiding in the diagnosis of CJD and other prion diseases.\nGenetic Testing: Some forms of familial prion diseases, such as familial CJD and GSS, are associated with specific mutations in the PRNP gene, which encodes the prion protein. Genetic testing can identify these mutations in affected individuals or at-risk family members, providing important diagnostic and prognostic information.\nBrain Imaging: Neuroimaging techniques such as magnetic resonance imaging (MRI) and positron emission tomography (PET) can help detect structural and functional abnormalities in the brain associated with prion diseases. These imaging modalities may reveal characteristic patterns of brain atrophy, diffusion changes, and abnormal protein deposition.\nPost-mortem Prion Detection: Post-mortem detection of prions in brain tissue remains the gold standard for confirming prion diseases. Techniques such as immunohistochemistry, Western blotting, and enzyme-linked immunosorbent assay (ELISA) can be used to detect abnormal prion protein aggregates in brain samples, providing definitive evidence of prion infection.\n\n\n\n10.3.2 More Information (not tested)\nMPTP-induced Parkinsonism is a model of Parkinson’s disease (PD) induced by the administration of a neurotoxin called 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). MPTP selectively damages dopamine-producing neurons in the brain, resulting in motor symptoms similar to those observed in Parkinson’s disease, including tremors, rigidity, bradykinesia, and postural instability. This model is commonly used in research to study the pathophysiology of PD and test potential therapeutic interventions.\n\n10.3.2.1 Medications and Treatments of PD:\n\nLevodopa: Levodopa is the most effective medication for managing the motor symptoms of Parkinson’s disease. It is converted into dopamine in the brain and helps replenish dopamine levels, alleviating symptoms such as bradykinesia and rigidity.\nDopamine Agonists: Dopamine agonists mimic the effects of dopamine in the brain and can be used as monotherapy or in combination with levodopa to manage PD symptoms. Examples include pramipexole and ropinirole.\nMAO-B Inhibitors: Monoamine oxidase type B (MAO-B) inhibitors, such as rasagiline and selegiline, increase dopamine levels in the brain by inhibiting the enzyme responsible for its breakdown. They can be used as adjunctive therapy to levodopa.\nCOMT Inhibitors: Catechol-O-methyltransferase (COMT) inhibitors, such as entacapone and tolcapone, prolong the effects of levodopa by inhibiting its peripheral metabolism. They are often used in combination with levodopa/carbidopa formulations.\nAnticholinergics: Anticholinergic medications, such as trihexyphenidyl and benztropine, can help reduce tremors and dystonia in Parkinson’s disease by blocking the activity of acetylcholine.\nDeep Brain Stimulation (DBS): Deep brain stimulation involves the implantation of electrodes into specific regions of the brain, such as the subthalamic nucleus or globus pallidus, followed by the delivery of electrical stimulation. DBS can help alleviate motor symptoms and improve quality of life in individuals with advanced PD who are not adequately controlled with medications.\n\nBlood-Brain Barrier (BBB): The blood-brain barrier (BBB) is a highly selective semipermeable membrane that separates the bloodstream from the brain’s extracellular fluid. It plays a crucial role in protecting the brain from circulating toxins, pathogens, and fluctuations in ion and nutrient levels while maintaining a stable internal environment conducive to neuronal function. The BBB is composed of specialized endothelial cells, tight junctions, and pericytes that regulate the passage of molecules between the blood and the brain. While the BBB helps maintain brain homeostasis, it can also pose challenges for drug delivery to the central nervous system, as many therapeutic agents have difficulty crossing this barrier.\nDeep Brain Stimulation (DBS): Deep brain stimulation (DBS) is a surgical procedure that involves the implantation of electrodes into specific regions of the brain, followed by the delivery of electrical stimulation through an implanted pulse generator. DBS is used to treat a variety of neurological and psychiatric disorders, including Parkinson’s disease, essential tremor, dystonia, and obsessive-compulsive disorder. In Parkinson’s disease, DBS is typically targeted to the subthalamic nucleus or globus pallidus interna and can help alleviate motor symptoms such as tremors, rigidity, and bradykinesia, as well as improve medication responsiveness and reduce medication-related side effects. DBS is generally considered safe and effective, although it carries risks associated with surgery and device implantation, as well as potential side effects such as speech or cognitive changes."
  },
  {
    "objectID": "chapters/week11.html",
    "href": "chapters/week11.html",
    "title": "11  ALS and Huntington’s Disease",
    "section": "",
    "text": "Huntington’s disease, also known as chorea, is a neurological disorder characterized by involuntary movements and progressive degeneration of brain cells. The term “chorea” derives from the Greek word for dance, reflecting the characteristic dancing-like movements exhibited by affected individuals. While not typically life-threatening, Huntington’s disease can significantly impact a person’s quality of life and ability to function.\nThe hallmark feature of Huntington’s disease is chorea, a type of involuntary movement that affects voluntary muscles. Unlike seizures in epilepsy, individuals with chorea maintain awareness and intention during these movements, but their ability to control their muscles is impaired. The movements may start as subtle twitches in the face and gradually progress in frequency and intensity.\nCommon early symptoms include facial twitching, blinking, raised eyebrows, nose movements, and various mouth contortions, resulting in a peculiar and sometimes comical appearance. Over time, chorea may affect the upper extremities and other voluntary muscles throughout the body, leading to jerky, uncontrollable movements that interfere with daily activities.\nWhile chorea is a prominent feature of Huntington’s disease, the condition can also cause a range of other symptoms, including cognitive decline, psychiatric disturbances, and behavioral changes. These symptoms can significantly impact a person’s emotional well-being and ability to engage in social interactions.\nHuntington’s disease is caused by a genetic mutation that leads to the progressive degeneration of nerve cells in certain regions of the brain. Currently, there is no cure for Huntington’s disease, and treatment focuses on managing symptoms and improving quality of life through medications, therapy, and support services.\n\n\nHuntington’s disease (HD) is an autosomal dominant genetic disorder caused by mutations in the HTT gene located on chromosome 4. This means that an affected individual only needs one copy of the mutated gene from either parent to develop the disease. Both males and females are equally affected by HD. The typical age of onset for Huntington’s disease is between 30 and 50 years old, although symptoms can appear at almost any age. The disease progresses gradually over approximately 15 years from the onset of symptoms. The prevalence of Huntington’s disease is relatively low, estimated to affect about 5 to 10 individuals per 100,000 people in the population.\n\n\n\n\n\n\n\n\nPathology of Huntington’s Disease\n\n\n\n\nHuntington’s disease (HD) is characterized by progressive degeneration of nerve cells in certain regions of the brain, leading to widespread neurological dysfunction. The pathology of HD involves several key features:\n\nStriatal Atrophy: One of the hallmark pathological changes in HD is atrophy (shrinkage) of the striatum, a region deep within the brain involved in motor control, cognition, and emotion. Specifically, there is pronounced loss of medium spiny neurons in the striatum, particularly in the caudate nucleus and putamen. This neuronal loss contributes to the motor symptoms, cognitive impairment, and psychiatric disturbances seen in HD.\nCortical Atrophy: In addition to striatal atrophy, individuals with HD also exhibit cortical atrophy, particularly in the frontal and temporal lobes of the brain. This cortical degeneration contributes to cognitive decline and behavioral changes observed in HD patients.\nNeuronal Inclusions: Another pathological hallmark of HD is the presence of intracellular aggregates of mutant huntingtin protein within neurons. These neuronal inclusions, known as Huntington protein aggregates or Huntington bodies, disrupt cellular function and contribute to neuronal dysfunction and death.\nGlial Activation: In response to neuronal damage and protein aggregation, glial cells, including astrocytes and microglia, become activated and contribute to neuroinflammation and neurodegeneration in HD. Glial activation may exacerbate neuronal damage and further impair brain function in individuals with HD.\nAltered Neurotransmission: HD is associated with dysregulation of neurotransmitter systems, including dopamine, glutamate, and gamma-aminobutyric acid (GABA). Imbalances in neurotransmission contribute to motor symptoms, cognitive deficits, and psychiatric disturbances in HD patients.\nWhite Matter Abnormalities: HD is also characterized by alterations in white matter integrity, including loss of myelin and disruption of axonal pathways. These white matter abnormalities contribute to connectivity deficits and cognitive dysfunction in HD.\n\n\n\n\nMutations in the huntingtin (HTT) gene are the underlying cause of Huntington’s disease (HD). The HTT gene provides instructions for making the huntingtin protein, which plays a role in various cellular functions, including neuronal development and survival. However, mutations in the HTT gene lead to the production of an abnormal form of the huntingtin protein, known as mutant huntingtin (mHTT), which is toxic to neurons.\nThe most common mutation associated with HD is an expansion of a CAG trinucleotide repeat within the HTT gene. Normally, this CAG repeat is present in the gene in a stable, repeat length of approximately 10 to 35 repeats. However, in individuals with HD, the CAG repeat expands beyond this normal range, resulting in an increased number of repeats. The length of the CAG repeat expansion is directly correlated with the age of onset and severity of HD symptoms, with longer repeat lengths typically associated with earlier onset and more severe disease progression.\nThe expanded CAG repeat leads to the production of an abnormal huntingtin protein with an elongated polyglutamine (polyQ) tract. This mutant huntingtin protein has a tendency to misfold and aggregate within neurons, forming toxic protein aggregates that disrupt cellular function and lead to neuronal dysfunction and death. The exact mechanisms by which mutant huntingtin exerts its toxic effects are still under investigation, but it is thought to disrupt various cellular processes, including mitochondrial function, protein quality control, neurotransmitter signaling, and gene transcription.\n\n\n\n\n\n\n\nHuntingtin Protein Fragments\n\n\n\n\n\n\n\n\n\n\n\n\n\nDifferences Between Adult and Juvenile Huntington’s Disease\n\n\n\n\nJuvenile Huntington’s disease (JHD) is a rare form of Huntington’s disease that begins in individuals under the age of 20. Unlike the more common adult-onset form of HD, JHD tends to progress more rapidly, with a shorter average life expectancy after diagnosis, typically around 15 years.\nOne notable difference between JHD and adult-onset HD is the pattern of motor symptoms. While adults with HD often experience prominent chorea (involuntary movements), children and young people with JHD may exhibit milder chorea or even no involuntary movements at all. Instead, they may develop stiffness and rigidity, making movements more difficult.\nAs JHD progresses, individuals may experience difficulties with chewing, swallowing, and speaking due to muscle stiffness and weakness. These challenges can significantly impact their ability to eat, communicate, and perform daily activities.\nIn approximately 25% of JHD cases, individuals may also experience epileptic seizures, a symptom that is rare in adult-onset HD. Seizures can further complicate the management of the disease and may require additional medical interventions.\n\n\n\n\n\n\n\n\nPathogenic Mechanisms of Huntington’s Disease\n\n\n\n\nHuntington’s disease (HD) is a neurodegenerative disorder characterized by the progressive dysfunction and loss of neurons in certain regions of the brain. While the exact pathogenic mechanisms underlying HD are complex and multifaceted, several key processes contribute to the development and progression of the disease:\n\nMutant Huntingtin Protein (mHTT) Aggregation: The primary genetic cause of HD is an expanded CAG repeat in the HTT gene, leading to the production of mutant huntingtin protein (mHTT). Mutant huntingtin has an elongated polyglutamine (polyQ) tract, which confers a propensity to misfold and aggregate within neurons. These aggregates, known as inclusion bodies or Huntington bodies, disrupt cellular function and contribute to neuronal dysfunction and death.\nDisruption of Protein Homeostasis: Mutant huntingtin protein interferes with protein homeostasis, leading to impairment of protein folding, trafficking, and degradation processes within neurons. This disruption of protein homeostasis results in the accumulation of misfolded proteins and aggregates, further exacerbating neuronal dysfunction and toxicity.\nMitochondrial Dysfunction: Mitochondrial dysfunction is a prominent feature of HD pathology, characterized by impaired mitochondrial function, oxidative stress, and energy deficits within neurons. Mutant huntingtin interferes with mitochondrial dynamics, leading to fragmentation of mitochondria and impaired energy production. Dysfunctional mitochondria contribute to neuronal degeneration and cell death in HD.\nExcitotoxicity and Neurotransmitter Dysregulation: Glutamate excitotoxicity, resulting from excessive glutamate release and impaired neurotransmitter regulation, plays a significant role in HD pathogenesis. Excitotoxicity leads to neuronal hyperexcitability, calcium influx, and activation of cell death pathways, contributing to neuronal dysfunction and degeneration in HD.\nNeuroinflammation: Neuroinflammation, characterized by activation of glial cells (astrocytes and microglia) and release of pro-inflammatory cytokines, is a prominent feature of HD pathology. Chronic neuroinflammation exacerbates neuronal damage and contributes to disease progression by promoting oxidative stress, excitotoxicity, and neuronal death.\nTranscriptional Dysregulation: Mutant huntingtin disrupts gene transcription and expression through interactions with transcriptional regulators and chromatin remodeling proteins. Dysregulated gene expression leads to alterations in neuronal function, synaptic plasticity, and cell survival pathways, contributing to HD pathogenesis."
  },
  {
    "objectID": "chapters/week11.html#amyotrophic-lateral-sclerosis",
    "href": "chapters/week11.html#amyotrophic-lateral-sclerosis",
    "title": "11  ALS and Huntington’s Disease",
    "section": "11.2 Amyotrophic Lateral Sclerosis",
    "text": "11.2 Amyotrophic Lateral Sclerosis\nALS, also known as “Lou Gehrig’s Disease” in the states is a progressive neurodegenerative disorder that affects nerve cells in the brain and spinal cord. Unfortunately, ALS is indeed invariably fatal, and most individuals diagnosed with the disease typically succumb to it within 3 to 5 years after diagnosis.\nThe prevalence of ALS is relatively low, but it still represents a significant burden of disease in the United States and the United Kingdom. In these countries, ALS accounts for more than 1 in 500 deaths among adults, highlighting the severity of the condition and the need for continued research and support for individuals and families affected by ALS.\nDespite ongoing efforts to understand the underlying causes and develop effective treatments for ALS, the disease remains challenging to treat, and there is currently no cure. However, advances in research have led to the development of supportive therapies that can help manage symptoms and improve quality of life for individuals living with ALS.\n\n11.2.1 Symmptoms\nALS, or amyotrophic lateral sclerosis, presents with a range of symptoms that can affect mobility, speech, and breathing. Initially, individuals may notice difficulties with walking, running, or writing, as well as speech problems. As the disease progresses, muscle weakness worsens, eventually leading to the inability to move. When the muscles involved in breathing become affected, respiratory failure occurs, which is the primary cause of death for most people with ALS. While a breathing machine can assist with breathing, it does not cure the disease.\nALS typically manifests between the ages of 40 and 60, with more men than women being affected. The exact cause of ALS is unknown, although it can sometimes run in families. However, in most cases, it occurs randomly without a clear genetic predisposition. Unfortunately, there is currently no cure for ALS, but medications can help alleviate symptoms and, in some cases, prolong survival.\nEating problems are common in ALS due to muscle weakness affecting swallowing. This can lead to malnutrition, dehydration, and an increased risk of pneumonia from food, liquids, or saliva entering the lungs. To address these issues and ensure proper nutrition and hydration, a feeding tube may be recommended for individuals with ALS.\n\n\n11.2.2 SOD1\nSuperoxide dismutase 1 (SOD1) was the first gene to be identified as linked to amyotrophic lateral sclerosis (ALS). Mutations in the SOD1 gene were discovered in the early 1990s and are found in a subset of individuals with familial ALS, which is inherited from one or both parents.\nSOD1 encodes an enzyme called copper-zinc superoxide dismutase, which plays a crucial role in antioxidant defense by converting superoxide radicals into oxygen and hydrogen peroxide. Mutations in the SOD1 gene lead to a toxic gain of function in the enzyme, causing it to misfold and aggregate within motor neurons, leading to neuronal damage and death.\nAlthough SOD1 mutations account for only a small percentage of ALS cases, studying the role of SOD1 in the disease has provided valuable insights into the underlying mechanisms of ALS pathology.\n\n\n11.2.3 TDP-43 Inclusion Body in the Cytoplasm\n\n\n\n\n\nTDP-43 Visualization\n\n\n\n\nIn amyotrophic lateral sclerosis (ALS) and certain other neurodegenerative diseases, including frontotemporal lobar degeneration (FTLD), abnormal protein aggregates are commonly found in affected neurons. One of the hallmark pathological features of ALS and FTLD is the presence of cytoplasmic inclusions containing TDP-43 protein.\nTDP-43 (transactive response DNA-binding protein 43 kDa) is a nuclear protein involved in RNA processing and regulation of gene expression. In ALS and FTLD, TDP-43 is abnormally cleaved and aggregated, leading to its accumulation in the cytoplasm of neurons. These cytoplasmic TDP-43 inclusions, also known as TDP-43 proteinopathies, are considered a pathological hallmark of these diseases.\nThe aggregation of TDP-43 into insoluble amyloid fibrils is a prominent pathological feature observed in the brains and spinal cords of individuals with ALS and certain other neurodegenerative diseases, such as frontotemporal lobar degeneration (FTLD). These TDP-43 aggregates disrupt normal cellular functions, including RNA metabolism, protein homeostasis, and cellular signaling pathways, ultimately leading to neurodegeneration and motor neuron death.\n\n\n\n\n\nExamples of Other ALS Genes\n\n\n\n\nIn addition to TDP-43, other RBPs have also been implicated in ALS pathogenesis, including FUS (fused in sarcoma) and hnRNPA1 (heterogeneous nuclear ribonucleoprotein A1). Like TDP-43, mutations in these RBPs can lead to their abnormal aggregation and accumulation in ALS-affected neurons, further contributing to disease pathology.\n\n\n11.2.4 Stress Granules\n\n\n\n\n\nDepiction of Stress Granules\n\n\n\n\nStress granules are membraneless organelles found in the cytoplasm of eukaryotic cells, particularly during times of cellular stress. Unlike traditional organelles with distinct membrane boundaries, stress granules are dynamic, transient structures that form in response to various stressors, such as heat shock, oxidative stress, viral infection, or nutrient deprivation.\nThe primary function of stress granules is to sequester and store specific messenger RNA (mRNA) molecules and associated proteins, preventing their translation into proteins. This sequestration allows the cell to conserve energy and prioritize essential cellular processes under stress conditions. Additionally, stress granules serve as sites for mRNA triage, where transcripts are sorted based on their stability and translation efficiency.\nStress granules are composed of a diverse array of RNA-binding proteins, ribosomal subunits, translation initiation factors, and other RNA-binding proteins. These components dynamically assemble and disassemble within stress granules in response to changing cellular conditions. Importantly, aberrant regulation of stress granule dynamics has been implicated in the pathogenesis of various neurodegenerative diseases, including amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD).\n\n11.2.4.1 Amyloid Fibril Formation\n\n\n\n\n\nRAN Translation\n\n\n\n\nThe hexanucleotide repeat expansion in the C9orf72 gene is a common genetic abnormality associated with both amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD). This repeat expansion consists of an abnormal expansion of a hexanucleotide (GGGGCC) within a non-coding region of the C9orf72 gene. Normally, this hexanucleotide repeat is present in a small number of copies, but in affected individuals, it can be repeated hundreds to thousands of times.\nOne of the consequences of the hexanucleotide repeat expansion is the generation of abnormal RNA structures, including RNA foci, which can sequester RNA-binding proteins and disrupt normal cellular functions. Additionally, the expanded repeat region can undergo repeat-associated non-ATG (RAN) translation, a phenomenon in which the repeat sequence is translated into abnormal proteins in the absence of an initiating ATG codon.\nRAN translation leads to the production of dipeptide repeat (DPR) proteins, which are toxic to cells and have been implicated in the pathogenesis of ALS and FTD. These DPR proteins can aggregate and form insoluble intracellular inclusions, contributing to neuronal dysfunction and cell death.\nInterestingly, stress granules, which are membraneless organelles that form in response to cellular stress, have been implicated in the sequestration and aggregation of DPR proteins. Under conditions of stress, such as heat shock or oxidative stress, stress granules may provide a site for the accumulation and aggregation of DPR proteins, potentially exacerbating cellular dysfunction and contributing to disease progression in ALS and FTD."
  }
]